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Age-related macular degeneration (AMD) is the leading cause of blindness among people 
over the age of 65. Epidemiological studies have indicated that people with a high intake 
of two dietary carotenoids, lutein and zeaxanthin that accumulate in the human macula, 
are at a reduced risk of AMD. Possible role of lutein and zeaxanthin in the prevention of 
AMD has been attributed to their antioxidant function and their ability to act as optical 
filters. The objectives of this study were to investigate the association between three 
doses of orally ingested lutein supplements and serum levels of this carotenoid in elderly 
with and without AMD; to evaluate the possible interaction between supplemental lutein  
 
and other dietary carotenoids, retinol, α- and γ-tocopherol; to correlate the serum levels 
of lutein with the total macular pigment optical density (MPOD). 
Forty-five subjects over the age of 60 were divided into 3 groups: subjects 
without AMD and subjects with middle and end stage of AMD. Subjects in each group 
were randomized to receive one of the three doses of 2.5, 5, and 10 mg/day of lutein 
(containing 5% zeaxanthin) for 6 months. Subjects were followed up for 6 months. 
Carotenoids and their metabolites in the serum of subjects were analyzed by HPLC at 
weeks 0, 1, 4, 12, 26, 38, and 52. The MPOD of subjects was measured by 
Heterochromatic Flicker Photometry (HCFP). The data were analyzed using analysis of 
variance and covariance with repeated measurements (SAS, version 8.2). 
 The mean serum concentrations of lutein in all subjects increased with 
supplementation. Subjects receiving 10 mg/day of lutein had a 3-4 fold increase in their 
serum levels of lutein, while those receiving 2.5 and 5 mg/day dose had approximately 2 
fold increase. In conclusion, the serum concentration of lutein appears to be dose 
dependent and the presence or the absence of AMD does not interfere with the serum 
levels of this carotenoid. Supplemental lutein does not interact with other dietary 
carotenoids, retinol, α- and γ-tocopherol. The results from MPOD measurements by 
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 Age-related macular degeneration is the leading cause of blindness among 
Caucasians over the age of 60 in the United States. The Eye Diseases Prevalence 
Research Group estimates that 1.8 million Americans are legally blind and another 7.3 
million people are at risk for vision loss from Age-related macular degeneration (The Eye 
Diseases Prevalence Research Group, 2004). An epidemiological study published in 1994 
was the first study to bring the attention to AMD (Seddon et al., 1994). Almost a decade 
later, studies have revealed that the general public is still not aware of AMD when 
compared to other eye diseases and chronic diseases (Rosenthal et al., 2003; Prahlad, 
2002). 
 Age-related macular degeneration (AMD) is a degenerative disorder of the central 
area of the retina (the macula) often associated with visual impairment, which causes 
progressive loss of central vision. The disorder was first described in 1875 and a decade 
later the disease was defined as the disease senile macular degeneration (cited in Bird et 
al., 1995). The etiology of AMD is still not known, however, since the early 1990, the 
attention has been particularly focused on the damaging role of oxidative processes as a 
result of exposure of the photoreceptors to harmful blue light.  
The macula is an oval area situated about 2 disc diameters temporal and slightly 
inferior to the optic disc centered on the fovea, which is a small depression on the retina. 
In 1945, Wald tentatively identified the yellow pigment in the human macula as a 
carotenoid belonging to the xantophyll families in green leaves. In 1985, Bone et al. 
presented preliminary evidence that the human macular pigment is a mixture of lutein 
and zeaxanthin. Finally, in 1993 Bone et al. established the complete identification and 
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stereochemistry of the human macular pigment as lutein [(3R,3’R,6’R)-β,ε-carotene-3,3’-
diol], zeaxanthin [(3R,3’R)-β,β-carotene-3,3’-diol], and meso-zeaxanthin [(3R,3’S)-β,β-
carotene-3,3’-diol].   
It has been hypothesized that the presence of lutein and zeaxanthin in the macula 
protects the retina against AMD by absorbing short-wavelenght visible light and reducing 
chromatic aberration (Schalch et al., 1999). Macular carotenoids are also thought to 
function as antioxidant by quenching free radicals and singlet oxygen, which are 
generated in the retina as a consequence of the simultaneous presence of light and oxygen 
(Schalch et al., 1992; Snodderly, 1995). In 1997, Khachik et al. provided preliminary 
evidence for the possible antioxidant role of lutein and zeaxanthin in the retina by 
identifying and quantifying lutein, zeaxanhtin, and their oxidation products in human and 
monkey retinas. More recently, carotenoids and their metabolites have also been 
identified and quantified in other ocular tissues of the human eye (Bernstein et al., 2001).  
Additional evidence for the beneficial role of carotenoids in the prevention of 
neovascular AMD was obtained from epidemiological studies. The results from the Eye 
Disease Case-Control Study Group indicated that individuals with medium and high 
serum carotenoid concentrations in comparison with those with low serum carotenoid 
levels, were at significantly reduced risk for neovascular AMD (EDCCS, 1993).  In 1994, 
Seddon et al. showed that a high consumption of fruits and vegetables, specifically rich in 
lutein and zeaxanthin, reduced the risk of exudative AMD by 43% relative to subjects in 
the lowest quintile. Meantime, two other epidemiological studies did not find an 
association between serum carotenoid concentration and a reduced risk of AMD (Mares-
Perlman et al. 1995; Mares-Perlman et al. 2001).  
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The promising results from the observational and epidemiological studies 
obtained in the 1990’s, led to a multi-center clinical intervention trial known as the Age-
related Eye Disease Study (AREDS). This study began in 1992 and was conducted for 5 
years involving 3,640 subjects at 11 retinal specialty clinics across the United States. 
Subjects were randomly divided into 4 treatment groups receiving supplements of various 
combinations of vitamin C, vitamin E, β-carotene, and zinc. The results from this 
randomized clinical trial suggested that supplementation with 500 mg of vitamin C, 400 
IU vitamin E, 15 mg β-carotene, and 80 mg zinc daily provided a protective effect 
against the progression to advanced neovascular AMD in people with moderate or severe 
disease (AREDS, 2001). At the planning stage of AREDS lutein and zeaxanthin were not 
commercially available to be included in this study.  
The first article addressing human supplementation with lutein and zeaxanthin 
was published by Khachik et al. 1995. In two separate studies, three subjects were 
supplemented with 10 mg/day of lutein for 18 days and 10 mg/day of zeaxanthin for 21 
days. The results of this study showed that the serum levels of lutein and zeaxanthin 
increased four fold after one week of supplementation. Several years later, Landrum et al. 
(1997) conducted a supplementation study with 30 mg/day of lutein esters for 140 days in 
2 subjects. In this study, serum lutein concentrations in both subjects increased by tenfold 
increase within 10 to 20 days. After 20 days of supplementation a plateau of 1761 nmol/L 
was established and maintained throughout the supplementation period.  After 40 days of 
supplementation, an increase in the macular pigment optical density (MPOD) at an 
average rate of 1.13 ± 0.12 milliabsorbance units/day was observed. 
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It has been hypothesized that lutein and zeaxanthin protect the macula against 
photooxidative damage by their possible function as antioxidant and/or optical filter 
mechanisms (Schalch et al., 1992; Snodderly, 1995). Another evidence for the protective 
role of lutein and zeaxanthin against AMD is their presence in the human rod outer 
segment (ROS), which is the region of the retina most exposed to oxidation because of its 
relatively high oxygen tension and its high concentration of long–chain polyunsaturated 
fatty acids (Rapp et al. 2000). Because polyunsaturated fatty acids are readily susceptible 
to oxidation, the presence of a high concentration of carotenoids would be expected to 
suppress such oxidative processes and provide protection to the ROS by an antioxidant 
mechanism of action.  
 To date there are no published studies that have examined the serum response of 
individuals with and without AMD supplementation study with various doses of lutein 
containing 5% zeaxanthin. Therefore, the research presented in this dissertation was 
designed to investigate the association between three doses of orally ingested lutein (2.5, 
5, and 10 mg/day) supplements with the serum levels of this carotenoid in subjects over 




REVIEW OF THE LITERATURE 
 
The Anatomy of the Human Eye 
The eyeball consists of three layers: fibrous tunic, vascular tunic and retina. The 
fibrous tunic is the most external layer, it is avascular and it is composed of cornea and 
sclera (Figure 1). The vascular tunic consists of choroid that provides nutrients to the 
posterior surface of the retina; ciliary body, which secrets aqueous humor and alters the 
shape of the lens; and iris that regulates the amount of light entering the vitreous 
chamber. The third layer is the retina, which consists of the retinal pigment ephitelium 


















The retina is a multilayered structure, consisting of the photosensitive cells 
(photoreceptors) that are deepest within the eye. Midway are the integrative elements-
horizontal cells, bipolar cells, and amacrine cells that process and analyze visual 
information. Innermost are the ganglion cells, whose axons form the optic nerve (Figure 
2). On the other side of the photoreceptors is a layer of cells called the retinal pigment 
epithelium (RPE) that helps to control the metabolic environment. The RPE is separated 
by a thin layer of collagenous tissue called Bruch’s membrane from the choroid or 
vascular coat of the eye.  
 




The initial process of vision occurs in the outer segment of the photoreceptors. 
The outer segment consists of a dense stack of lipid membranes containing 50% of 
polyunsaturated fatty acids, mainly docosahexanoic acid (DHA) (22:6ω-3), and the 
remaining 50% are composed of proteins (Beatty et al., 2000). The membrane discs are 
continually being renewed by synthesis of new discs and by removal of old discs at the 
tips, which are phagocytized by the RPE (Young, 1976). 
There are two types of photoreceptors: rods, which contain the visual pigment 
rhodopsin and provide colorless night vision and cones, which contain one of the three 
pigments: red, green, or blue and are responsible for color vision and sharp acuity. The 
cone photoreceptors are predominant in the macula, which provides good visual acuity 
(20/20) for the central vision. The zone of highest rod density is 15-20o away from the 
fovea and is the most light-sensitive area at night.  
 
The Macula 
 The macula is an oval area situated about 2 disc diameters temporal and slightly 
inferior to the optic disc.  The macula is anatomically defined as the exact center of the 
retina at the visual axis of the eye, and it has an approximate diameter of 5.5 mm. The 
fovea is a small depression in the center of the macula and in this region only cone 
photoreceptors are present. The macula appears darker than the surrounding retina (see 
Figure 3) and this is because of the presence of two dietary carotenoids, lutein and 
zeaxanthin, which are also known as macular xanthophyll pigments (Bone et al., 1985; 



















The spatial distribution of the carotenoids has been described by Snodderly et al., 
1984 & 1991. The authors showed that macular carotenoids are asymmetrically 
distributed and are found mostly in the inner retinal layers. Rapp et al. (2000) 
demonstrated that lutein and zeaxanthin were three times more concentrated in the 
perifoveal retina (1.5 to 4 mm eccentricity excluding the fovea) than the remaining area 
of the retina (peripheral retina). The combined lutein and zeaxanthin were also 70% 
higher in the human rod outer segment (ROS) compared with residual membranes.  ROS 
is the region of the retina most exposed to oxidation because of its relatively high oxygen 




Age-Related Macular Degeneration (AMD) 
Age-related Macular degeneration (AMD) is defined as late stages of age-related 
maculopathy (ARM), which includes both geographic atrophy (end stage of dry AMD) 
and choroidal neovascularization (wet AMD).  
In 1995 the International Age Related Maculopathy (ARM) Epidemiological 
Study Group published the International Classification and Grading System for Age 
Related Maculopathy and Age Related Macular Degeneration (Bird et al., 1995). ARM 
was defined as a disorder of the macula. ARM is most often apparent after 50 years of 
age and is characterized by the presence of soft drusen (≥63µm); choroidal 
hyperpigmentation associated with drusen; and depigmentation of the RPE. Drusen are 
extracellular deposits of varying size and morphology that accumulate between the RPE 
and Bruch’s membrane. Soft drusen are irregular in shape without distinct borders while 
hard drusen are nodular with well-defined borders. Hard drusen typically extend further 
into the retina while soft drusen have a much larger lateral spread.  
Recently, Johnson et al. (2003) showed that photoreceptors in the macular and 
extramacular region overlying drusen deposits, exhibited structural and molecular 
abnormalities. As AMD progresses, drusen increase in size and number, eventually 
compromising the function of RPE. No significant differences in the molecular 
composition of hard and soft drusen have been identified (Sarks et al., 1999). In addition, 
the depigmentation of the RPE is a result of the degradation of the melanin caused by an 
accumulation of lipofuscin, a lipid-protein aggregate, mainly formed during the 
phagocytosis of photoreceptor outer segment by the RPE (Feeney-Burns et al., 1980). 
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Geographic Atrophy  
 The atrophic form of macular degeneration has been called “geographic” because 
the areas of retinal pigment epithelial atrophy tend to form well-demarcated borders 
(Gass, 1973). Geographic atrophy has also been called senile choroidal sclerosis (Sarks, 
1973), senile macular degeneration (Schatz, 1978) and central areola choroidal atrophy 
(Young, 1987). The cause of geographic atrophy is not known, but several mechanisms 
have been hypothesized. In 1973 Gass suggested that the presence of drusens can lead to 
elevation of the retinal pigment epithelium and as the drusens fade they are replaced by 
areas of atrophy. However, it has been shown by Maguire and Vine (1986) that the fading 
of drusens did not always result in atrophy of the overlying pigment epithelium. In 
another study, a spontaneous flattening of the pigment epithelial detachment led to the 
atrophy that slowly expanded (Schatz & McDonald, 1989). 
Patients with dry AMD describe blurring of vision and a gradual visual loss as 
opposed to the dramatic loss of vision in patients with subretinal neovascularization. The 
progressive loss of central vision caused by geographic atrophy of the retinal pigment 
epithelium has been described by Maguire and Vine (1986). In the initial stage of the dry 
AMD, there is gradual enlargement of focal circular areas of atrophy of the retinal 
pigment epithelium in the parafoveal area. In the second stage of the disease there is a 
relatively rapid loss of visual acuity due to the thinning of the foveal pigment epithelium 
and increasing encirclement of the fovea. At the end stage of dry AMD the area of 
atrophy involves the entire central macula and the individual is considered legally blind 
(visual acuity: 20/200). An average rate of growth of the atrophic area have been reported 
to be 139 µm per year (range: 15 to 375 µm per year), and an 8% annual rate of 
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deteriorating visual acuity from 20/50 or better to 20/100 or worse (Schatz and 
McDonald, 1989).        
 Several studies have been conducted to evaluate the extent of the visual function 
of eyes with geographic atrophy.  Sunness et al. (1999) reported that 31% of the eyes 
with geographic atrophy had a three-line visual acuity loss after 2 years of examination, 
which increased to 53% by the 4-year examination. Fourteen percent of the patients with 
geographic atrophy in one or both eyes who had a visual acuity better than 20/50 at 
baseline showed a visual acuity of 20/200 or worse after 2 years of the study and the 
percentage of the patients with this visual acuity increased to 27% after 4 years. All 
patients had an increase in the amount of enlargement of total atrophy independent of 
their initial levels of atrophy. 
Geographic atrophy also decreases contrast sensitivity and dark-adapted function, 
even in cases where the fovea is still preserved. The foveal dark-adapted sensitivity in 
eyes with geographic atrophy who had a visual acuity better than 20/25 were significantly 
different compared to eyes with drusens with similar acuity (Sunness et al., 1997). The 
same authors also found a decrease in visual function, particularly when these functions 
were measured in dim light even in subjects with a good visual acuity (≥ 20/50).  
“Dry” AMD can develop following a gradual appearance of drusens and can lead 
to RPE detachment, geographic atrophy or involution of choroidal neovascularization 
(CNV). In 1989 Schatz and McDonald reported that 10 of 50 eyes with geographic 




Choroidal neovascularization (CNV) or “wet” AMD refers to the growth of new 
blood vessels from the choroids into the retina. These vessels may remain beneath the 
RPE, or breach the RPE and enter the subretinal space. Repeated leakage of blood can 
stimulate fibroglial organization forming a cicatricial scar (Ambati et al., 2003). In eight 
of ten eyes in which subretinal neovascularization developed, the new vessel membrane 
began at the edge of the atrophy and grew out from the atrophic area. In two cases, 
however, subretinal neovascularization did grow over the atrophic area.  
Although wet AMD occurs in only 10 percent of patients diagnosed with AMD, it 
accounts for 80 percent of the vision loss (The Washington Advisory Group, 2002). To 
date there is no treatment available for the “dry” AMD and only a limited number of 
cases with “wet” AMD can be treated with laser surgery successfully. Laser treatment 
may stop the progression of “wet” AMD but cannot eliminate the disease itself.  
 
Prevalence of Age-Related Macular Degeneration 
 There have been a number of prevalence studies; the majority of these have been 
undertaken in industrialized countries. On the other hand, there is very little information 
on the prevalence of AMD in non-industrialized countries. 
Three large population–based epidemiologic studies have been conducted in 
Beaver Dam, Wisconsin (Klein et al., 1992), Rotterdam, The Netherlands (Vingerling et 
al., 1995) and the Blue Mountains area, west of Sydney, Australia (Mitchell et al., 1995). 
These studies have provided prevalence estimates for geographic atrophy and 
neovascular AMD. In these three sites the prevalence of geographic atrophy was 0.44%, 
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0.66%, and 0.45%, respectively. However, the prevalence of neovascular AMD for the 
same sites was 0.88%, 0.72%, and 1.20%, respectively. In the Beaver Dam and the Blue 
Mountains populations the prevalence of neovascular AMD was almost twice as 
geographic atrophy. 
 
AMD Risk Factors 
The etiology of age-related macular degeneration is not known, but it has been 
attributed to a combination of several factors. Epidemiological studies have shown 
associations of certain characteristics and the risk of developing AMD.  
One of the most important risk factors for AMD is age. In the Framingham Eye 
Study, 28% of individuals aged between 75-85 years presented AMD compared with 
22% of individuals aged between 52-74 (Kahn et al., 1977). A five-year cohort study 
conducted in Australia showed that the rate of incidence for all age-related maculopathy 
(ARM) lesions increased significantly with age. In this study the rate of incidence of 
ARM after 5 years was zero percent in people aged 60 years and younger, 0.6% in people 
60-69 years old, 2.4% for those with 70-79 years of age, and 5.4% for those with 80 years 
and older (Mitchell et al., 2002a). The Beaver Dam Eye Study, investigating the 10-year 
incidence of ARM, revealed that individuals 75 years or older at baseline had a 
significant increase in the incidence of retinal pigment abnormality (19.5%) compared to 
individuals aged 43-54 (0.8%). The former age group also presented higher risk for the 
development of the two forms of AMD, exudative macular degeneration, 4.1% vs. 0%, 
and geographic atrophy, 3.1% vs. 0% (Klein et al., 2002).  
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Family history is another important risk factor and it has been significantly 
associated with late AMD and early ARM (Smith et al., 1998). A genetic influence has 
been proposed from several studies with twins (Meyers & Zachary, 1988; Dosso & 
Bovet, 1992; Klein et al., 1994), however the relative importance of genes and 
environment in these studies were not defined. A study with twins conducted in Iceland 
showed a significantly higher concordance of age-related macular degeneration in 
monozygotic twin pairs (90%) compared to their respective spouse pairs (70%) 
suggesting the importance of genetic factors in age-related macular degeneration 
(Gottfredsdottir et al., 1999). The concordance in monozygotic twins were also compared 
to dizygotic twins to exclude the influence of shared family environment and the results 
showed a 45% overall heritability at the early stage of ARM (Hammond et al., 2002).    
Among the modifiable risk factors of AMD, cigarette smoking has shown strong 
association with AMD; however, this risk factor appears to be more associated with 
neovascular AMD than with geographic atrophy (Hyman et al., 1992; Klein et al., 1993). 
The Eye Disease Case-Control Study Group (EDCCS, 1992) showed a strong association 
between current cigarette smoking and the risk of neovascular AMD, (odds ratio, 
OR=2.2).  
Three major cross-sectional studies have shown the association of cigarette 
smoking and risk of AMD. In a French cross-sectional study known as POLA study, 
former and current smokers had a 3.2 and 3.6-fold increased risk of late AMD, 
respectively, when compared with nonsmokers (Delcourt et al., 1998).  The authors also 
showed an association of increasing risk of late AMD with an increasing number of pack-
years smoked. This findings were also showed in the 5-year follow-up of the Beaver Dam 
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Eye Study, Wisconsin, where men who smoked greater numbers of cigarettes (10 pack-
years smoked) were more likely to develop early AMD (OR=1.06, 95% CI: 1.00-1.13) 
than men who had smoked to a lesser extent. This association was not observed in 
women (Klein et al., 1998). The Blue Mountains cross-sectional eye study, which 
included 3,654 residents of Sydney, Australia, demonstrated that the current smokers 
were at a 2.5 times higher risk for developing late AMD, either geographic atrophy or 
neovascular AMD, than persons who had never smoked. The authors also reported that 
current smokers were more likely to develop late AMD approximately 10 years earlier 
than the typical age for the onset of AMD (Mitchell et al., 2002b). 
Several mechanisms have been proposed to explain the association between 
smoking and AMD. Smoking has been demonstrated to cause oxidative damage in 
biologic molecules (Morrow et al., 1995) and reduce plasma antioxidant levels (Sanders 
et al., 1993). By reducing antioxidant levels, smoking may increase oxidative insult to the 
retina, specially the rod and cone outer segment, which accumulate a high concentration 
of polyunsaturated fatty acids that are highly susceptible to oxidation (Fliesler et al., 
1983; Anderson et al., 1984). 
One of the major dietary antioxidants that may be adversely affected by smoking 
is carotenoids. For example, cigarette smoking has caused the depletion of several serum 
carotenoids such as, lycopene, β-carotene, and β-cryptoxanthin as well as the macular 
pigments lutein and zeaxanthin (Handelman et al., 1996). A low macular pigment optical 
density, which refers to the total concentration of lutein and zeaxanthin in the macula, has 
also been associated with risk of AMD. Bernstein et al. (2002) employed an in vivo 
resonance Raman spectroscopy technique to demonstrate that eyes with AMD had 32% 
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lower levels of macular carotenoids when compared to age-matched control eyes. In 
another study Hammond et al. (1996a) showed that smokers had significantly reduced 
macular pigment optical density (MPOD), less than half of the mean MPOD, when 
compared to non-smokers. 
Epidemiological studies have also addressed the hypothesis that AMD may be 
associated with cardiovascular diseases and related risk factors, such as high blood 
pressure, high serum cholesterol, and smoking, as well as clinical manifestations of 
atherosclerosis. However, the role of cardiovascular disease and high blood pressure in 
the incidence of AMD remains unclear. 
The investigators of the Eye Case Control Study Group (EDCCS, 1992), did not 
find a significant association between hypertension, defined as an elevated blood 
pressure, and neovascular AMD, but found a significant trend with higher systolic blood 
pressure. Systolic blood pressure was also significantly associated with the incidence of 
exudative AMD in the Beaver Dam Eye Study (Klein et al., 2003a). In addition, a direct 
association of HDL cholesterol and the incidence of AMD has been suggested but the 
reason is not known (Hyman et al., 2000; Klein et al., 2003a). Several epidemiological 
studies did not find any association between AMD and hypertension, stroke, angina, and 
acute myocardial (Smith et al., 1998; Klein et al., 2003b). 
The investigators of the Rotterdam prospective cohort study reported that some 
measures of atherosclerosis have been associated with AMD. Among these, carotid wall 
thickness and carotid plaques showed the strongest association with AMD, whereas no 
association was found for calcifications in the abdominal aorta and peripheral arterial 
disease (Leeuwen et al., 2003). This study suggests that as a consequence of thickening 
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of the vessel wall, the lumen diameter is decreased resulting in an increase in the blood 
flow resistance, and a decrease in tissue perfusion. This process may either directly 
impair the functioning of the retinal pigment epithelium, which is responsible for the 
metabolism of rod and cone outer segments, or may lead to leakage and deposition of 
proteins and lipids due to elevated hydrostatic pressure (Friedman, 2000). However, 
results from the Cardiovascular Health Study, concluded that neither mild nor severe 
hypertension were specifically associated with left ventricular hypertrophy, a history of 
myocardial infraction, nor stroke was associated with early AMD (Klein et al., 2003b). 
Possible association between AMD and body mass index has also been 
investigated. The results from the Blue Mountains Eye Study and the Physicians Health 
Study indicate an increased risk for dry AMD among overweight (BMI: 25.0-29.9) and 
obese (BMI≥30) as well as among lean (BMI<22.0) individuals (Smith et al., 1998; 
Schaumberg et al., 2001). Therefore, the relationship between BMI with AMD appears to 
be more complex and nonlinear.  Other measurements for obesity, such as larger waist 
circumference and a higher waist-hip ratio were found to be statistically significant for an 
increased risk for progression to advanced AMD (Seddon et al., 2003).   
It is interesting to note that AMD has been shown to be more prevalent among 
Caucasians. In a study by Friedman et al. (1999) known as the Baltimore Eye Survey, it 
has been shown that prevalence of AMD was 2.1% among whites over 70 years of age, 
while no cases of AMD were detected among 243 black subjects in this age group. In this 
study severe forms of maculopathy and late AMD were more prevalent in older whites, 
although drusens were common in both African Americans and Caucasians over age of 
40. Other studies also suggest that choroidal neovascularization is rare in African 
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Americans patients (Sommer et al., 1991; Jampol et al., 1992). The explanation for the 
differences in the prevalence of choroidal neovascularization among African Americans 
and Caucasians remains uncertain. One possibility is that an increased amount of melanin 
in African american patients’ eye is protective. This melanin could act as a free radical 
scavenger, or in some other way protect the pigment epithelium, Bruch’s membrane, 
choroids, or outer retina from degenerative changes predisposing the patient to choroidal 
neovascularization (Jampol et al., 1992). In the Baltimore Eye Survey more than one 
third of the cases with blindness were associated with AMD or disciform scaring, while 
not even a single case in the African Americans group could be attributed to these cases 
(Sommer et al., 1991).  
In the Beaver Dam Eye Study, the prevalence in the Caucasian population with 
“exudative AMD” was found to be 6.7% for women and 2.6% for men older than 75 
years of age (Klein et al., 1992). In the African American population, women also 
presented a greater prevalence of AMD compared to men (2:1), indicating that the 
difference in gender is consistent across racial groups (Pieramici et al., 1994). The high 
risk of incidence of AMD in women may be explained in terms of their low MPOD, 
which exposes the central retina to damaging short wave length light. Hammond et al. 
(1996b) showed that men had in average 38% or more MPOD than women (p<0.001). 
This was despite the fact that men and women in that study were found to have similar 
plasma carotenoid concentrations and similar dietary intake, except for fat. 
The association of iris color and the risk of AMD is still a controversy. In several 
epidemiological studies (Hyman et al., 1983; Mitchell et al., 1998) light iris color has 
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been associated with early AMD and late ARM, while other studies have found no 
significant association between iris color and AMD (West et al., 1989; EDCCS, 1992).  
The analysis of the cross-sectional data from the Blue Mountain Eye Study has 
shown that blue iris color was significantly associated with an increase risk of early ARM 
(OR=1.45) as well as late ARM (OR=1.69) (Mitchell et al., 1998). In contrast to this 
finding, the Beaver Dam Eye Study (Tomany et al., 2003) people with brown irises were 
more likely to develop soft indistinct drusens than were people with blue irises. On the 
other hand, in the same study, people with blue irises had significantly higher risk of 
developing retinal pigment ephithelial depigmentation, which is associated with early 
AMD. However, the investigators did not find an association between iris color and the 
incidence of late AMD. A possible explanation for the higher risk of AMD in people with 
light colored irises may be based on their lower levels of melanin in the RPE/choroid 
compared with people with brown irises. It has been hypothesized that melanin may 
protect the retina from direct exposure to sunlight, protecting against oxidative damage 
and thereby reducing the risk of AMD (Young, 1988).  
Conflicting results have been reported from studies investigating the relationship 
between dietary fat and age-related macular degeneration. In the Beaver Dam Eye Study, 
intake of saturated fatty acids in subjects in the highest quintile was significantly 
associated with an increase in early AMD (OR=1.8, 95%CI: 1.2-2.7, P trend=.01) in 
comparison with those subjects in the lowest quintile (Mares-Perlman et al., 1995). On 
the other hand, results from the Blue Mountains Eye Study did not show a significant 
association between AMD and saturated fat but established an association between intake 
of monounsaturated fat (OR=1.48; 95%CI:087-2.53, P trend=.05) and a significant 
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borderline increase in the risk of early AMD (Smith et al., 2000). Similarly, the Eye 
Disease Case-Control Study did not find an association between AMD and saturated fat 
and/or monounsaturated fat; the odds ratio for the fifth compared with the first quintile 
was 1.71 (95% CI: 1.00-2.94, P trend=.03). However, this study found an association 
between AMD and the intake of polyunsaturated fat; the odds ratio for the fifth compared 
with the first quintile was 1.86 (95%CI: 1.11-3.14, P trend =.03) (Seddon, et al., 2001).  
Linoleic acid, a polyunsaturated fat, has also been associated with risk of AMD 
(Seddon et al., 2001). The results from a prospective follow-up of the Nurses Health 
Study and the Health Professionals Follow-up Study suggested that linoleic acid was 
positively associated with risk of AMD in both women and men (Cho et al., 2001). In this 
study, participants who ate fish more than 4 times/week had a lower risk of AMD than 
did those whose intake was less than 3 times/month (RR:0.65; 95%CI: 0.46-0.91). 
Another factor that has been associated with the risk of AMD is cholesterol. The Eye 
Disease Case-Control Study Group (EDCCS, 1992) indicated an association between 
increases in the cholesterol levels and late AMD (OR=2.71; 95%CI:0.93-7.96, P 
trend=.04). Patients with midrange (4.9 to 6.7 mmol/L) to high (≥ 6.7 mmol/L) total 
cholesterol levels had markedly increased risk of neovascular AMD compared with those 
with low levels of cholesterol.  
On the other hand, dietary factors such as antioxidants may prevent the 
progression of AMD. Carotenoids are among the abundant dietary antioxidants that 
effectively quench singlet oxygen and other free radical species in liposomes, 
lipoproteins, membranes and cells (Krinsky, 1989). A multicenter Eye Disease Case-
Control Study has also revealed that individuals consuming the highest levels of 
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carotenoids had a statistically significant 43% lower risk for AMD compared with those 
who consumed the lowest levels. In particular, a higher frequency of intake of spinach or 
collard greens, specifically rich in lutein and zeaxanthin, was associated with a 
substantially lower risk for AMD (Seddon et al., 1994). 
In 1992 the Eye Disease Case control Study Group (EDCCS) reported that 
individuals with a high carotenoid serum levels (lutein, zeaxanthin, β-carotene, α-
carotene, β-cryptoxanthin, α-cryptoxanthin, and lycopene) had markedly reduced risks of 
neovascular AMD. Almost ten years later the AREDS suggested that supplementation 
with 500 mg of vitamin C, 400 IU vitamin E, 15 mg β-carotene, and 80 mg zinc daily 
provided a protective effect against the progression to advanced neovascular AMD in 
people with moderate or severe disease (AREDS, 2001). In an attempt to better clarify 
the possible role of carotenoids in the prevention of AMD, the chemistry and properties 
of these compounds are described as follows. 
 
Carotenoids, Structure and Natural Occurrence 
Carotenoids are one of the most widespread groups of natural pigments that are 
found in all families of plants and animal kingdoms (Isler, 1971). Carotenoids are 
tetraterpenoid compounds with a general chemical structure of C40H56. Although in 
excess of 600 carotenoids have been isolated and identified from natural sources 
(Pfander, 1987), only 50 to 60 carotenoids are present in fruits and vegetables commonly 
consumed in the United States (Khachik et al., 1991). 
There are two classes of carotenoids, the hydrocarbon carotenoids (carotenes) and 
oxygenated carotenoids. Some of the major dietary hydrocarbon carotenoids found in 
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fruits and vegetables are α-carotene, β-carotene, γ-carotene, ζ-carotene, lycopene, 
phytofluene, and phytoene. Other common dietary carotenoids that are found in human 
plasma, such as lutein, zeaxanthin, α-cryptoxanthin and β-cryptoxanthin are among the 
oxygenated carotenoids and more specifically classified as hydroxycarotenoids. Among 
plasma carotenoids, only α-carotene, β-carotene, β-cryptoxanthin, and γ-carotene can be 
converted to vitamin A. The chemical structures of α-carotene and β-carotene are shown 

























Figure 4- Chemical Structures of the Hydrocarbon Carotenoids α-Carotene 
                      and β-Carotene. 
 
 Lutein with 3 stereogenic centers at C-3, C-3’, and C-6’ can exists as 8 possible 
configurational isomers. However, among these (3R,3’R,6’R)-lutein is the only isomer 
found in foods. In addition to (3R,3’R,6’R)-lutein, another configurational isomer of this 
carotenoid, (3R,3’S,6’R)-lutein (3’-epilutein), has also been identified in human plasma, 
tissues, and particularly ocular tissues (Khachik et al., 2002). Unless otherwise stated in 
this dissertation, lutein refers to the naturally occurring form with a configuration of  
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(3R,3’R,6’R)-lutein. 3’-Epilutein is absent in the diet and is a presumed metabolite of 
dietary lutein and/or zeaxanthin. Because zeaxanthin is a symmetrical molecule and has 
only two chiral centers at C-3 and C-3’,  three configurational isomers are possible, these 
are:  (3R,3’R)-, (3R,3’S, meso)-, (3S,3’S)-zeaxanthin. However, (3R,3’R)-zeaxanthin is 
the form commonly found in foods and human plasma and unless otherwise stated is the 
configuration of zeaxanthin referred to in this dissertation. meso-Zeaxanthin has not been 
detected in foods, human plasma and liver but a relatively high concentration of this 
carotenoid has been found in nearly all ocular tissues (Khachik et al., 2002). The 
chemical structures of (3R,3’R,6’R)-lutein, 3’-epilutein [(3R,3’S,6’R)-Lutein], (3R,3’R)-









































































Figure 5- Chemical Structures of Lutein [(3R, 3’R, 6’R)-Lutein], 3’-Epilutein 
                          [(3R,3’S,6’R)-Lutein], (3R,3’R)-Zeaxanthin, (3R,3’S, meso)- 
                          Zeaxanthin, and (3S,3’S)-Zeaxanthin. 
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The terms all-E and Z isomers of carotenoids used in this dissertation refer to all-
trans and cis-isomers of carotenoids, respectively. The terms all-trans and cis, have been 
used with the old nomenclature and no longer appropriate. The most common 
geometrical isomers of lutein are: (9Z)-lutein, (9’Z)-lutein, (13Z)-lutein, and (13’Z)-
lutein. Meantime because of its symmetrical structure, the most common geometrical 
isomers of zeaxanthin are: (9Z)-zeaxanthin and (13Z)-zeaxanthin. The chemical 
structures of lutein and zeaxanthin isomers are shown in Figures 6 and 7, respectively. 
The Z(cis)-isomers of carotenoids at the positions C-7 and C-11 are not formed because 
they are sterically hindered and unstable. Similarly, the central 15Z–isomers of 
carotenoids are not common and thermodynamically unstable. The only di-Z-isomer that 
has been isolated from human plasma is the (13Z,13’Z,3R,3’R,6’R)-lutein, which was 
also isolated from extracts of marigold flowers and raw kale (Khachik et al., 1999) as 





























































Figure 6-The Most Common Geometrical Isomers of Lutein in the Order of 
                           Chromatically Elution: (9Z)-Lutein, (9’Z)-Lutein, (13Z)-Lutein, and 
































Figure 7- Geometrical Isomers of Zeaxanthin shown in the Order of Chromatically 








Dietary Sources of Carotenoids 
The combined content of lutein and zeaxanthin in foods consumed in the United 
States were reported in the Carotenoid Database which was prepared as part of the U.S. 
Department of Agriculture (USDA) and the Nutrition Coordinating Center (NCC) at the 
University of Minnesota (http://www.nal.usda.gov/fnic/foodcomp/Data/car98/car98.html) 
Among the green vegetables listed, kale, collards, spinach, and turnip greens were shown 
to have the highest concentration of lutein and zeaxanthin (Table 1). Recently Humphries 
et al. (2003) reported the individual concentrations of lutein (Table 2) and zeaxanthin 
(Table 3) as well as their geometrical isomers in fruits, vegetables and pasta consumed in 
the United States and wheat from Australia. The yellow-orange fruits and vegetables 
were shown to have a greater ratio of lutein to zeaxanthin while lutein was found to be 
the prominent carotenoid in greens. Based on the data listed in Tables 2 and 3, in addition 





Table 1- Lutein and Zeaxanthin Values (µg/100g Edible Portion) Reported in the 
               USDA-NCC Carotenoid Database for U.S. Foods-1998 
Food Description Mean1 SEM2 #S3 Min Max 
Babyfood, vegetables, squash, strained 3,527 1,850 3 586 6,943 
Beans, snap, green, cooked, boiled, drained, without salt 700  2 660 740 
Beans, snap, green, raw 640  2 590 690 
Broccoli, cooked, boiled, drained, without salt 2,226  2 1,707 3,265 
Broccoli, frozen, chopped, cooked, boiled, drained, without salt 830  1   
Broccoli, raw 2,445  2 2,060 2,830 
Brussels sprouts, cooked, boiled, drained, without salt 1,290  1   
Brussels sprouts, raw 1,590  1   
Cabbage, raw 310  1   
Carrots, baby, raw 358  1   
Celery, cooked, boiled, drained, without salt 250  1   
Celery, raw 232  1   
Chicken pot pie, with carrots, potatoes, and peas, frozen 105  1   
Collards, cooked, boiled, drained, without salt 8,091  2 6,500 8,887 
Corn, sweet, yellow, cooked, boiled, drained, without salt 1,800  1   
Cornmeal, degermed, enriched, yellow 1,355  1   
Egg, whole, raw, fresh 55  1   
Fruit cocktail, canned, heavy syrup, drained 112  1   
Grapefruit, raw, pink, and red, all areas 13  2 0 20 
Green pepers stuffed with beef and rice with tomato sauce 75  1   
Kale, cooked, boiled, drained, without salt 15,798  2 10,902 25,590 
Kale raw 39,550  1   
Lasagna with meat and tomato sauce, cooked 97  1   
Lettuce, cos or romaine, raw 2,635  1   
Melons, cantaloupe, raw 40  1   
Okra, cooked, boiled, drained, without salt 390  1   
Orange juice, frozen concentrate, unsweetened, diluted with 3 
volumes water 
138  1   
Orange juice, raw 36     
Oranges, raw, all commercial varieties 187  1   
Papayas, raw 75  1   
Pasta with chicken and vegetables (includes carrots, peas, 
onions, and mushrooms) with oriental sauce, low calorie frozen 
entrée, cooked 
312  1   
Pasta with shrimp and vegetables (includes broccoli, red 
peppers, yellow zucchini, and onions in lemon pepper sauce, low 
fat frozen entrée, cooked 
177  1   
Peaches, canned, heavy syrup, drained 33  1   
Peaches, raw 57  2 10 80 
Peas, green, canned, regular pack, drained solids 1,350  1   
Pizza, supreme with sausage and pepperoni, mushrooms, 
peppers, onions, cheese, and sauce, thin crust, frozen 
20  1   
Pizza, with pepperoni, cheese, and sauce, thin crust, frozen 15  2 0 25 
Spinach, cooked, boiled, drained, without salt 7,043 1,097 3 5,300 9,665 
Spinach, raw 11,938 1,462 3 9,500 15,940 
Squash, summer, crookneck and straightneck, raw 290  1   
Squash, summer, zucchini, includes skin, raw 2,125  1   
Squash, winter acorn, raw 38  1   
Tangerine juice, raw 166     
Tangerines, (mandarin oranges), raw 243  1   
Tomato juice, canned, without salt 60  1   
Tomato products, canned, paste, without salt 170  2 0 340 
Tomato products, canned, puree, without salt 90  1   
Tomatoes, red, ripe, cooked, boiled, without salt 150  1   
Tomatoes, red, ripe, canned, whole, regular pack 40  2 0 80 
Tomatoes, red, ripe, raw, year round average 130  1   
Turnip greens, cooked, boiled, drained, without salt 8,440  1   
Vegetable juice cocktail, canned 80  1   
Watermelon, raw 17  1   
  1 Mean value for lutein and zeaxanthin (µg/100g edible portion) 
  2 SEM-Standard Error of the Means were reported when values for #S were ≥ 3. 
  3 #S is the total number of means/individual values used to calculate the mean and SEM. 
 Source:  http://www.nal.usda.gov/fnic/foodcomp/Data/car98/car98.html. 
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Table 2- Quantitative Distribution of Lutein and its Geometric Isomers in Selected  
               Fruits and Vegetables1 
Lutein (µg/100g) Food Description 










Greens          
  Beans, green 390.0 19.5 5.8 1.6 1.2 418.1 
  Beans, lima (canned) 275.5 27.5 27.5 19.6 6.0 356.1 
  Broccoli 1343 65.0 16.4 81.7 4.5 1510.6 
  Collards 4940 72.0 77.0 11.0 20.0 5120.0 
  Kale 13053 390.0 815.0 678.0 64.0 15000.0 
  Lettuce, romaine2 148.0 12.0 3.0 5.0 2.0 170.0 
  Parsley 9924.0 351.7 53.1 481.2 10.0 10820.0 
  Peas (canned) 661.8 21.1 8.0 26.1 2.0 719.0 
  Spinach 8447.0 223.7 38.0 442.3 6.0 9157.0 
Yellow-orange       
  Corn (canned) 163.8 21.0 3.0 10.2 nd 198.0 
  Mango 10.0 nd nd nd nd 10.0 
  Nectarine 12.2 4.5 3.3 nd nd 20.0 
  Oranges 350.0 nd nd nd nd 350.0 
  Oranges, mandarine 48.3 14.2 2.0 6.0 nd 70.5 
  Papaya 23.1 nd nd nd nd 22.1 
  Peaches 20.0 nd nd nd nd 20.0 
  Plum, red 40.0 nd nd nd nd 40.0 
  Squash, acorn 50.0 nd nd nd nd 50.0 
  Squash, butternut 1793.0 146.0 334.0 127.0 nd 2400.0 
Wheat       
  Catoctin 28.7 1.0 0.9 1.8 nd 32.4 
  Pioneer 195.8 7.6 7.6 13.1 nd 224.1 
  Freekeh 624.5 44.1 81.5 32.7 9.1 791.9 
Pasta       
  Egg noddles 1095 77.0 74.1 117.6 28.4 1391.6 
  Lasagne 226.6 14.9 15.2 25.7 6.3 288.7 
1 with the exception of canned food, all fruits and vegetables were analyzed in the raw form. The 
  detection limit for HPLC analysis of carotenoids was 0.1 ng. 
2 Romaine lettuce also contained lactucaxanthin, 148 µg/100g of edible food. 
   nd- not detected. 





















Table 3- Quantitative Distribution of Zeaxanthin and its Geometric Isomers in Selected 
               Fruits and Vegetables1 













Greens       
  Beans, green 23.0 12.0 nd 35.0 418.1 12 
  Beans, lima (canned) 16.0 nd nd 16.0 356.1 22 
  Broccoli 9.4 33.4 nd 42.8 1510.6 35 
  Collards 128.0 12.0 nd 140.0 5120.0 37 
  Kale 50.2 189.8 nd 240.0 15000.0 63 
  Lettuce, romaine2 2.5 5.5 nd 8.0 170.0 21 
  Parsley 134.0 368.0 nd 502.0 10820.0 22 
  Peas (canned) 40.1 10.9 nd 51.0 719.0 14 
  Spinach 130.8 394.3 nd 525.1 9157.0 17 
Yellow-orange       
  Corn (canned) 310.0 22.7 nd 332.7 198.0 0.6 
  Mango 10.0 nd nd 10.0 10.0 1.0 
  Nectarine 62.0 108.0 nd 170.0 20.0 0.1 
  Oranges 250.0 nd nd 250.0 350.0 1.4 
  Oranges, mandarine 52.0 8.0 nd 60.0 70.5 1.2 
  Papaya 22.1 nd nd 22.1 22.1 1.0 
  Peaches 20.0 nd nd 20.0 20.0 1.0 
  Plum, red nd nd nd nd 40.0  
  Squash, acorn nd nd nd nd 50.0  
  Squash, butternut 280.0 nd nd 280.0 2400.0 8.6 
Wheat       
  Catoctin 1.9 1.2 nd 3.1 32.4 11 
  Pioneer 19.0 10.3 nd 29.3 224.1 7.6 
  Freekeh 242.5 59.9 12.9 315.3 791.9 2.5 
Pasta       
  Egg noddles 352.7 140.7 51.5 544.9 1391.6 2.6 
  Lasagne 11.3 12.5 nd 23.8 288.7 12.1 
1 with the exception of canned food, all fruits and vegetables were analyzed in the raw form. The 
  detection limit for HPLC analysis of carotenoids was 0.1 ng. 
2 Romaine lettuce also contained lactucaxanthin, 148 µg/100g of edible food. 
nd- not detected. 




Distribution of Carotenoids and their Metabolites in Human Serum and Breast Milk 
 
 
To date, 34 carotenoids consisting of 25 dietary (13 all-trans- and 12 cis-
compounds) and 9 carotenoid metabolites (1 cis- and 8 all-trans-compounds) have been 
identified and quantified in human serum and breastmilk (Khachik et al., 1992a & 
1997a). Other carotenoids such as, carotenoid epoxides and carotenol acyl esters that are 
abundant in many fruits and vegetables have not been detected in human serum (Khachik 
et al., 1991).  The chemical structures of dietary carotenoids that have been isolated and 
characterized from human plasma and breast milk are shown in Figure 8. The chemical 
structures of lutein and zeaxanthin metabolites as well as oxidation products of lycopene 





















Figure 8- Major Dietary Carotenoids Identified in Human Serum and Breast Milk. 
































Figure 9- Carotenoid Metabolites Identified in Human Serum and Breast Milk. 





Distribution of Carotenoids in Human Organs and Tissues 
 The presence of carotenoids in various human organs and tissues were reported as 
early as 1990 (Tanumihardjo et al. 1990, Kaplan et al. 1990, Schmitz et al. 1991, Stahl et 
al. 1992, and Clinton et al. 1996). However, recently, Khachik et al. (1998) have reported 
the detection of a more comprehensive list of dietary carotenoids which include lutein, α- 
and β-cryptoxanthin, lycopene, ζ-carotene, α- and β-carotene, phytofluene, and phytoene 
in µg-ng/g quantities in human lung, liver, breast, and cervical tissues. The presence of 
the wide range of dietary carotenoids and their metabolites in humans as well as the 
results from recent in vitro and in vivo studies involving rodents clearly indicate an 
important biological function for carotenoids in human health. 
 
Distribution of Carotenoids in the Human Eye 
 In 1945, Wald tentatively identified the yellow pigment in the human macula as a 
carotenoid belonging to the xanthophylls families in green leaves. For nearly 40 years, no 
attempt was made to establish unequivocally the identity of this carotenoid in the human 
macula, which is still referred to as xanthophylls in many ophthalmology texts. In 1985, 
for the first time, Bone et al presented preliminary evidence that the human macular 
pigment is a mixture of lutein and zeaxanthin. In 1993, Bone et al. elegantly established 
the complete identification and stereochemistry of the human macular pigment as lutein 
[(3R,3’R,6’R)-β,ε-carotene-3-3’diol], zeaxanthin [(3R,3’R)- β,β-carotene-3,3’diol] , and 
meso-zeaxanthin [(3R,3’S)- β,β-carotene-3,3’diol]. 
In 1997, Khachik et al., in addition to lutein and zeaxanthin, identified several 
oxidation products of these carotenoids in human and monkey (Khachik et al., 1997b). 
These oxidation products were: 3’-hydroxy-ε,ε-caroten-3-one, ε,ε-carotene-3,3’-dione, 
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(all E+Z)-3-hydroxy-β,ε-caroten-3’-one, and 3’-epilutein Figure 9. Other compounds 
identified were an oxidation product of lycopene (the red pigment in tomatoes), 2,6-
cyclolycopene-1,5-diol I, which was identified in low concentration as well as several of 
the geometric isomers of lutein and zeaxanthin such as 9-cis-lutein, 9’-cis-lutein, 13-cis-
lutein, 13’-cis-lutein, 9-cis-zeaxanthin, and 13-cis-zeaxanthin.  
As a possible mechanism Khachik et al. (1997b) proposed a series of oxidation–
reduction and double-bond isomerization reactions, to explain the transformation of 
dietary lutein and zeaxanthin to their metabolites in ocular tissues (Figure 10).  
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Figure 10- Proposed Metabolic Transformations of Dietary Lutein and Zeaxanthin in 
                 Ocular Tissues. 
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Based on this proposed metabolic pathways the major oxidation product in the 
human and monkey retinas identified as 3-hydroxy-β-ε-caroten-3’-one, could probably 
result either from oxidation of the hydroxyl group of lutein at C-3’ position, or could be 
formed indirectly from oxidation of 3’-epilutein, which is another metabolite of lutein 
identified in the retina.  For example, the compound identified as 3’-epilutein could be 
formed by reduction of 3-hydroxy-β-ε-caroten-3’-one (oxidation product of dietary 
lutein) or by double bond isomerization of dietary zeaxanthin. It was also suggested that 
the non-dietary (3R,3’R, meso)-zeaxanthin, previously identified by Bone et al. 1993, is 
probably formed by a double bond isomerization of dietary (3R,3’R,6R)-lutein.  
The most compelling evidence for the metabolic conversion of dietary 
(3R,3’R,6’R)-lutein to (3R,3’S; meso)-zeaxanthin in the eye was recently provided by 
Khachik et al. who observed no detectable concentration of (3R,3’S; meso)-zeaxanthin in 
human plasma and liver, while establishing the presence of this carotenoid in human eye 
tissues (Khachik et al., 2002). The authors of this study concluded that understanding the 
metabolism of dietary (3R,3’R,6’R)-lutein and (3R,3’R)-zeaxanthin in the human eye can 
provide valuable information about the possible function of these carotenoids in the 
prevention of AMD. 
Besides the human RPE/choroid and peripheral retina, lutein, zeaxanthin and 
significant amounts of 3’-epilutein and 3-hydroxy-β,ε-caroten-3’-one were also identified 
and quantified in the human ciliary body, iris and lens (Bernstein et al., 2001). Ciliary 
body was also shown to accumulate other dietary carotenoids such as, α-carotene, β-
carotene, neurosporene, α-cryptoxanthin and β-cryptoxanthin. The presence of 
significant levels of lycopene in human RPE and ciliary body was interesting since 
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Khachik et al. had previously identified an oxidative metabolite of this carotene (2,6-
cyclolycopene-1,5-diol) in the human and monkey retinas (Khachik et al., 1997b). The 
presence of oxidation products of lutein and/or zeaxanthin provides preliminary evidence 





The main purpose of the research presented in this dissertation was to investigate 
the association between three doses of orally ingested lutein (2.5, 5, and 10 mg/day) 
supplements with the serum levels of this carotenoid in subjects over the age of 60 
without AMD as well as those with the middle stage, and end stage of AMD. Secondary 
objectives were: 1) to evaluate possible interaction between supplemental lutein and other 
dietary carotenoids, vitamin A, and two forms of vitamin E (α- and γ- tocopherol); 2) 




Three null hyphothesis were designed to be tested. It was hyphothesized that (1) 
there was no change in serum lutein, zeaxanthin, their metabolites concentrations over 
time in the subjects supplemented with lutein containing 5% of zeaxanthin at the dose 
levels of 2.5, 5.0, and 10.0 mg/day across all groups, no AMD, middle stage, and end 
stage of AMD, (2) there was no difference in the serum levels of other dietary 
carotenoids, vitamin A, and the two forms of vitamin E (α- and γ- tocopherol) during- 
and post- supplementation relative to baseline, and (3) there was no relationship between 







1) How do the serum levels of lutein, zeaxanthin, and their metabolites vary over 
time in the subjects supplemented with 2.5, 5.0, and 10.0 mg/day of lutein 
containing 5% zeaxanthin? Which one of the three doses results in a significant 
increase in the serum levels of lutein? 
2)  Are there any differences in concentration of lutein, zeaxanthin, and their 
metabolites in the serum of subjects with and without AMD receiving the same 
dose of lutein containing 5 % of zeaxanthin? 
3) How does supplementation of lutein containing 5% of zeaxanthin affect the serum 
levels of other dietary carotenoids, vitamin A and the two forms of vitamin E (α- 
and γ- tocopherol)? 
4) Can supplementation with the 3 doses of lutein increase MPOD of subjects? If 
this happens to be the case, what is the most effective dose of lutein that can 







Selection of Human Subjects 
 
Forty-five subjects, male and female, aged 60 years and older participated in the 
study. Subjects not diagnosed with AMD were recruited by advertisement posted in the 
Newsletter of the National Institutes of Health (NIH) and the patients with AMD were 
recruited from the Retina Clinic at the National Eye Institute (NEI). The procedures and 
methods used in this study were reviewed and approved by the Institutional Review 
Board of the NEI and the University of Maryland, College Park. Written, informed 
consent was obtained from all participants. 
 
Source and Formulation of Lutein Containing 5% Zeaxanthin  
Lutein containing 5% of zeaxanthin were extracted from marigold flowers and 
formulated into water dispersable beadlets by Roche Vitamins. The beadlet formulation 
protects carotenoids from oxidation and degradation that may occur as a result of 
exposure to air, heat, and light. Beadlets were composed of lutein containing 5% of 
zeaxanthin, collagen, disaccharides, ascorbyl palmitate, natural vitamin E, and modified 
food starch. All of these ingredients are among the food additives approved by the Food 
and Drug Administration (FDA). 
 
Study Design 
The study was designed as a double-blinded randomized clinical trial involving 
45 subjects. The subjects were divided into 3 groups of 15 into the following categories: 
subjects with minimal or small drusen not diagnosed with AMD, subjects with large 
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drusen in one or both eyes (middle stage of AMD), and subjects with the end stage of 
AMD in one eye (geographic atrophic, retinal pigment epithelial detachment, 
neovascular/exudative AMD). Subjects in each group were randomized to receive one of 
the three doses of lutein, 2.5, 5, and 10 mg per day for 6 months and at the end of the 
supplementation period, the subjects were followed up for 6 months. The lowest dose 
given in the present study was based on the daily mean intake of lutein in the United 
States. The 5 and 10 mg/day dose were two and four times the daily intake, respectively. 
The lutein supplements consisted of 1 tablet that was taken once a day with a meal. Blood 
samples were collected at the beginning of the study (week 0) and at weeks 1, 4, 12, 26, 
38 and 52 to determine the serum concentrations of lutein, zeaxanthin, other dietary 
carotenoids, vitamins A and E, and cholesterol. Subjects were required fasting and not 
smoking 4 hours prior to blood drawing. Sera were then stored at –80oC until analysis. 













                                          Subjects 60 years and older: 

















Figure 11- Study Design of Lutein Supplementation and Blood Collection Intervals. 
 
During the first week of enrollment in the study, subjects underwent a series of 
ophthalmologic exams, these were: visual acuity, fundus photographs, and 
Heterochromatic Flicker Photometry for measurement of macular pigment optical density 
(MPOD). Heterochromatic Flicker Photometry is the most common noninvasive method 
to measure human MPOD. However, this is a subjective psychophysical method 
week 1 6 months 6 months 
Baseline Supplementation Follow-up 
Start              1        4             12                      26                      38                      52 
Blood collection (weeks) 
Lutein/5%Zeaxanthin: 
2.5 mg/0.13 mg (n=5) 
5.0 mg/0.25 mg (n=5) 
10 mg/0.50 mg (n=5) 
No AMD 
(n=15) 
Middle Stage of 
AMD 
End Stage of AMD 
(n=15) 
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involving color intensity matching of a light beam aimed at the fovea and another aimed 
at the parafoveal area. Subjects were required to complete a medical history 
questionnaire, including a detailed list of medications, cigarette smoking habits, alcohol 
consumption, and current intake of supplements. A modified Block Food Frequency 
Questionnaire was also administered at each visit for blood collection to assess for 
dietary intake of lutein (Appendix D); subjects were on a self-selected diet throughout the 
entire study. Heights and weights were also recorded and the subject’s body mass index 
were calculated using the following formula: weight (Kg) / height 2 (meters). At all visits 
that blood samples were collected (see Figure 11) the subjects had a complete 
ophthalmologic examination, visual acuity, fundus photographs, and a side effect 
questionnaire.  
The eligibility criteria for the study were: men and women aged 60 years or older, 
available for the duration of the study (one year), and classified in one of the three 
following categories: (1) without diagnosis of AMD, presence of minimal or small 
drusen; (2) for this study, middle-stage of AMD, refers to large drusen in one or both 
eyes; and (3) end-stage of AMD, geographic atrophic, retinal pigment epithelial 
detachment, neovascular/exudative AMD. Unfortunately, because of limited funding, no 
lutein treated groups (controls) were included in the design of the study. Subjects were 
excluded if they had ocular disease other than age-related macular degeneration, or were 
taking ocular medication; those who had been taking lutein supplements for up to three 
months prior to the start of the study; and those who presented abnormal liver function 
and had individual history of lung cancer.  
 
 45
Extraction of Carotenoids from Human Serum 
 Human serum was accurately measured by disposable syringe (latex free syringe, 
5 mL, VWR Scientific Products) and transferred into a centrifuge tube (Blue MaxTM 50 
mL, polypropylene conical tube). The serum was treated with ethanol (5 mL) to 
precipitate proteins. The carotenoids present in the serum were extracted by adding 
tetrahydrofuran (THF, 10 ml) containing 0.1% butylated hydroxytoluene (BHT) and the 
tube was then vortexed for 2 minutes. The tube was centrifuged at 2000 g for 5 minutes 
to separate the proteins (residue) and the supernatant. The extract was removed and the 
solid was re-extracted by adding 5 mL of THF (0.1% BHT) to the residue. The combined 
extracts were evaporated to complete dryness on an evaporator (RapidVap Vacuum, 
model 79000-02, LABCONCO Co., MO). The residue was dissolved in dichloromethane, 
sonicated, centrifuged, and filtered through a 0.45 µm disposable polyvinylidene fluoride 
filter (VWR, Scientific Products, NJ) into a 5 mL graduated micro-sample vial. The 
dichloromethane was evaporated under nitrogen (Nitrogen Evaporator, N-EVAPTM 112, 
Organomation Associates, Inc., MA) and 250 µL of solvent for HPLC normal phase was 
added to the residue. The vial was sonicated and centrifuged at 2000 g for 5 minutes. The 
resulting extract was then divided into half for analysis by normal phase and reversed 
phase HPLC. For normal phase analysis, an accurate volume of 120 µL was transferred 
to a chromatography vial and 50 µL was injected into the HPLC system. The remaining 
extract was stored at  –80oC in case a duplicate HPLC analysis was needed.  For reversed 
phase analysis, the extract (130 µL) was evaporated under nitrogen and an accurate 
volume of 130 µL of the reversed phase injection solvent was added in order to maintain 
the original concentration. 
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HPLC Systems for Analysis of Serum Carotenoids, Vitamin A, and Tocopherols 
 Extracts were analyzed by HPLC using normal-phase and reversed-phase 
separations according to a published procedure (Khachik et al., 1997). The analyses were 
performed on an HPLC System (model 1100; Agilent Technology, CA) equipped with a 
quaternary solvent delivery system (model G1311A), an autosampler (model G1313A), a 
thermostat-controlled column compartment (model G1316A), and a photodiode array 
detector (model G1315B).  
Normal phase HPLC separations were carried on a silica-based nitrile bonded 
column (25 cm length x 4.6 mm i.d.; 5-µm spherical particle; Regis Chemical Company, 
IL). The column was protected with a nitrile-bonded guard cartridge (3 cm length x 4.6 
mm i.d.; 5-µm spherical particle). The mobile phase consisted of an isocratic mixture of 
hexanes (75%), dichloromethane (25%), methanol (0.35%), and N,N-
diisopropylethylamine (DIPEA, 0.1%). The column flow rate was 0.7 ml/min, and the 
HPLC runs were simultaneously monitored at 325, 446, and 456 nm. 
Reversed phase HPLC separations were carried out on a C18-Microsorb column 
(25 cm length x 4.6 mm i.d.; 5-µm spherical particle; Rainin Instrument Co., MA). The 
column was protected with a Brownlee guard cartridge (3 cm length x 4.6 mm i.d.; 
packed with Spheri-5-C18, 5-µm spherical particle). A two pump system with a 
combination of isocratic and gradient HPLC was employed for separations. Pump A 
pumped a mixture of acetonitrile (90%) and methanol (10%); and pump B pumped a 
mixture of hexane (45%), methylene chloride (45%), methanol (10%), and N,N-
diisopropylethylamine (DIPEA, 0.1%). At time zero, an isocratic mixture of 95% pump 
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A and 5% pump B was pumped for 10 minutes. After 10 minutes, a linear gradient was 
run for 30 minutes resulting in a final composition of 45% of pump A and 55% of pump 
B, which consisted of acetonitrile (45%), dichloromethane (22.5%), hexane (22.5%), and 
methanol (10%). At the end of each run, the column was re-equilibrated under the 
original isocratic conditions for 20 minutes. The column flow rate was 0.7 ml/min, and 
the HPLC runs were simultaneously monitored at 470, 446, 400, 350, and 290 nm. 
All operations and HPLC analyses were conducted under yellow laboratory light 
to prevent photo-isomerization and degradation of carotenoids.  
 
Reproducibility and Accuracy of Extraction and HPLC Analysis  
The accuracy of extraction was monitored on a regular basis by extraction, 
identification, quantification of carotenoids in standardized Red Cross plasma. No 
internal standard in the extraction and analysis of various samples was employed because 
of the possibility that HPLC peak could interfere with the presence of possible unknown 
carotenoids. 
In order to monitor the reproducibility of the normal phase HPLC analysis of 
carotenoids, a solution containing known concentrations of (3R,3’R,6’R)-lutein, 
(3R,3’R)-zeaxanthin, and 3’-epilutein was routinely analyzed to evaluate the consistency 
of retention times and peak areas. Similarly, for the C18-reversed phase HPLC a 
standardized mixture of lycopene, α-carotene, β-carotene, α-cryptoxanthin, β-




Source and Purity of Carotenoid Standards 
 (3R,3’R,6’R)-lutein (85% pure) was isolated from a saponified extract of 
marigold flowers (Kemin Foods, IA) and was purified to greater than 98% by two 
consecutive crystallizations (Khachik et al., 1999). (3R,3’S,6’R)-lutein (3’-epilutein) was 
synthesized from (3R,3’R,6’R)-lutein according to published procedures (Liaaen-Jensen 
et al., 1966; Khachik et al., 1992). All-E-lycopene was synthetic samples from Hoffmann-
La Roche. Other carotenoids standards and their metabolites were prepared according to 
previously published methods (Khachick et al. 1992a, 1992b). Retinol, α-tocopherol, and 
γ-tocopherol were obtained from Sigma Chemical Co. (St. Louis, MO).  
Butylated hydroxytoluene (BHT) and N,N-diisopropylethylamine (DIPEA) were 
purchased from Aldrich Chemical Co. (Milwaukee, WI). THF, ethanol, and the HPLC-
grade solvents, hexane, dichloromethane, methanol, and acetonitrile (VWR Scientific 












ANALYSIS OF DATA 
 
Analysis of Serum Carotenoids by High Performance Liquid Chromatography (HPLC) 
 
Qualitative Analysis of Carotenoids in Human Serum  
To date, 34 carotenoids including 9 metabolites have been identified and 
quantified in human serum and breastmilk (Khachik et al., 1992a & 1997a). The analyses 
of human serum were conducted by high performance liquid chromatography (HPLC) 
employing a reversed-phase and a silica-based nitrile bonded column. A typical HPLC 
profile of an extract from human serum on a C18-reversed phase column is shown in 
Figure 12. In this HPLC profile, dihydroxycarotenoids such as lutein, zeaxanthin, and 
their geometrical isomers appear as several unresolved peaks, while 
monohydroxycarotenoids and hydrocarboncarotenoids are well separated. A typical 
HPLC profile of an extract from human serum on a silica based nitrile-bonded column 
(normal phase) is shown in Figure 13. This HPLC profile results in a complete separation 
of lutein and zeaxanthin (polar carotenoids), their Z-geometrical isomers, vitamins A and 
E, while failing to separate monohydroxycarotenoids and hydrocarboncarotenoids. 
Therefore, it is essential to employ both of these HPLC columns to separate all the 
carotenoids listed on Table 4.   
 The HPLC profiles were simultaneously monitored at 470, 446, 400, 350, and 290 
nm, to allow the detection of a wide range of carotenoids at their wavelength of 
absorption maxima. This also allowed the separation and quantification of retinol and 
tocopherols. For example, all-E-lutein, all-E-zeaxanthin, their metabolites (3’-epilutein, 
3’-hydroxy-ε,ε-caroten-3-one, ε,ε-carotene-3,3’-dione, 3-hydroxy-β,ε-caroten-3’-one and 
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(Z)-3-hydroxy-β,ε-caroten-3’-one) and their Z-geometric isomers (9Z-lutein, 9’Z-lutein, a 
mixture of 13Z-lutein and 13’Z-lutein, 9Z-zeaxanthin, and 13Z-zeaxanthin) were 
monitored at 446nm. Lycopene were monitored at 470 nm, and ξ-carotene at 400 nm. 
Meantime, retinol (λmax=325 nm) and phytofluene (λmax=350 nm) were detected at 350 
nm, and α-tocopherol (λmax=292 nm), γ-tocopherol (λmax=294 nm), and phytoene 
(λmax=286 nm) were monitored at 290 nm. 
The identification of carotenoids was achieved by comparison of their absorption 
spectra and their retention times with those of fully characterized standards as previously 
published (Khachik et al., 1992b & 1997a). A total of 25 serum carotenoids and these 
carotenoids and their wavelength of their absorption maxima are shown in Table 4. 
  
             Figure 12- Typical HPLC Profile of Dietary Carotenoids, Retinol, α-Tocopherol, 
                               and γ–Tocopherol, of an Extract from Human Serum on a  















        
   Figure 13- Typical HPLC Profile of Lutein, Zeaxanthin, their Z-geometrical 
                     isomers, and their Metabolites of an Extract from Human Serum  











Table 4- Human Serum Carotenoids and their Wavelength of Absorption Maxima  
              Obtained by Photodiode Array Detection in Normal Phase and Reversed Phase 
              HPLC Eluents  
Serum Carotenoids Absorption maxima (nm)a 
                                                      Normal Phase 
Eluentsb 
 
Carotenoid Metabolites  
ε,ε-carotene-3,3’-dione 420, 442, 472 
3’-hydroxy-ε,ε-caroten-3-one 422, 442, 472 
2,6-cyclolycopene-1,5-diol I 434, 458, 492 
3-hydroxy-β,ε-3’caroten-one (3’-oxolutein)           (424), 448, 476 
(3S,6S,3’S,6’S)-ε,ε-carotene-3,3’-diol (lactucaxanthin)             416, 442, 470 
(all-E,3R,3’S,6’R)-lutein or (3’-epilutein)            (424), 448, 476 
  
Dihydroxycarotenoids  
(all-E,3R,3’R,6’R)-lutein           (428), 454, 482 
(all-E,3R,3’R)-zeaxanthin           (424), 448, 476 
(9Z,3R,3’R,6’R)-lutein   334, (420), 442, 470 
(9’Z,3R,3’R,6’R)-lutein   332, (420), 444, 472 
(13Z,3R,3’R,6’R)-lutein + (13’Z,3R,3’R,6’R)-lutein   334, (418), 440, 468 
(9Z,3R,3’R)-zeaxanthin   340, (424), 450, 474 
(13Z,3R,3’R)-zeaxanthin   338, (419), 446, 472 
                                                     Reversed Phase Eluents  
  
Monohydroxycarotenoids  
β,ε-caroten-3-ol (α-cryptoxanthin)           (424), 446, 476 
3-hydroxy-β-carotene (β-cryptoxanthin)           (428), 454, 480 
  
Hydrocarbon carotenoids  
ψ,ψ-carotene (lycopene)              446, 474, 502 
7,8,7’,8’-tetrahydro-ψ,ψ-carotene (ζ-carotene) 378, 400-402, 426 
β,ε-carotene (α-carotene) (428), 446-448, 474 
(all-E)-β, β-carotene [(all-E)- β-carotene]            (430), 454, 478 
(all-E) or (Z)-7,8,11,12,7’,8’-hexahydro-ψ,ψ-carotene 
[(all-E) or (Z)-phytofluene] 
              334, 350, 368 
7,8,11,12,7’,8’,11’,12’-octahydro-ψ,ψ-carotene 
(phytoene) 
            (276), 286, (295) 
aValues in parentheses represent points of inflection.  








Quantitative Analysis of Carotenoids in Human Serum  
The carotenoids in the extracts of serum were quantified from the HPLC response 
factors at five or six different concentrations employing reversed phase and normal phase 
HPLC. The relative standard deviations for the calibration curves (i.e., area response at 
various concentrations) for the reference samples of carotenoids, tocopherols, and retinol 
were less than 5%. The HPLC peak area of Z-geometrical isomer/s of lycopene was 
combined with all-E-lycopene. Therefore, it has been assumed that the response factors 
of the Z-geometrical isomer/s of lycopene and phytofluene are reasonably close to that of 
all-E-lycopene.  
Using this approach, all carotenoids, retinol, α-tocopherol, and γ-tocopherol were 
quantified from the serum of the subjects collected at various intervals throughout the 
study. The results are shown in Appendices H to BB. A summary table containing only 
the serum concentrations of lutein and zeaxanthin at every blood collection are shown in 
the Appendices F and G, respectively. The quantitative data obtained in this step were 




Data were analyzed using mixed model techniques of SAS, version 8.2 (SAS 
Institute Inc, Cary, NC). Means and standard error of the means were determined for 
demographic (age, ethnicity, gender), anthropometric (body mass index) and clinical 
(cholesterol) data at the baseline for each stage disease group. The percentage of smokers 
and alcohol consumption at baseline for each stage group were also calculated as well as 
the means and standard error of the means for dietary lutein intake. The least significant 
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difference (LSD) protected test was used to determine which groups were significantly 
different from one another. A p value less than 0.05 was considered statistically 
significant.  
These data were analyzed by two-way Analysis of Variance and Covariance 
(ANCOVA) with repeated measurements to determine the differences in the serum lutein 
and zeaxanthin concentrations among the three AMD disease stage groups. The model 
included the fixed effects of treatment (treatment 1= 2.5 mg/day of lutein and 0.13 
mg/day of zeaxanthin; treatment 2= 5.0 mg/day of lutein and 0.25 mg/day of zeaxanthin; 
treatment 3= 10 mg/day of lutein and 0.5 mg/day of zeaxanthin), stage of disease (no 
AMD, middle stage AMD and end stage AMD), and the time of repeated measures (0, 1, 
4, 12, 26, 38 and 52 weeks). The effects of age, BMI, and gender were also modeled as 
fixed effects while subject variation among disease group and the residual variation were 
modeled as random effects. Goodness of fit statistics were used to select an appropriate 
variance-covariance structure for the repeated measures. After selecting the variance-
covariance structure, non-significant higher sources of variation were removed one at a 
time from the initial full model until the model contains only the variables and covariates 
as well as their significant interactions. For all the analyses a p value less than 0.05 was 
considered statistically significant.  
 
Determination of Sample Size 
 
The variance approximation for the estimation of sample size was obtained from 
the literature of lutein supplementation studies, which tested a similar hypothesis and 
used lutein as the dependent variable. Landrum et al. 1997, observed an increase of 
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approximately 0.7-0.9 µg/mL (1.2-1.58 µmol/L) after 140 days of supplementation with a 
dose equivalent to 30 mg. In an additional experiment, 18 normal volunteers had a mean 
baseline serum lutein concentration was 0.14 µg/mL with a standard deviation of 0.07 
µg/mL which changed by an average of 0.15 µg/mL with a standard deviation of 0.08 
µg/mL after supplementation with tablets of 2.4 mg of lutein per day (Bone et al. 2003). 
In the presence of a significant interaction between dose and disease, 9 pairwise 
comparisons (n=5), 3 in each disease stage group, would be made in order to assess the 
differences between the dose groups within the treatment groups. If the interaction were 
not significant, a total of 3 pairwise comparisons (n=15) would be made to assess the 
differences between the dose groups across the disease stage groups. The level of 
significance was defined as 0.05. Table 5 lists the power to detect pairwise differences 
between two dose groups for several true differences in lutein levels based on the 
increases observed in the literature. 
 
Table 5- Potential true differences in post-treatment serum lutein concentrations and the 
              associated power to detect them in pairwise comparisons between dose groups  




0.15 5 74% 
0.20 5 96% 
>0.30 5 ~100% 
0.10 15 94% 








 Forty-five subjects, 33 females and 12 males, aged 60 years and older were 
recruited to participate in this study and forty-four completed this one year study. The 
subject who dropped out of the study belonged to the group with end stage of AMD and 
participated in the study for only three months. None of the subjects showed any side 
effect throughout the entire study. For the purpose of statistical analysis, means and 
standard error of the means were determined for dietary lutein intake, demographic (age, 
ethnicity, gender), anthropometric (body mass index), and clinical (cholesterol) data. The 
least significant difference (LSD) test was used to determine which groups were 
significantly different from one another. Data with p values equal or less than 0.05 were 
considered statistically significant.  
 
Demographic and Clinical Profile 
 
The demographic variables at baseline for all subjects without AMD as well as 
those with middle stage, and end stage of AMD are shown in Table 6. The majority of the 
subjects in this study were Caucasian; there were only three Asians without AMD and 
two African Americans with end stage of AMD.  
There were significant differences in the mean ages of the subjects in the three 
groups. Subjects with end stage of AMD were significantly older (79.2 ± 0.74) than 
subjects with middle stage of AMD (70.1 ± 0.73) and those without AMD (64.1 ± 0.43). 
The demographic information for all subjects is listed in Appendix A. 
The frequency of alcohol consumption among the subjects was relatively low. 11 
subjects without AMD, 14 subjects with middle stage of AMD, and 10 subjects with end 
stage of AMD, reported occasional alcohol consumption. Only one subject without AMD 
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and one with end stage of AMD consumed alcohol on a daily basis. Although half of the 
subjects in each category were previous smokers, only 1 subject without AMD and 4 
subjects with end stage of AMD smoked during the study. None of the subjects with 
middle stage of AMD were current smokers. The alcohol consumption and smoking 




Table 6- Baseline Demographic Characteristics for Subjects without Age-related 
              Macular Degeneration (AMD), with Middle Stage and End Stage of AMD1,2,3 









64.1 ± 0.43 a 70.1 ± 0.73 b 79.2 ± 0.74 c 
BMI (Kg/m2) 26.0 ± 0.41 b 
(20.6 – 31.3) 
27.3 ± 0.44 a 
(22.6 – 40.9) 
25.7 ± 0.32 b 
(20.0 – 33.9) 
Ethnicity  
              Caucasian 
              Asian 
              African American 
 
12 









  2 
Gender  
              Female 
              Male 
 
10 
  5 
 
12 
  3 
 
11 
  4 
Smokers  
              Former 









  4 
Alcohol Consumption  
              Never 
              Occasionally 
              Daily 
 
  3 
11 
  1 
 






  1 
  1  Mean ± SEM (Min-Max). 
  2 Within a row, means followed with identical superscripts are not significantly  
     different with means comparisons by LSD at 5% level of significance. 






The anthropometric data, height, weight and body mass index (BMI) that were 
taken at baseline for all subjects are also listed in the Appendix B. Subjects with middle 
stage of AMD had significantly higher BMI (27.3 ± 0.44) in comparison with subjects 
without AMD (26.0 ± 0.41) and those with end stage of AMD (25.7 ± 0.32) at 5% level 
of significance. The mean BMI values of subjects with the end stage of AMD were not 
significantly different from the subjects without AMD. 
The total serum cholesterol levels (mg/dL) that were measured for subjects during 
all visits are shown in Appendix C. Subjects with the middle stage of AMD presented a 
significantly higher level of total serum cholesterol in comparison with subjects without 
AMD (p=0.0419) and those with the end stage of AMD (<0.0001) (Figue 14). There were 
no significant differences (p>0.05) in the mean values of total serum cholesterol among 



























Figure 14- Mean Values (n=15) for Total Serum Cholesterol (mg/dL) in Subjects without 
                 AMD, with Middle Stage, and with End Stage of AMD Throughout the Study. 
                 Bars with Different Letters are Significantly Different at 5% Level of  





Dietary Intake of Lutein 
 
 Mean values for dietary intakes of lutein throughout the entire study are shown in 
Figure 15. Subjects with the middle stage of AMD had the highest dietary intake of lutein 
(3.1 ± 0.19 mg/day) in comparison with subjects without AMD (2.2 ± 0.19 mg/day) as 
well as those with the end stage of AMD (2.4 ± 0.19 mg/day). There were no significant 
differences in dietary intake of lutein between subjects without AMD and subjects with 
the end stage of AMD (p=0.3701).  
The dietary intake of lutein was also significantly different among subjects 
receiving different treatments. Subjects on 2.5 mg/day of lutein supplements showed a 
significantly lower dietary intake of lutein (1.9 ± 0.18 mg/day) in comparison with 
subjects on 5 mg/day dose (3.0 ± 0.18 mg/day) and those on 10 mg/day dose (2.9 ± 0.18 
mg/day). The dietary intakes of lutein were assessed at each visit for blood collection and 


























































Figure 15- Mean Values (n=15) for Dietary Intake of Lutein (mg/day) for Subjects 
                  Throughout the Study. Panel A: Intake of Subjects without AMD, with 
                  Middle Stage, and End Stage of AMD. Panel B:  Intake of Lutein Treated 
                  Groups. In both Panels Bars with Different Letters are Significantly Different 
                  at 5% Level of Significance. The Data has been Corrected for Differences in 















Serum Concentrations of Lutein in Subjects Supplemented with Lutein Containing 5% 
Zeaxanthin  
 
The heterogeneous compound symmetry structure presented a better fit based on 
the goodness of fit statistics and was chosen as the variance-covariance structure. Only 
two covariates were significant in the final model, total serum cholesterol (p=0.0024) and 
dietary intake of lutein (p=0.0039). The mean serum concentrations of lutein were 
significantly different among treatments (p=0.0086) and at different weeks (p<0.0001); 
however these values were not significantly different (p=0.6017) among the three groups 
(no AMD, middle stage, and end stage of AMD). Based on these results, the mean serum 
concentrations (nmol/L) of lutein for subjects receiving the three different doses of lutein 
regardless of the presence or absence of AMD were combined and are shown in Figure 
16. The serum concentrations of lutein and its Z-isomers for subjects at each blood 
collection interval are listed in Appendices H through N. A summary table with serum 



































treatment 1 treatment 2 treatment 3
 
Figure 16- Mean (± SEM; n=15) Serum Lutein Concentration (nmol/L serum) Time 
                  Curves For Subjects Supplemented Daily with 2.5 mg of Lutein and 0.13 mg 
                  of Zeaxanthin (treatment 1), 5.0 mg of Lutein and 0.25 mg of Zeaxanthin 




Repeated measures analysis demonstrated that the mean serum lutein levels of 
the subjects were significantly different (p=0.0031) by treatment and week. Since the 
mean serum lutein concentrations of the three groups (no AMD, middle stage, and end 
stage of AMD) were not significantly different (p=0.6017), only the treatment and week 
effects were considered for the least significant difference test (LSD) (Table 7). By 
combining the subjects of the three groups, the number of replications was increased 





 Table 7– Mean Serum Concentrations (nmol/L) of Lutein for All Subjects on Different 
                Treatments Throughout the Study 1,2,3 
Lutein (nmol/L) Weeks 
Treatments 
            1                              2                            3 
          0 (baseline) 280 ± 34 xc 210 ± 34xb 210 ± 34xc 
          1 (baseline) 260 ± 31xc 190 ± 31xb 220 ± 31xc 
          4 (supplementation) 450 ± 86xa,b 490 ± 86xa 810 ± 86ya 
        12 (supplementation) 550 ± 94xa 560 ± 94xa 920 ± 94ya 
        26 (supplementation) 500 ± 110xa,b,c 720 ± 108x,ya 1000 ± 111ya 
        38 (follow-up) 300 ± 47xb,c 290 ± 46xb 330 ± 48xb 
        52 (follow-up) 290 ± 33xb,c 250 ± 32xb 260 ± 33xb,c 
  1 Mean (n=15) ± SEM. 
  2 Within a column, means followed with identical superscript letters (a,b,c) are not 
    significantly different by week as determined by repeated measures analysis of 
    variance with means comparisons by LSD at 5% level of significance.  
  3 Within a row, means followed with identical subscript letters (x,y) are not significantly 
     different by treatment as determined by repeated measures analysis of variance with 




As shown in Table 7, after three weeks of supplementation (week 4), all 
subjects showed a significantly higher serum concentration of lutein in comparison with 
the presupplementation period (baseline: weeks 0 and 1). In addition, subjects who were 
supplemented with 10 mg of lutein/day showed a significantly higher serum 
concentration of lutein (920 ± 94 nmol/L) in comparison with subjects who were on 5 
mg/day (560 ± 94 nmol/L) and 2.5 mg/day (550 ± 94 nmol/L) of this carotenoid after 11 
weeks of supplementation (week 12).  
Serum concentrations of lutein increased after 3 weeks of supplementation (week 
4) and continued to escalate during the supplementation period until the end of week 26; 
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however, during this period the values were not significantly different. At this time point 
(week 26), lutein serum levels of subjects on 10 mg/day dose (1000 ± 111 nmol/L) were 
not significantly different from subjects who were on 5.0 mg/day (720 ± 108 nmol/L); 
however, the mean serum concentrations of lutein in subjects on 10 mg/day doses were 
higher than those who were on 2.5 mg/day dose (500 ± 110 nmol/L). The mean serum 
concentrations of lutein in all 45 subjects between weeks 4 and 26 (end of 
supplementation period) were not significantly different; therefore, a range of plateau for 
lutein was achieved between 3 to 25 weeks of supplementation (weeks 4 and 26, 
respectively). During the follow up period serum concentrations of lutein declined to 
approximately 300 nmol/L for all 45 subjects. There were no significant differences 
among all subjects at 5% level of significance. 
 
Serum Concentrations of Zeaxanthin in Subjects Supplemented with Lutein Containing 
5% Zeaxanthin  
 
In the lutein supplements provided by Roche Vitamins for the present study 5% 
was zeaxanthin. Therefore, in this supplementation study with lutein, subjects also 
received a small dose of zeaxanthin. For example, subjects who received treatment 1 (2.5 
mg of lutein/day) also received 0.13 mg/day of zeaxanthin. Similarly, subjects who were 
on treatment 2 (5.0 mg of lutein/day) and on treatment 3 (10 mg of lutein/day) received 
0.25 and 0.50 mg/day of zeaxanthin, respectively. 
The serum concentrations of zeaxanthin were the dependent variable in the 
repeated measures analysis and the heterogeneous compound symmetry structure was 
chosen as the variance-covariance structure. The mean serum concentrations (nmol/L) of 
zeaxanthin for subjects without AMD, and those with the middle stage, and the end stage 
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of AMD for the duration of the entire study are shown in the Figures, 17, 18, and 19, 
respectively. The serum concentrations of zeaxanthin and its Z-isomers for subjects at 
each blood collection interval are listed in Appendices H through N. A summary table 






















treatment 1 treatment 2 treatment 3
 
 
Figure 17- Mean (± SEM; n=5) Serum Zeaxanthin Concentrations (nmol/L serum) Time 
                  Curves For Subjects without AMD Supplemented Daily with 2.5 mg of Lutein 
                  and 0.13 mg of Zeaxanthin (treatment 1), 5.0 mg of Lutein and 0.25 mg of  
                  Zeaxanthin (treatment 2), and 10 mg of Lutein and 0.5 mg of Zeaxanthin  


























treatment 1 treatment 2 treatment 3
 
Figure 18- Mean (± SEM; n=5) Serum Zeaxanthin Concentrations (nmol/L serum) Time 
                 Curves For Subjects with the Middle Stage of AMD Supplemented Daily with 
                 2.5 mg of Lutein and 0.13 mg of Zeaxanthin (treatment 1), 5.0 mg of Lutein 
                 and 0.25 mg of Zeaxanthin (treatment 2), and 10 mg of Lutein and 0.5 mg of  






















treatment 1 treatment 2 treatment 3
 
Figure 19- Mean (± SEM; n=5) Serum Zeaxanthin Concentrations (nmol/L serum) Time 
                 Curves For Subjects with the End Stage of AMD Supplemented Daily with 2.5 
                  mg of Lutein and 0.13 mg of Zeaxanthin (treatment 1), 5.0 mg of Lutein and 
                  0.25 mg of Zeaxanthin (treatment 2), and 10 mg of Lutein and 0.5 mg of 
                  Zeaxanthin (treatment 3). 
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The serum concentration of zeaxanthin in the subjects indicated that there is a 
significant interaction (p=0.0414) between treatment (0.13, 0.25, and 0.50 mg/day of 
zeaxanthin) and group (no AMD, middle stage, and end stage of AMD) effect. 
Consequently, the least significant difference test (LSD) was performed for these means 
and the results are shown in Table 8. The serum concentrations of zeaxanthin for all 45 
subjects were significantly different by week (p<.0001) and revealed a marginal non-
significant interaction among treatment, group and week (p=0.0508). The 
supplementation of 0.13 mg/day of zeaxanthin (treatment 1) did not increase the mean 
serum concentration of zeaxanthin in subjects with the middle stage and the end stage of 
AMD, while it had a significant increase (79%) in the mean serum levels of subjects 
without AMD. Even at the dose of 0.25 mg/day of zeaxanthin, only a modest increase in 
the serum levels of zeaxanthin in subjects with the middle stage of AMD was noticeable. 
For subjects with the end stage and those without AMD a significant increase in the mean 
serum levels of zeaxanthin was only observed after 25 weeks of supplementation (week 
26). Only the supplementation of subjects without AMD and end stage of AMD with 0.50 
mg/day of zeaxanthin (treatment 3) resulted in a significant increase in the mean serum 
concentration of this carotenoid after 3 weeks of treatment (week 4). Subjects with 
middle stage of AMD showed a significant increase in their serum levels of lutein after 
11 weeks of supplementation (week 12). 
In addition, the mean serum concentration of zeaxanthin in all 45 subjects was not 
accompanied by a significant interaction between treatment and week (p=0.1625); this 
trend was not observed with the mean serum concentrations of lutein in all subjects. 
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Other significant covariates were: total serum cholesterol (p<.0001), ethnicity 
(p=0.0021), and smoking status by group interaction (p=0.0070). 
 
 Table 8- Mean Serum Concentrations (nmol/L) of Zeaxanthin in Subjects without AMD, 
               Middle Stage, and End Stage of AMD on Different Treatments1,2,3 
Zeaxanthin (nmol/L) Groups 
Treatments 
            1                             2                            3 
No AMD 90 ± 10ya 50 ± 10xb 80 ± 11ya 
Middle Stage of AMD 70 ± 11xa 70 ± 11xa,b 60 ± 11xa 
End Stage of AMD 70 ± 11xa 80 ± 10xa 90 ± 12xa 
   1 Mean (n=5) ± SEM. Treatment 1 = 0.13 mg/day of Zeaxanthin; Treatment 2 = 0.25 
     mg/day of Zeaxanthin; and Treatment 3 = 0.50 mg/day of Zeaxanthin. 
   2 Within a column, means followed with identical superscript letters are not significantly 
     different by week as determined by repeated measures analysis of variance with 
     means comparisons by LSD at 5% level of significance.  
  3 Within a row, means followed with identical subscript letters are not significantly 
     different by treatment as determined by repeated measures analysis of variance with 
     means comparisons by LSD at 5% level of significance. 
 
  
 The mean serum concentrations of zeaxanthin in subjects without AMD were 
different among the three treatments (0.13, 0.25, and 0.50 mg/day of zeaxanthin). 
Subjects who received treatment 2 (0.25 mg/day) showed significantly lower serum 
concentrations of zeaxanthin in comparison with those who received treatments 1 (0.13 
mg/day) and 3 (0.50 mg/day). In addition, subjects on treatment 2 with end stage of AMD 
revealed significantly higher serum concentrations of zeaxanthin in comparison with 





Serum Concentrations of Lutein and Zeaxanthin Metabolites in Subjects Supplemented 
with Lutein Containing 5% Zeaxanthin  
 
 The mean serum concentration (nmol/L serum) of the following oxidation 
products of lutein and zeaxanthin were measured: 3-hydroxy-β,ε-caroten-3’-one (3’-
oxolutein), 3’-hydroxy-ε,ε-caroten-3-one and ε,ε-caroten-3,3'-dione. Among the fixed 
effects, the serum levels of all three oxidation products were significantly different by 
week (p<.0001). Therefore, the mean serum concentration time curve of 3’-oxolutein, 3’-
hydroxy-ε,ε-caroten-3-one and ε,ε-caroten-3,3'-dione for all subjects regardless of their 
lutein treatment or group (no AMD, middle stage, and end stage of AMD) are shown in 
Figure 20. The serum concentrations of lutein and/or zeaxanthin metabolites for subjects 
throughout the study are shown in Appendices O through U. 
The mean serum concentration time curve of 3’-oxolutein and 3’-hydroxy-ε,ε-
caroten-3-one in all subjects followed a similar pattern, where values of 3’-hydroxy-ε,ε-
caroten-3-one were found to be lower than that of 3’-oxolutein.  The mean serum 
concentration of 3’-oxolutein and 3’-hydroxy-ε,ε-caroten-3-one at baseline were 49 ± 3.5 
and 31 ± 2.9 nmol/L, respectively. After 3 weeks of supplementation with lutein 
containing 5 % of zeaxanthin the mean serum levels of 3’-oxolutein and 3’-hydroxy-ε,ε-
caroten-3-one in all subjects increased from a baseline value of  49 ± 3.5 and 31 ± 2.9 
nmol/L to 78 ± 6.0 and 59 ± 5.1 nmol/L, respectively. The highest mean serum levels for 
3’-oxolutein (97 ± 7 nmol/L) and 3’-hydroxy-ε,ε-caroten-3-one (79 ± 7.3 nmol/L) in the 
serum of all 45 subjects were achieved after 25 weeks of supplementation with lutein 
containing 5% of zeaxanthin. Three months post-supplementation the mean serum levels 
of these oxidation products returned to baseline values. 
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The mean serum at baseline level of ε,ε-caroten-3,3'-dione was originally low in 
all subjects and was measured to be 2.4 ± 5 nmol/L. The mean serum level of this 
metabolite increased to 18 ± 6 nmol/L and 23 ± 9 nmol/L after 3 and 25 weeks of 
supplementation, respectively; however, these increases were not significantly different. 
One of the data points obtained for the mean serum concentration of ε,ε-caroten-3,3'-
dione in all 45 subjects on week 12 was found to be 14 ± 6 nmol/L and did not fall in the 
range described above (see Figure 21). Similar to the other two oxidation products, the 
mean serum level of ε,ε-caroten-3,3'-dione returned to baseline 3 months post-
supplementation. 
The mean serum concentrations of 3’-oxolutein for all 45 subjects were also 
significantly different in relation to the covariates: total serum cholesterol (p=0.0003), 
and dietary intake of lutein (p=0.0469). In addition, the mean serum concentration of 3’-
hydroxy-ε,ε-caroten-3-one in all subjects was significantly different when examined by 
the effect of their blood cholesterol (p=0.0230). Meantime, the mean serum concentration 
of ε,ε-caroten-3,3'-dione in the subjects were shown to be significantly different by the 
























3'-oxolutein 3’-Hydroxy-e,e-Caroten-3-one e,e-Caroten-3,3'-dione 
 
 
Figure 20- Mean (± SEM; n=45) Serum Concentration (nmol/L serum) Time Curves of  
                  3’-Oxolutein [3-Hydroxy-β,ε-Caroten-3’-one], 3’-Hydroxy-ε,ε-Caroten-3- 
                  one, and ε,ε-Caroten-3,3'-dione for all Subjects.  
 
 
 The mean serum concentrations of 3’-epilutein, a metabolite of lutein and/or 
zeaxanthin, were significantly different in the three groups (no AMD, middle stage and 
end stage of AMD). As shown in Figure 21, after 3 weeks of supplementation with lutein, 
subjects without AMD revealed a significantly higher (p=0.0017) mean serum level of 
3’-epilutein (34 ± 2.8 µmol/L) in comparison with those with the middle stage of AMD 
(19 ± 3.4 µmol/L). The mean serum concentration of 3’-epilutein in subjects with the end 
stage of AMD was lower (27 ± 3.1 µmol/L) than those subjects without AMD; however, 
the values were not significantly different (p=0.1243). The mean serum concentrations of 
3’-epilutein in all 45 subjects were also significantly different by week (p=0.0235), total 
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Figure 21- Mean (± SEM; n=15) Serum Concentration (nmol/L serum) Time Curves of  
                  3’-Epilutein in Subjects without AMD, with the Middle Stage, and the End 




Serum Concentrations of Other Carotenoids in Subjects Supplemented with Lutein 
Containing 5% Zeaxanthin  
 
 Other dietary carotenoids besides lutein and zeaxanthin were also identified and 
quantified in the serum of the subjects, these were: α-carotene, β-carotene, α-
cryptoxanthin, β-cryptoxanthin, lycopene and its metabolites 2,6-cyclolycopene-1,5 diols 
I and II (cyclolycopenes), phytofluene, and phytoene. The results from statistical analysis 
of the mean serum concentration of these carotenoids indicated no interaction with 
supplemental lutein for all subjects at all dose levels. The serum concentrations of other 
dietary carotenoids throughout the study are shown in Appendices V through BB. 
The mean serum concentrations of α-carotene, β-carotene, lycopene, and 
cyclolycopenes in subjects on different lutein treatments were found to be significantly 
different. The concentrations of these carotenoids in subjects who received 2.5 mg/day of 
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lutein (treatment 1) were significantly higher in comparison with those who were on the 
other two treatments throughout the entire study. For example, the mean serum 
concentration of lycopene was significantly higher (p=0.0063) in subjects on treatment 1 
(170 ± 14 nmol/L) in comparison with subjects on treatment 3 (140 ± 16 nmol/L). 
However, the mean serum levels of lycopene in subjects on treatment 3 were not 
significantly different from those who were on treatment 2 (158 ± 13 nmol/L, p= 0.3998). 
Similar results were obtained with regard to the mean serum concentrations of α-carotene 
values and β-carotene values, which were shown to be significantly higher in subjects on 
treatment 1 who had mean serum concentrations of (37 ± 4.03 nmol/L, and 160 ± 15 
nmol/L, respectively) in compare to those on treatment 2 (17 ± 4.5 nmol/L, and 70 ± 15 
nmol/L, respectively). These data are summarized in Table 9. 
 
     Table 9- Mean Serum Concentrations (nmol/L) of α-carotene, β-carotene, and 
                   Lycopene, in Subjects on Different Treatments1,2 
Carotenoids (nmol/L) Treatments 
α-carotene β-carotene Lycopene 
1 37 ± 4.0a 160 ± 15a 170 ± 14a 
2 17 ± 4.5b 70 ± 15c 158 ± 13a,b 
3 24 ± 4.1b 110 ± 15b 140 ± 16b 
      1  Mean (n=15) ± SEM.  
      2 Within a column, means followed with identical superscripts are not significantly  
       different as determined by repeated measures analysis of variance with means 
       comparisons by LSD at 5% level of significance. 
 
 
The statistical analysis revealed that the mean serum concentrations of 
cyclolycopenes (lycopene metabolites) were significantly different in subjects by 
treatments throughout the study (see Table 10). The mean serum concentrations of 
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cyclolycopenes in all subjects were not significantly different in the first 3 weeks of 
supplementation. The subjects on treatment 1 had significantly higher mean serum 
concentration of cyclolycopenes than those on treatments 2 and 3 between weeks 12 and 
38 in comparison to baseline. There were no significant differences in the mean serum 
concentration of cyclolycopenes for subjects on treatments 2 and 3 with the exception of 
one data point that was obtained for subjects on treatment 3 at week 38. 
 
 Table 10– Mean Serum Concentrations (nmol/L) of Cyclolycopenes for Subjects on 
                Different Treatments Throughout the Study 1,2,3 
Cyclolycopenes (nmol/L) Weeks 
Treatments 
             1                              2                          3 
          0 (baseline) 61 ± 6.7 xa,b,c 53 ± 7.0xa 44 ± 7.0xb 
          1 (baseline) 51 ± 6.7xc 43 ± 7.0xa 45 ± 7.0xb 
          4 (supplementation) 53 ± 6.8xb,c 43 ± 7.1xa 44 ± 7.0xb 
        12 (supplementation) 64 ± 6.7xa,b 39 ± 7.1ya 33 ± 7.0yb 
        26 (supplementation) 71 ± 6.8xa 46 ± 7.1ya 45 ± 7.3yb 
        38 (follow-up) 73 ± 6.7xa 45 ± 7.0ya 69 ± 7.1xa 
        52 (follow-up) 63 ± 6.7xa,b,c 39 ± 7.0ya 44 ± 7.2x,yb 
  1 Mean (n=15) ± SEM. 
  2 Within a column, means followed with identical superscript letters are not significantly 
     different by week as determined by repeated measures analysis of variance with 
     means comparisons by LSD at 5% level of significance.  
  3 Within a row, means followed with identical subscript letters are not significantly 
     different by treatment as determined by repeated measures analysis of variance with 
     means comparisons by LSD at 5% level of significance. 
 
 
 The serum concentrations of α-carotene and β-carotene in the subjects were 
significantly different by gender. The serum concentration of α-carotene and β-carotene 
in females (α-carotene: 23 ± 2.8 nmol/L; β-carotene: 81 ± 8.5 nmol/L) were significantly 
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lower than those measured in males (α-carotene: 30 ± 3.0 nmol/L; β-carotene: 140 ± 14.8 
nmol/L). Only the serum values of α-carotene and β-carotene in males showed 
interaction with lutein treatments. Males on treatment 1 showed significantly greater 
serum values of α-carotene (49 ± 5.3 nmol/L) and β-carotene (240 ± 25 nmol/L) in 
comparison with males on treatment 2 (α-carotene: 16 ± 5.5 and β-carotene: 62 ± 24 
nmol/L) and treatment 3 (α-carotene: 25 ± 5.2 and β-carotene: 130 ± 26 nmol/L). 
Although the present study revealed no interactions between supplemental lutein and 
other carotenoids, several interesting differences among serum levels of other dietary 
carotenoids were noteable. 
Males in the three groups (no AMD, middle stage, and end stage of AMD) also 
showed interactions for α-carotene, β-carotene, lycopene, and cyclolycopenes; these data 
are listed in Table 11. Significant differences were found in the mean serum levels of α-
carotene, lycopene, and cyclolycopenes between males with the end stage of AMD in 
comparison with males without AMD who had a higher mean serum level of the fore-
mentioned carotenoids. β-Carotene was found to be higher in the serum of males with 
middle stage of AMD in comparison with males in the other two groups.  
Females without AMD, middle stage, and end stage of AMD showed a significant 
difference in their mean serum levels of α-carotene. Females with the end stage of AMD 
were found to have significantly higher serum concentrations of α-carotene (29 ± 5.2 
nmol/L) than females with the middle stage of AMD (14 ± 3.8 nmol/L). The mean serum 
concentrations of α-carotene in females without AMD were not significantly different in 
comparison with females with the end stage of AMD. 
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Table 11- Mean Serum Concentrations (nmol/L) of α-carotene, β-carotene, Lycopene, 
                and Cyclolycopenes in Male Subjects in the Three Groups (No AMD, 
                Middle Stage, and End Stage of AMD)1,2  
Carotenoids (nmol/L) Groups 
 α-carotene      β-carotene        Lycopene        Cyclolycopenes   
No AMD 39 ± 5.7a 100 ± 24b 200 ± 20a 75 ± 8.8a 
Middle Stage 32 ± 5.8a,b 220 ± 29a 140 ± 22b 70 ± 10.9a,b 
End Stage 17 ± 5.3b 110 ± 24b 140 ± 19b 47 ± 9.7b 
   1  Mean (n=15) ± SEM. 
   2 Within a column, means followed with identical superscripts are not significantly  
     different as determined by repeated measures analysis of variance with means 
     comparisons by LSD at 5% level of significance. 
 
 
 In this study, former smokers revealed significantly lower mean serum levels of 
β-carotene and lycopene in comparison with non-smokers. The mean serum 
concentrations of β-carotene and lycopene for all 45 subjects in relation to their smoking 
status are shown in Table 12. 
 
 Table 12- Mean Serum Concentrations (nmol/L) of β-carotene and Lycopene in Subjects 
                  in Relation to their Smoking Status 1,2 
Carotenoids (nmol/L) Former Smoker 
                β-carotene                         Lycopene 
No (n=19) 130 ± 13a 170  ± 16a 
Yes (n=26) 96 ± 9.8b 140 ± 12b 
  1  Mean ± SEM. 
  2 Within a column, means followed with identical superscripts are not significantly  
    different as determined by repeated measures analysis of variance with means 










Serum Concentrations of Retinol, α-Tocopherol, and γ-Tocopherol in Subjects 
Supplemented with Lutein Containing 5% Zeaxanthin  
 
 Several changes occurred in the mean serum levels of α-tocopherol and γ-
tocopherol throughout the present study. The mean serum concentrations of α-tocopherol 
in all subjects were significantly different by week (p=0.0001), while the mean serum 
concentrations of γ-tocopherol were significantly different by week and treatment 
interaction (p=0.0165). There were no significant changes in the serum levels of retinol in 
all subjects throughout the entire study. The serum concentrations of retinol, α-
tocopherol and γ-tocopherol for subjects throughout the study are shown in Appendices V 
through BB. 
Serum concentrations of α-tocopherol were significantly higher after 11 weeks of 
lutein supplementation (17 ± 1 µmol/L), 26 (16 ± 1 µmol/L) and 38 (18 ± 1 µmol/L) in 
comparison with baseline (14 ± 1 µmol/L). The mean serum concentration (µmol/L) time 


























Figure 22- Mean (± SEM; n=45) Serum Concentration (µmol/L serum) Time Curves  




 The mean serum concentrations of γ-tocopherol in subjects who received the three 
treatments are shown in Table 13. Comparison of the mean serum concentrations of γ-
tocopherol by weeks and across treatments revealed significant difference only at week 
26 for subjects on treatment 1 who had significantly lower γ-tocopherol levels (0.8 ± 0.20 
µmol/L) than those on treatment 2 (1.8 ± 0.20 µmol/L) and treatment 3 (1.5 ± 0.21 
µmol/L). 
Differences in the mean serum concentrations of γ-tocopherol in subjects on 
different treatments were greater within treatment rather than among treatments. The 
mean serum levels of γ-tocopherol in subjects on treatment 1 were significantly lower at 
week 26 (0.8 ± 0.20 µmol/L) in comparison with weeks 1 (1.4 ± 0.20 µmol/L), 4 (1.3 ± 
0.20 µmol/L) and 12 (1.2 ± 0.20 µmol/L). The opposite was noted in subjects on 
treatment 2, whose mean serum concentrations of γ-tocopherol were significantly higher 
α-t c r l 
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at week 26 (1.8 ± 0.20 µmol/L) in comparison with the mean serum concentrations 
during the entire study, except for week 12 (1.5 ± 0.20 µmol/L). Subjects on treatment 3 
showed the lowest serum level of γ-tocopherol at week 4 (1.1 ± 0.20 µmol/L); this was 




Table 13- Mean Serum Concentrations (µmol/L) of γ-Tocopherol in Subjects on 
                Different Treatments Throughout the Study 1,2,3 
γ-Tocopherol (µmol/L) Weeks 
Treatments 
           1                            2                          3 
          0 (baseline) 1.0 ± 0.20xa,b 1.3 ± 0.20xb 1.2 ± 0.20xa,b 
          1 (baseline) 1.4 ± 0.20xa 1.2 ± 0.20xb 1.3 ± 0.20xa,b 
          4 (supplementation) 1.3 ± 0.20xa 1.3 ± 0.20xb 1.1 ± 0.20xb 
        12 (supplementation) 1.2 ± 0.20xa 1.5 ± 0.20xa,b 1.3 ± 0.20xa,b 
        26 (supplementation) 0.8 ± 0.20yb 1.8 ± 0.20xa 1.5 ± 0.21xa 
        38 (follow-up) 1.1 ± 0.20xa,b 1.3 ± 0.20xb 1.6 ± 0.21xa 
        52 (follow-up) 1.0 ± 0.20xa,b 1.2 ± 0.20xb 1.2 ± 0.21xa,b 
 1 Mean ± SEM. 
 2 Within a column, means followed with identical superscript letters are not significantly 
    different by week as determined by repeated measures analysis of variance with 
    means comparisons by LSD at 5% level of significance.  
 3 Within a row, means followed with identical subscript letters are not significantly 
    different by treatment as determined by repeated measures analysis of variance with 









Visual Acuity of Subjects Supplemented with Lutein Containing 5% Zeaxanthin 
 
Visual acuity was measured in all 45 subjects at various blood collection intervals 
and the results are shown in the Appendix CC. Subjects without AMD and those with 
middle stage AMD, for the most part, had moderate low vision (20/80 to 20/160). 
Subjects with end stage of AMD had difficulty during the measurements of visual acuity 
and consequently several subjects showed unusually low values. Subjects without AMD 
and those with the middle stage of AMD showed a large variation in visual acuity within 
the subjects in each group.  
Repeated measures analysis demonstrated that the visual acuity measurements in 
all subjects were significantly different by age (p=0.0434), group (no AMD, middle 
stage, and end stage of AMD) (p< .0001), and body mass index (p=0.0409). The visual 
acuity of all 45 subjects were not significantly different by week (p=0.0690) throughout 
the entire study. 
 
Macular Pigment Optical Density (MPOD) in Subjects Supplemented with Lutein 
Containing 5% Zeaxanthin 
  
 The macular pigment optical density (MPOD) was measured in subjects without 
AMD and subjects at the middle stage of AMD by Heterochromatic Flicker Photometry. 
Subjects at the end stage of AMD were incapable of performing in Heterochromatic 
Flicker Photometry measurements. The data on the visual acuity and MPOD for the 
subjects are listed on Appendices CC and DD, respectively.  
 The MPOD values of the subjects at baseline and throughout supplementation 
period are shown in Figure 23. Subjects without AMD on 2.5 mg and 5.0 mg/day of 
lutein supplements showed a decrease in their macular pigment optical density 
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throughout the supplementation period. On the other hand, subjects without AMD on 10 
mg/day of lutein supplements showed a higher MPOD after 3 weeks of supplementation 
in comparison with baseline and their values gradually declined after 24 weeks of 
supplementation. 
 Subjects with the middle stage of AMD had higher MPOD after 3 weeks of 
supplementation in comparison with their baseline values regardless of the dose of lutein 
supplements. Surprisingly, subjects with the middle stage of AMD who were on 2.5 
mg/day of lutein supplements had a higher MPOD than those who were on 5 and 10 
mg/day of lutein dose. As shown in Figure 23, subjects in different groups (no AMD, 
middle stage and end stage of AMD) and treatments had different values of MPOD at the 
baseline. In order to determine the changes in the MPOD relative to baseline a log ratio 
scale was created where the baseline values of MPOD were designated zero values and 
the MPOD values above zero reflected positive change in the MPOD with 
supplementation; similarly negative values indicated a decrease in the MPOD values. The 
graphic log ratio of MPOD for subjects is shown in Figure 24. 
 After adjusting for the baseline values, the MPOD of subjects with middle stage 
of AMD were found to be higher in subjects receiving the 10 mg/day of lutein dose 
compared to subjects receiving 5 and 2.5 mg/day after 6 months of supplementation. In 
addition, only subjects receiving the 5 mg/day of lutein exhibited a negative change in 
their MPOD at the end of supplementation period relative to baseline. Subjects without 
AMD receiving 2.5 and 5 mg/day of lutein showed a negative change in their MPOD at 
the end of supplementation period. Only subjects without AMD receiving 10 mg/day 
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Figure 23- Mean Macular Pigment Optical Densities of Subjects without AMD and 
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No AMD on 5 mg/day of lutein
No AMD on 10 mg/day of lutein
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Figure 24- Mean of Log Ratio of Macular Pigment Optical Densities of Subjects without 
                  AMD and Subjects with the Middle Stage of AMD. Horizontal Line at  
                  Zero Indicates no Change at Baseline Values of MPOD in Log-Scale. Lines 
                  Above the Zero Line Indicates Positive Changes in MPOD and Lines below 
                  the Zero Line Reflect a Negative Changes in MPOD.     
No Change 
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 The mean serum concentrations of lutein were plotted against the total macular 
pigment optical density values of subjects without AMD and those with middle stage of 
AMD and the results are depicted in Figure 25. The pearson correlation analysis of these 
data has revealed that there is no correlation (r=0.09, p=0.44) between the mean serum 
concentrations of lutein in subjects supplemented with this carotenoid and their total 
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Figure 25- Scatterplot of Mean Serum Concentrations of Lutein versus Total Macular 
                     Pigment Optical Density of Subjects without AMD and those with Middle 









 The study described in this dissertation was conducted to determine what would 
be a dose of lutein supplementation that would have a greater increase in the serum levels 
of lutein in subjects with and without age-related macular degeneration (AMD) and 
would accumulate in the macula. This was the first lutein supplementation study that 
involved a large number of participants, 45 elderly, with and without AMD. Subjects in 
each group (no AMD, middle stage, and end stage of AMD) were randomly assigned to 
receive one of the three dose levels of lutein (2.5, 5, and 10 mg/day). The serum lutein 
concentrations of subjects were measured throughout the study to investigate the 
association between these three dose levels of lutein and their serum levels of this 
carotenoid in the subjects. The serum concentrations of dietary carotenoids, other than 
lutein and zeaxanthin, were also measured in the subjects to evaluate possible interaction 
between supplemental lutein and dietary carotenoids, retinol, α- and γ- tocopherol. The 
total macular pigment optical density (MPOD) of subjects was measured in the groups 
without AMD, and those with middle stage of AMD. 
Majority of the subjects enrolled in this clinical study were Caucasians and 
women. As expected, subjects with the end stage of AMD were significantly older in 
comparison with subjects without AMD and those with the middle stage of AMD; this is 
probably because AMD is an age related disease. One of the problems associated with 
age is the change in gastric function that may influence the absorption of nutrients such 
as lutein. The changes that have been recognized are the decrease in the secretion of 
hydrochloric acid, intrinsic factor, and pepsin, which might interfere with the absorption 
of minerals, vitamins and proteins (Ausman et al., 1998). However, Cardinault et al. 
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(2003) reported that a five weeks supplementation with 9 mg/day of lutein did not show a 
significant difference in the plasma levels of lutein in young subjects when compared to 
elderly. 
Originally, one of the criteria of eligibility to participate in this study was that the 
subjects had to be non-smokers because previous supplementation study with β-carotene 
in smokers with lung cancer patients had shown an increase in the cases of lung cancer 
(Omenn et al., 1996). However, due to lack of subjects, especially with end stage of 
AMD, 4 smokers with end stage of AMD and 1 smoker without AMD were allowed to 
participate in the study. To avoid any complications due to possible interaction between 
smoking and lutein supplementation, the subjects with history of lung cancer were 
excluded from the present study.  
Most of the subjects reported that they consumed alcohol occasionally and only 1 
subject without AMD and 1 with the end stage of AMD reported drinking alcohol on a 
daily basis. Cho et al. (2000) in a prospective study did not find an inverse relationship 
between moderate alcohol consumption and risk of AMD. Even though, the data were 
adjusted for alcohol status, age, and smoking status.  
The data were also adjusted for body mass index (BMI) because fat and obesity 
have been shown to be risk factors for AMD (Marles-Perlman etal., 1995; Smith et al., 
1998). The mean values of BMI for the three groups (no AMD, middle stage, and end 
stage of AMD) were between 25-27 Kg/m2, which is in the range of desirable BMI for 
individual between the ages 55 and 64 (23-28 Kg/m2) and above 64 years old (24-29 
Kg/m2) (James et al. 1988). Although subjects with middle stage of AMD had a higher 
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BMI in comparison with subjects without AMD and those with end stage of AMD, see 
Table 5.  
 
Dietary Intake of Lutein 
 Dietary intake of lutein was assessed by a modified Block’s Food Frequency 
Questionnaire that was administered to subjects during all visits for blood collection. The 
mean intakes of dietary lutein in subjects without AMD and with end stage of AMD 
throughout the study were not significantly different and were determined from food 
frequency questionnaire to be 2.17 and 2.40 mg/day, respectively (Figure 16). These 
values for dietary intake of lutein are consistent with findings from the 1992 National 
Health Interview Survey that predicted the mean intake of lutein and zeaxanthin 
combined to be 2.2 mg/day for men, and 1.9 mg/day for women (Nebeling et al., 1997). 
Subjects with middle stage of AMD had a significantly higher mean intake of dietary 
lutein compared with those without AMD and those with end stage of AMD.  
It is important to note that for the calculation of lutein intake in the present study 
it was used the USDA-NCC Carotenoid Database 1998 which combines the content of 
lutein and zeaxanthin present in food. Although this should not be considered a major 
concern since the ratio of lutein to zeaxanthin in fruits and vegetables were in the range 
of 12:1 to 63:1 (Humphries et al. 2003).  
Subjects on 2.5 mg/day of lutein supplements had the lowest dietary intake of 
lutein (1.9 + 0.18 mg/day) compared with subjects on 5 mg/day dose (3.0 ± 0.18 mg/day) 
and 10 mg/day dose (2.9 ± 0.18 mg/day). However minute differences in dietary intake of 
carotenoids would not be expected to result in a dramatic change in the serum levels of 
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these compounds. This is because carotenoids in raw green leafy vegetables are bond to 
chloroplasts (Demmig-Adams et al. 1996) and is not as bioavailable as carotenoids 
supplements. Boileau et al. (1999) reported that the bioavailability of carotenoids from 
green leafy vegetables were less than 10% compared with greater than 70% from 
supplements, which were solubilized with emulsifiers and protected by antioxidants. 
 Another important factor in the absorption of carotenoids from food is the 
presence or absence of dietary fat in the diet. Several studies have shown that low fat 
diets or absence of dietary fat significantly reduce carotenoid absorption (Dimitrov et al. 
1988; Prince et al. 1993; Shiau et al. 1994). This is because dietary fat provides a 
hydrophobic domain in which carotenoids are solubilized and it stimulates bile flow from 
the gall blader. 
Carotenoid bioavailability also depends on the methods of food preparation 
(Castenmiller and West, 1998). However, the food frequency questionnaire used in this 
study did not address whether the foods were cooked or raw (see Appendix D). Although 
a study conducted by Castenmiller et al. (1999) showed that subjects receiving the same 
amount of lutein from spinach that had been processed in 5 different ways were not 
significantly different in their serum concentrations of lutein.  
Nonetheless, because the dietary intake of lutein could, to a lesser extent, affect 





Serum Concentrations of Lutein in Subjects Supplemented with Lutein Containing 5% 
Zeaxanthin 
In the present study, 45 subjects were equally divided into the 3 following groups: 
subjects without AMD, subjects with middle stage and end stage of AMD. Subjects in 
each group (no AMD, middle stage, and end stage of AMD) were randomly assigned to 
receive one of the three dose levels of lutein: 2.5 mg/day (treatment 1), 5 mg/day 
(treatment 2), and 10 mg/day (treatment 3). The serum levels of lutein were measured at 
baseline (weeks 0 and 1), during the supplementation period (weeks 4, 12 and 26), and 
during follow-up (weeks 38 and 52). 
The mean serum lutein concentrations at baseline for all 45 subjects were 233 
nmol/L, which is in agreement with the baseline lutein concentration of 280 nmol/L 
reported by Khachik et al. (1995).  The Third National Health and Nutrition Examination 
Survey (NHANES III) reported the serum concentration of lutein and zeaxanthin for U.S. 
adults above 51 years old to be 121 nmol/L in the 1st percentile and 1158 nmol/L in the 
99th percentile (IOM, 2000).  
After 3 weeks of supplementation (week 4) the lutein concentration in the serum 
of all 45 subjects was significantly higher in comparison with baseline (weeks 0 and 1). 
Khachik et al. (1995) reported after one week of supplementation with 10 mg/day of 
lutein, which is one of the doses of lutein given in this study, an increase of 4 to 5 fold in 
the serum levels of lutein of the 3 subjects. Few years later, in a 140 days 
supplementation study with 30 mg/day of lutein involving 2 subjects, Landrum et al. 
(1997) observed a 10 fold increase in the serum levels of lutein after 10 to 20 days of 
supplementation. 
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The mean values of serum lutein concentrations for subjects receiving the three 
dose levels of lutein throughout the entire study are shown in Table 6. The data from this 
table strongly suggests that lutein serum levels in subjects are dose dependent. This was 
certainly the case in the subjects who received the three doses of 2.5, 5, and 10 mg/day. 
For example, after 3 weeks of supplementation subjects receiving 10 mg/day of lutein 
had a 3-4 fold increase in their serum levels of lutein and was significantly different from 
serum lutein levels of subjects receiving 2.5 and 5 mg/day. Meantime, subjects receiving 
2.5 mg of lutein /day (treatment 1) and 5.0 mg of lutein /day (treatment 2) had almost 2 
fold increase in their serum lutein concentration but there were no significant difference 
between the two treatment groups.  
All 45 subjects receiving the three doses of lutein supplements reached a plateau 
after 3 weeks of supplementation. Although subjects had an increase in their serum lutein 
levels of 11% in those on treatment 1, 47% in those receiving treatment 2, and 23% in 
subjects on treatment 3 after 25 weeks of supplementation (week 26), this increase was 
not significantly different. The non-significance probably occurred due to a large 
variation in the serum values of subjects, which resulted in a large standard error 
becoming difficult to find significant differences, see Table 7. Even with a large variation 
in the lutein serum levels of subjects, the plateau after 3 weeks of supplementation for all 
three dose levels of lutein found in the present study is in agreement with Landrum et al. 
(1997); a supplementation study with 30 mg/day of lutein in which the serum levels of 
lutein in the 2 subjects plateau after 20 days of supplementation. The result from the 
present study is also in agreement with a study conducted by Sommerburg et al. (1999) 
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that showed a lutein half-life of 7.5 days and expect to reach 90% steady-state plasma 
concentrations by 25 days of supplementation.  
Unexpectedly, after 25 weeks of supplementation, subjects receiving treatment 1 
(2.5 mg/day) showed a decrease in their serum lutein levels when compared to their 
serum levels after 12 weeks of supplementation; however, this decrease was not 
significantly different. At the end of supplementation period (week 26) subjects receiving 
10 mg/day of lutein supplements had a higher serum levels (1000 nmol/L) compared with 
those receiving 5.0 mg/day of lutein (720 nmol/L), however these values were not 
significantly different. The Eye Disease Case-Control Study reported the lowest risk of 
AMD is associated with a plasma lutein and zeaxanthin concentrations equal or above 
670 nmol/L (EDCCSG, 1993). Therefore, the results from the present study suggest that a 
supplementation with at least 5 mg/day for 25 weeks of supplementation would provide 
the serum levels of lutein necessary to lower the risks of AMD.  
During the follow up period, the mean lutein serum levels of all 45 subjects 
returned to baseline after approximately 3 months of post-supplementation (see Figure 
17).  
 
Serum Concentrations of Zeaxanthin in Subjects Supplemented with Lutein Containing 
Zeaxanthin 5% 
In the present study subjects were taking 2.5, 5 and 10 mg/day of lutein tablets 
that also contained 5% of zeaxanthin. Therefore, the subjects also received the following 
doses of zeaxanthin in the three treatment groups: 0.13 mg/day (treatment 1), 0.25 
mg/day (treatment 2), and 0.50 mg/day (treatment 3). The mean serum concentration time 
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curves for the three dose levels in subjects in the three groups, no AMD, middle stage of 
AMD, and end stage of AMD are shown in Figures 18, 19, and 20, respectively.  
Although the interaction among 3 variables, treatment, group and week were determined 
to be not significant (p=0.0508) some interesting differences among subjects without 
AMD and those with middle stage as well as and end stage of AMD, receiving the three 
doses of lutein supplements were notable. The serum concentrations of zeaxanthin in 
subjects with middle stage of AMD revealed minor changes throughout the study. Only 
subjects supplemented with 0.50 mg/day of zeaxanthin (treatment 3) showed an increase 
in their serum levels of this carotenoid after 11 weeks of supplementation. Subjects with 
end stage of AMD supplemented with 0.25 mg/day of zeaxanthin (treatment 2) showed a 
significant increase after 25 weeks of supplementation while those supplemented with 
0.50 mg/day (treatment 3) of this carotenoid showed an increase after 3 weeks of 
supplementation. Regardless of the dose of supplemental zeaxanthin, only subjects 
without AMD showed significant differences in their serum levels of zeaxanthin after 3 
weeks of supplementation.  
However, zeaxanthin supplementation resulted in a significant interaction 
between groups (no AMD, middle stage AMD, and end stage AMD) and treatments 
(0.13, 0.25, and 0.50 mg/day). Subjects without AMD supplemented with 0.25 mg/day of 
zeaxanthin (treatment 2) showed a significant lower serum zeaxanthin concentration in 
comparison with subjects with middle and end stage of AMD receiving the same 
treatment (Table 8). One would expect that presence of disease in subjects with midlle 
stage and end stage of AMD to have an impact in the serum levels of zeaxanthin in 
comparison with the serum levels of this carotenoid in subjects without AMD. However, 
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the data shown in Table 8, indicates that presence or absence of disease has no impact on 
the serum concentration of supplemental zeaxanthin.  
The 1992 National Health Interview Survey that combined the mean dietary 
intake of lutein and zeaxanthin were 2.0 mg/day (Nebeling et al. 1997). Meantime, in a 
recent publication by Humphries et al. 2003, the ratio of lutein to zeaxanthin in fruits and 
vegetables were in the range of 12:1 to 63:1. Therefore, the mean dietary intake of 
zeaxanthin would be expected to fall in the range of 0.03 to 0.17 mg/day. Consequently 
supplementation with 0.13, 0.25, and 0.50 mg/day of zeaxanthin is much higher than the 
dietary intake of this carotenoid.  
Two supplementation studies with zeaxanthin have been previously conducted. In 
the first study, Khachik et al. (1995) reported that supplementation of 3 subjects with 10 
mg/day of zeaxanthin resulted in a 4 fold increase in the serum levels of zeaxanthin after 
one week of treatment. Recently, Bone et al. (2003) conducted a zeaxanthin 
supplementation study with 30 mg/day in 2 subjects and observed 5 to 6 fold increase in 
the serum levels of zeaxanthin, which plateau for each subject after 10 and 30 days of 
supplementation, respectively.  
 
Serum Lutein and Zeaxanthin Metabolites in Subjects Supplemented with Lutein 
Containing 5% Zeaxanthin 
The chemical structures of the lutein and zeaxanthin metabolites are shown in 
Figure 7.  Khachik et al. (1997) have identified the following oxidation products of lutein 
and zeaxanthin in sera of humans: 3’-hydroxy-ε,ε-caroten-3-one, ε,ε-carotene-3,3’-dione, 
(all E+Z)-3-hydroxy-β,ε-caroten-3’-one and 3’-epilutein. These metabolites were 
identified and quantified in the serum of all 45 subjects in the present study. The serum 
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concentration time curves for three of these metabolites, 3’-oxolutein [(all E+Z)-3-
hydroxy-β,ε-caroten-3’-one], 3’-hydroxy-ε,ε-caroten-3-one and ε,ε-carotene-3,3’-dione 
for all 45 subjects, regardless their lutein dose, are shown in Figure 21. The serum 
concentration time curves of 3’-epilutein in subjects without AMD, with middle stage, 
and end stage of AMD, irrespective of the lutein dose, are shown separately in Figure 22. 
This study showed that supplementation with lutein containing 5% of zeaxanthin, 
regardless of dose, results in a significant increase in the mean serum levels of 3’-
oxolutein [3-hydroxy-β,ε-caroten-3’-one], 3’-hydroxy-ε,ε-caroten-3-one and ε,ε-
carotene-3,3’-dione in all 45 subjects after 3 weeks. In an 18 day lutein supplementation 
(with 10 mg/day) of 3 subjects, Khachik et al. (1995) observed an increase in the serum 
levels of the three fore-mentioned oxidation products of lutein and zeaxanthin in all 3 
subjects.  
The identification of the oxidative metabolites of lutein and zeaxanthin in the 
serum of humans has provided preliminary evidence for the protective role of these 
carotenoids as antioxidants in the prevention of AMD. Possible metabolic pathways to 
account for the conversion of dietary lutein and zeaxanthin to their metabolites have been 
proposed by Khachik et al. (1997). According to this pathway, allylic oxidation of dietary 
lutein at the C3’-position yields its metabolite 3’-oxolutein, which is one of the 
metabolites of this carotenoid identified in human serum. This metabolite can then be 
reduced to form 3’-epilutein [(3R,3’S,6’R)-lutein] or to revert back to dietary 
(3R,3’R,6’R)-lutein. Alternatively, 3’epilutein can be formed by doble bond 
isomerization of dietary (3R,3’R)-zeaxanthin (see Figure 9). The metabolic pathways 
shown in Figure 9 also depicts the conversion of dietary lutein to (3R,3’S;meso)-
 95
zeaxanthin. However, Khachik et al. (2002), have recently shown that this carotenoid is 
absent in human serum and liver but present in human ocular tissue. 
The mean serum levels of 3’-oxolutein in the present study increased in all 45 
subjects after 3 weeks of supplementation with lutein containing 5% of zeaxanthin 
(Figure 21). The fact that mean serum levels of 3’-oxolutein and 3’-epilutein were shown 
to be significantly high in all subjects, provides support for the metabolic pathways of 
dietary lutein and zeaxanthin in humans proposed by Khachik et al. (1997). The mean 
serum concentration of 3’-epilutein and 3’-oxolutein were found not to be dependent on 
the dose of supplemental lutein. This observation suggests that once 3’-oxolutein and 3’-
epilutein are formed, these carotenoids, for the most part, are reverted back to regenerate 
their parent dietary lutein and zeaxanthin. This is in agreement with the expected 
mechanism of action of antioxidants. 
However, it was interesting to note that the mean serum concentrations of 3’-
epilutein were significantly different among subjects without AMD and those with 
middle stage and end stage of AMD. Subjects without AMD had a significantly higher 
3’-epilutein serum levels compared to subjects with the middle stage of AMD, but not 
when compared to subjects at the end stage of AMD. Furthermore, subjects without 
AMD receiving treatment 2 (5 mg/day of lutein and 0.25 mg/day of zeaxanthin) showed a 
lower serum zeaxanthin concentration in comparison with subjects with middle and end 
stage of AMD. In two separate supplementation studies with lutein and zeaxanthin, 
Khachik et al. (1995) did not find any significant increase in the plasma concentration of 
3’-epilutein in healthy humans supplemented with lutein but found a significant increase 
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in the plasma levels of this metabolite when the subjects were supplemented with 
zeaxanthin.  
In the post-supplementation period on weeks 38 and 52, the mean serum 
concentration of all four lutein/zeaxanthin metabolites, 3’-hydroxy-ε,ε-caroten-3-one, ε,ε-
carotene-3,3’-dione, (all E+Z)-3-hydroxy-β,ε-caroten-3’-one, and 3’-epilutein in all 45 
subjects gradually declined and returned to baseline (see Figures 21 and 22).  
The role and biological function of the oxidation products of lutein/zeaxanthin are 
not known at present even though all of these metabolites have been isolated and 
characterized in nearly all human ocular tissues such as, ciliary body, retinal pigment 
epithelium (RPE), iris, lens, macula, and peripheral retina (Khachik et al. 2001). 
Meantime, the oxidation products of carotenoids have also been found in human plasma, 
and tissues (Khachik et al., 2002).  Therefore, it is not clear whether or not the oxidative 
metabolites of lutein and zeaxanthin are formed exclusively in the human ocular tissues 
or these oxidation products are transported from the circulatory blood to the eye. 
 
Serum Levels of Other Dietary Carotenoids including Lycopene and its Metabolites in 
Subjects Supplemented with Lutein Containing 5% Zeaxanthin 
 In the present study, the serum levels of other dietary carotenoids besides lutein 
and zeaxanthin, and their metabolites were also measured. These were: α-carotene, β-
carotene, α-cryptoxanthin, β-cryptoxanthin, lycopene and its metabolites 2,6-
cyclolycopene-1,5 diols I and II (cyclolycopenes), phytofluene, and phytoene.  
The purpose of measuring the serum levels of other dietary carotenoids in the 
present study was to observe whether or not supplementation with lutein containing 5% 
of zeaxanthin at various dose levels could interfere with the serum levels of these 
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carotenoids. Several studies have shown interactions between combinations of 
supplemental lutein, β-carotene, and canthaxanthin. In 1994, White et al. reported that the 
ingestion of 25 mg of β-carotene together with 25 mg of canthaxanthin resulted in 38% 
reduction in the bioavailability of the latter carotenoid when compared with the serum 
levels of canthaxanthin when this carotenoid was administered alone. However, 
canthaxanthin did not interfere with the serum levels of β-carotene. Kostic et al. (1995) 
conducted a supplementation study with combination of β-carotene and lutein. In this 
study 8 subjects were supplemented with 0.5 mol/Kg of body weight with individual and 
a combination of lutein and β-carotene. For a 60 Kg human being, this dose corresponds 
to 16-17 mg/day for each carotenoid. The results of this study showed 50 to 60% 
reduction in the serum concentration of lutein in subjects supplemented with lutein and β-
carotene in comparison with the serum levels of lutein when this carotenoid was 
administered alone in the same subjects. 
In the present study the supplementation in human subjects with lutein at three 
dose levels of 2.5, 5 and 10 mg/day did not show any significant interaction with the 
serum levels of other dietary carotenoids in comparison with their baseline carotenoid 
levels. Although it should be noted that 2.5, 5 and 10 mg/day doses administered in the 
present study were much lower than 17 and 25 mg/day of lutein that were given in the 
two fore-mentioned supplementation studies. Although supplemental lutein did not 
interact with other carotenoids, an interesting observation with regards to the serum 
levels of other carotenoids is worth mentioning.  
 As shown in Table 8, the mean serum concentrations of α-carotene, β-carotene, 
and lycopene in subjects receiving the three dose levels of lutein happened to be 
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significantly higher in those subjects who received 2.5 mg/day of lutein supplements. 
Inversely, subjects who received 5 and 10 mg/day doses of lutein had a lower serum 
concentration of these carotenoids.  
The mean serum levels of the cyclolycopenes (total 2,6-cyclolycopene-1,5 diols I 
and II) were also higher in subjects receiving 2.5 mg/day of lutein when compared to 
subjects on 5 and 10 mg/day dose (see Table 9). The higher concentration of these 
lycopene metabolites in subjects receiving 2.5 mg/day of lutein would be expected since 
this group also showed higher serum levels of lycopene compared to subjects on 5 and 10 
mg/day lutein dose. There was no interaction between supplemental lutein and serum 
levels of cyclolycopenes in the present study. This was not surprising since no interaction 
were found between supplemental lutein and serum lycopene. 
  In the present study, the mean serum levels of α-carotene and β-carotene were 
significantly lower in females compared to males. The serum concentration of these 
carotenoids in the participants of this study differs from the data published by the Third 
National Health and Nutrition Examination Survey (NHANES III) for the same age 
group, in which females showed in average have a 26 % and 35 % higher serum levels of 
α-carotene and β-carotene, respectively, in comparison with males (IOM, 2000). This 
difference occurred probably because of the small sample size of the present study.  
 As shown in Table 11 males without AMD (n=5) revealed a higher mean serum 
concentrations of α-carotene, β-carotene, lycopene, and cyclolycopenes compared to 
males with the end stage of AMD (n=4).  This may be attributed to the presence of 
disease that may alter with the serum levels of these carotenoids. However, once again, it 
must be emphasized that a very limited number of subjects in each group (no AMD, 
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middle stage AMD, and end stage AMD) is one of the major limitations in arriving at 
such a conclusion. 
 One of the observations of the present study was that former smokers had 
significantly lower mean serum levels of β-carotene and lycopene when compared to 
non-smokers (Table 12). This finding is in agreement with observation made by 
Handelman et al. (1996) who reported that exposure to cigarette smoke caused depletion 
of certain carotenoids from human plasma and among those carotenoids were lycopene 
and β-carotene. It must be pointed out that in the present study 26 out of 45 subjects were 
former smokers and only 4 subjects were current smokers.  
Another observation in the present study was the fact that Asians showed a higher 
mean serum concentration of α-cryptoxanthin and β-cryptoxanthin compared to 
Caucasians and African Americans (Table 13). This result is in agreement with the 
dietary habit of Chinese-Americans (http://cc.purdue.edu/~hobaugh/safefood.html), 
which is composed of fruits, and vegetables that are rich in α-cryptoxanthin and β-
cryptoxanthin, such as mango, papaya, peaches, and winter squash (Khachik et al. 1991).  
 
Serum Concentrations of Retinol, α-Tocopherol, and γ-Tocopherol in Subjects 
Supplemented with Lutein Containing 5% Zeaxanthin 
Because carotenoids are considered among the fat-soluble nutrients, it was 
imperative to establish whether or not supplementation with lutein could interfere with 
the serum levels of fat-soluble vitamins such as vitamin A and E. Therefore, in the 
present study retinol and the two forms of vitamin E, α-tocopherol, and γ-tocopherol, 
were also measured in the serum of all 45 subjects supplemented with lutein containing 
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5% of zeaxanthin at 3 dose levels (2.5, 5, and 10 mg/day). This is clearly shown in Figure 
23, which shows the mean serum concentration time curves of retinol and α-tocopherol 
for all 45 subjects combined.  
The statistical analysis of the data indicated that there were no significant 
interaction in subjects at the 3 dose levels (n=15 for each dose level) between 
supplemental lutein and retinol. This was also the case for α-tocopherol.  Interestingly, 
the mean serum levels of α-tocopherol in all 45 subjects were significantly higher 
(p<0.0001) after 11 weeks of supplementation with lutein, regardless of the dose, in 
comparison to baseline (weeks 0 and 1) and these levels remained elevated up to week 
38. It must be noted that the dietary intake of α-tocopherol were not assessed in subjects 
and as a result the elevation of α-tocopherol in the mean serum levels of the subjects may 
be due to a greater dietary intake of this vitamin. 
Although the mean serum levels of γ-tocopherol fluctuated throughout the study, 
there were no significant interaction between this vitamin and supplemental lutein at all 
dose levels.  
 
Visual Acuity of Subjects Supplemented with Lutein Containing 5% Zeaxanthin 
Visual acuity is a measurement of the smallest object a person can identify at a 
given distance from the eye. Acuity is scored as a set of two numbers (e.g., 20/80), with 
the numerator representing the testing distance in feet between the chart and the patient, 
and the denominator representing the distance at which an individual with normal vision 
can see the object (Lee and Higginbotham, 1999). Normal vision ranges from 20/12 to 
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20/25, near-normal vision ranges from 20/30 to 20/70, and moderate low vision ranges 
from 20/80 to 20/160 (Bradford, 1999).  
In the present study the lutein supplementation did not show any improvement in 
the visual acuity of subjects throughout the study. However, the measurements on visual 
acuity showed a large variation within subjects and the data could not be employed to 
interpret the possible effect of supplemental lutein. 
  
Macular Pigment Optical Density of Subjects Supplemented with Lutein Containing 5% 
Zeaxanthin 
The macular pigment optical density (MPOD) were measured in the left and/or 
right eye of subjects without AMD (n=11) and those with middle stage of AMD (n=9) by 
Heterochromatic Flicker Photometry (HCFP) and the results are shown in Appendix DD. 
Because of the presence of the disease, subjects with end stage of AMD were unable to 
perform the test.  
 The mean MPOD time curve of subjects in the groups with no AMD and middle 
stage of AMD who received one of the three doses of lutein (2.5, 5, and 10 mg/day) 
appeared to be no correlation between MPOD values and supplemental lutein, regardless 
of the dose. The accuracy and precision of HCFP is questionable, especially in the view 
of the fact that there was a considerable variation in the MPOD data of all subjects. 
Indeed, several MPOD data points were found to decline upon lutein supplementation. 
For example, subjects without AMD on 2.5 and 5.0 mg/day of lutein as well as those with 
the middle stage of AMD receiving 5.0 mg/day dose had a lower MPOD values in 
compare to baseline at the end stage of supplementation period (week 26). Since the 
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subjects of the present study had significantly different MPOD values at baseline, the 
MPOD data had to be adjusted to account for these differences in the groups with no 
AMD and middle stage of AMD who received the three doses of lutein. 
The data were then transformed to a log ratio scale, where a value of zero was 
assumed for baseline and positive and negative. As expected, subjects with the middle 
stage of AMD receiving 2.5 and 10 mg/day of lutein had an increase in the MPOD during 
the supplementation period and a greater change was seen with subjects receiving the 10 
mg/day dose. As shown in Figure 23 there appeared to be a negative MPOD change in 
subjects with the middle stage of AMD receiving 5 mg/day of lutein. Similarly, subjects 
without AMD who were on 2.5 and 5 mg/day dose of lutein had a negative change at the 
end of the supplementation period (week 26). In subjects without AMD the decline in 
their MPOD values were even more substantial than the MPOD levels in subjects with 
the middle stage of AMD. Only subjects receiving 10 mg/day of lutein showed a positive 
change in their MPOD levels in comparison to baseline after 6 months of 
supplementation.  
The Heterochromatic Flicker Photometry is a subjective method and is based on 
the adjustment of the frequency of a blue light until the flicker that is shown in the field 
test disappears. In this method a flickering green light, which is not absorbed by the 
macular pigment (MP), is matched in a test field with an adjustable flickering blue, which 
is absorbed by the MP. The basic principle is the fact that individuals with a higher MP 
will absorb more effectively blue light than those with a lower MPOD values. Because 
the frequency of the green light remains constant, individuals with higher MP will have 
to adjust the equipment to a higher frequency blue light to match with the green light 
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until the flicker disappears. Therefore, the HCFP test relies on the subject’s ability to 
judge when the disappearance of the flicker. Another concern associated with this test is 
that the individual looking at the light may not be able to look straight ahead and focus on 
the light. In HCFP test, measurements will have to be taken directly on the fovea, which 
is exactly the center of the macula where carotenoids accumulate. Any deviation from the 
center of the fovea would result in the measurements of carotenoids in the parafovea, 
which, presumably, has a lower carotenoid levels and leads to a lower MPOD reading.  
Only recently, Snodderly et al. (2004) developed a standardized protocol for 
measuring macular pigment optical density (MPOD) by Heterochromatic Flicker 
Photometry. The authors have affirmed that by following this protocol the results 
obtained by HCFP can be more reliable and meaningful. Another non-invasive technique 
used for the measurement of macular pigment is by Raman Spectroscopy (Bernstein et al. 
2002). The advantage of this method compared with HCFP is that it does not rely on the 
judgment of the subjects. In this technique, the subject’s macula (1mm spot) is 
illuminated for 0.5 second with an argon laser light, the backscattered light is the 
collected and related to the total carotenoids present in the illuminated region. The 
Raman Spectroscopy was used at the beginning of the study but the variation within 
subjects in the readings was greater in compare to those obtained by HCFP. Therefore, in 
this study the MPOD collected with HCFP were considered. The optics of the Raman 
Spectroscopy Instrument has only recently been improved to eliminate the variation 




Limitations of the Study 
 One of the limitations of this study was the fact that subjects at the end stage of 
AMD were unable to perform the MPOD measurements by the Heterochromatic Flicker 
Photometry (HCFP).  At the time that this study began, there was no other non-invasive 
technique available for in vivo measurement of MPOD. Only recently, Raman 
spectroscopy technique has been modified and utilized for the non-invasive measurement 
of MPOD and promises to be the method of choice for future clinical studies. Another 
drawback of HCFP was the lack of precision in MPOD measurements of subjects without 
AMD and those with middle stage of AMD. 
Because of the lack of funding and personnel, only a limited number of subjects 
were recruited for the present study and this narrows the extent to which certain 
conclusions can be made. For example, a study with a large population supplemented 
with three doses of lutein containing 5% zeaxanthin, may reveal certain association 
between variables such as dose, gender, ethnicity, groups (no AMD, mid-stage AMD, 
end-stage AMD), and the changes in the mean serum concentration of carotenoids and 
their metabolites; such changes may not be apparent and/or conclusive from the present 
study with 45 subjects subdivided into smaller groups.  However, consideration of all of 
the above variables was not the major focus of this clinical study. Nonetheless, the study 
presented in this dissertation, has achieved its main objective and has clearly established 
that the mean serum concentration of lutein in three groups of 15 subjects, each 
supplemented with 2.5, 5.0, and 10 mg/day of this carotenoid, is dose dependent. Another 
limitation of the present study was the lack of a more comprehensive food frequency 
questionnaire that could provide useful information with regard to the intake of other 
dietary carotenoids, retinol, and tocopherols besides lutein and zeaxanthin.  
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CONCLUSIONS 
In the present study, the subjects without age-related macular degeneration 
(AMD) and those with middle stage and end stage of AMD were supplemented with 
three lutein dose levels of 2.5, 5.0 and 10 mg/day for a period of six months. Because the 
supplemental lutein also contained approximately 5% of zeaxanthin, the subjects also 
received 0.13, 0.25, and 0.50 mg/day of the latter carotenoid. The mean serum 
concentration of lutein, zeaxanthin, and their metabolites were measured for all subjects 
at baseline and throughout the entire six months of supplementation period. The serum 
levels of other dietary carotenoids, retinol, α- and γ-tocopherol were also monitored for 
possible interaction. The total macular pigment optical density (MPOD) of subjects was 
also measured by Heterochromatic Flicker Photometry at baseline and throughout the 
supplementation period.  
The results from this study indicate that the mean serum concentrations of lutein 
in human subjects increases with lutein supplementation in comparison with baseline. 
The mean serum concentrations of lutein in subjects who were supplemented with 2.5, 
5.0, and 10 mg/day of lutein reached a range of plateau between 3 to 25 weeks of 
supplementation at 450, 490, and 810 nmol/L, respectively. These findings suggest that 
the mean serum concentration of lutein is dose dependent and it reaches a higher plateau 
at 10 mg/day dose in comparison with 2.5 and 5.0 mg/day dose. 
Supplemental lutein at the three dose levels of 2.5, 5.0, and 10 mg/day did not 
interact with other dietary carotenoids, retinol, and α- and γ-tocopherols. The mean 
serum concentrations of zeaxanthin also increased with lutein supplementation containing 
5% of zeaxanthin and the presence or absence of disease had no impact on the serum 
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levels of this carotenoid. One of the evidences for the antioxidant activity of lutein and 
zeaxanthin is the presence of their oxidation products in human plasma and ocular tissues 
(Khachick et al. 1997a & 1997b). In the present study, the serum levels of the  oxidation 
products of lutein and zeaxanthin namely, 3’-oxolutein [3-hydroxy-β,ε-caroten-3’-one], 
3’-hydroxy-ε,ε-caroten-3-one, ε,ε-carotene-3,3’-dione, and 3’-epilutein increased as a 
result of   supplementation  with lutein and gradually returned to the baseline levels  6 
months post-supplementation. These findings are in agreement with published studies by 
Khachik et al. (1995) that revealed an increase in the serum levels of the fore-mentioned 
carotenoid oxidation products in human subjects who were supplemented with lutein and 
zeaxanthin in two separate studies. The role and impact of carotenoid oxidation products 
on human health is not known at present.  However, despite the increase in the serum 
levels of carotenoid oxidation products, the subjects did not show any side effect as a 
result of supplementation with lutein at the three dose levels of 2.5, 5.0, and 10 mg/day 
throughout the entire study. Therefore, it appears that elederly human subjects with and 
without AMD can be safely supplemented with lutein up to 10 mg/day. Another 
interesting finding from this study is the fact that presence or absence of AMD does not 
influence with the mean serum levels of lutein in human subjects supplemented with 
lutein at the three dose levels of 2.5, 5.0 and 10 mg/day. 
Increasing the serum concentration of lutein in humans by means of 
supplementation is crucial since the origin and accumulation of this carotenoid in ocular 
tissues (RPE, macula, iris, ciliary body, lens) is clearly due to transport from circulating 
blood. Because a high serum concentration of lutein would be expected to result in a high 
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MPOD in humans (Landrum et al., 1997), the 10 mg/day dose appears to be safe and 
effective for future clinical trials. 
  The data from the macular pigment optical density (MPOD) measurements by 
Heterochromatic Flicker Photometry were not consistent and could not be used to reach 
any conclusion with regard to the changes in the MPOD of the subjects. Consequently, it 
is not clear whether or not the presence of disease can interfere with the transport of 
lutein from circulating blood and its accumulation in the macula. However, the present 
study provides the much needed data with regard to serum carotenoid response of 
humans supplemented with lutein and can serve as a pilot study for designing a much 
larger multiclinical trial that plan to investigate the efficacy of this carotenoid in the 














APPENDIX A. SUBJECT DEMOGRAPHIC CHARACTERISTICS 
 
     Demographic characteristics of subjects: age, gender, and ethnicity.  
Subjects ID# Treatment* Age Gender Ethnicity 
     
No AMD     
9 1 63 Female Caucasian 
11 1 63 Female Caucasian 
13 1 70 Female Caucasian 
5 2 65 Female Caucasian 
6 2 60 Female Caucasian 
7 2 60 Female Caucasian 
8 3 60 Female Caucasian 
12 3 63 Female Caucasian 
10 1 63 Male Caucasian 
2 3 65 Male Caucasian 
4 3 77 Male Caucasian 
14 3 62 Male Caucasian 
15 1 68 Female Asian 
1 2 62 Female Asian 
3 2 61 Male Asian 
     
Middle Stage of AMD     
16 1 62 Female Caucasian 
20 1 86 Female Caucasian 
26 1 77 Female Caucasian 
28 1 76 Female Caucasian 
22 2 78 Female Caucasian 
23 2 66 Female Caucasian 
29 2 62 Female Caucasian 
18 3 66 Female Caucasian 
21 3 71 Female Caucasian 
24 3 70 Female Caucasian 
27 3 75 Female Caucasian 
30 3 61 Female Caucasian 
25 1 62 Male Caucasian 
17 2 63 Male Caucasian 
19 2 76 Male Caucasian 
     
End Stage of AMD     
33 1 66 Female Caucasian 
37 1 91 Female Caucasian 
41 1 71 Female Caucasian 
42 1 79 Female Caucasian 
32 2 84 Female Caucasian 
39 2 75 Female Caucasian 
31 3 80 Female Caucasian 
34 3 81 Female Caucasian 
43 3 87 Female Caucasian 
40 1 74 Male Caucasian 
35 2 69 Male Caucasian 
36 3 78 Male Caucasian 
38 3 76 Male Caucasian 
44 2 90 Female Black 
45 2 87 Female Black 
  * Treatments:1= 2.5 mg of lutein/day; 2= 5.0 mg of lutein/day; 3= 10 mg  




APPENDIX B. SUBJECT CHARACTERISTICS AT BASELINE 
 
 Anthropometric characteristics of subjects: height, weight, and body mass index (BMI); 















       
No AMD       
1 1.49 48.4 21.80 No No Occasionally 
2 1.73 89.9 30.04 Yes No Occasionally 
3 1.62 63.1 24.04 Yes No Occasionally 
4 1.80 80.8 24.94 Yes No Occasionally 
5 1.55 63.1 26.26 No - Never 
6 1.53 73.3 31.31 No - Occasionally 
7 1.58 66.5 26.64 Yes No Never 
8 1.56 54.3 22.33 No - Occasionally 
9 1.58 74.7 29.92 No - Occasionally 
10 1.83 81.8 24.43 Yes No Occasionally 
11 1.75 69.3 22.63 Yes No Occasionally 
12 1.68 54.3 19.24 No - Occasionally 
13 1.61 73.5 28.36 No - Occasionally 
14 1.69 80.7 28.26 Yes Yes Daily 
15 1.52 47.7 20.65 No - Never 
       
Middle Stage of AMD       
16 1.66 73.2 26.56 Yes No Never 
17 1.66 71.3 25.87 Yes  No Occasionally 
18 1.57 100.7 40.85 Yes No Occasionally 
19 1.61 77.6 29.94 Yes  No Occasionally 
20 1.53 67.6 28.88 Yes  No Occasionally 
21 1.64 67.3 25.02 Yes  No Occasionally 
22 1.61 68.8 26.54 Yes  No Occasionally 
23 1.61 72.0 27.78 No - Occasionally 
24 1.64 66.7 24.80 No - Occasionally 
25 1.85 77.4 22.62 No - Occasionally 
26 1.58 57.8 23.15 No - Occasionally 
27 1.52 54.5 23.55 No - Occasionally 
28 1.63 63.9 24.05 Yes  No Occasionally 
29 1.64 71.2 26.47 No - Occasionally 
30 1.48 67.7 30.91 No - Occasionally 
       
End Stage of AMD       
31 1.63 74.4 28.00 Yes No Daily 
32 1.53 43.86 18.74 No - Occasionally 
33 1.68 95.7 33.91 No - Never 
34 1.47 60.8 28.14 Yes  No Occasionally 
35 1.72 83.1 28.09 Yes  No Occasionally 
36 1.83 80.1 23.92 Yes  No Occasionally 
37 1.58 68.3 27.36 No - Occasionally 
38 1.76 67.3 21.73 Yes Yes Occasionally 
39 1.62 52.5 20.00 Yes No Never 
40 1.66 66.8 24.54 Yes  No Occasionally 
41 1.69 73.8 25.84 Yes Yes Occasionally 
42 1.64 63.5 23.61 Yes  No Occasionally 
43 1.44 67.6 32.60 No - Never 
44 1.44 45.7 22.04 Yes  Yes Occasionally 




APPENDIX C.  TOTAL SERUM CHOLESTEROL CONCENTRATIONS  
 
  Total serum cholesterol concentration (mg/dL) in human subjects measured at various 
  intervals throughout the entire study.  
Cholesterol (mg/dL) Subjects ID# 
Week 0 Week 4 Week 12 Week 26 Week 38 Week 52 
       
No AMD       
1 223 209 231 227 196 215 
2 144 158 107 136 131 127 
3 226 * 243 251 264 245 
4 255 * 225 270 246 254 
5 257 246 243 234 240 235 
6 222 233 249 223 231 230 
7 190 196 200 220 235 238 
8 246 256 246 231 212 233 
9 317 224 249 229 263 214 
10 130 139 140 143 139 140 
11 225 213 229 224 220 245 
12 192 215 208 190 196 214 
13 157 156 156 143 175 168 
14 285 239 277 225 254 261 
15 232 199 211 188 222 * 
       
Middle Stage of AMD       
16 * * 261 242 256 299 
17 * * 287 235 256 267 
18 240 232 270 230 219 255 
19 169 176 170 179 175 190 
20 250 234 246 222 239 238 
21 173 163 178 171 181 188 
22 215 * 215 231 264 208 
23 270 261 272 252 258 207 
24 240 199 246 229 233 214 
25 176 187 205 198 201 190 
26 207 210 230 230 207 199 
27 209 193 214 219 201 188 
28 174 184 201 192 193 189 
29 267 287 163 168 * 203 
30 * 295 296 231 297 301 
       
End Stage of AMD       
31 * * 209 * 201 * 
32 183 171 175 173 165 169 
33 224 172 193 172 204 176 
34 184 192 186 162 211 190 
35 112 123 113 127 129 116 
36 191 208 194 * * * 
37 223 * * * 232 227 
38 213 263 235 231 241 231 
39 226 203 199 184 197 198 
40 208 * 185 * 217 218 
41 171 188 193 169 209 199 
42 208 207 205 220 224 208 
43 167 161 * 133 * * 
44 198 165 179 168 201 218 
45 183 179 183 173 217 189 



































































































APPENDIX E.  LUTEIN DIETARY INTAKES  
 
 Dietary intake of lutein (mg/day) as assessed by a food frequency questionnaire 
 at various intervals throughout the entire study.  
Lutein (mg/day) Subjects ID# 
Week 0 Week 4 Week 12 Week 26 Week 38 Week 52 
       
No AMD       
1 3.86 2.29 3.19 6.65 1.34 1.92 
2 0.78 1.00 2.77 1.00 0.67 3.31 
3 8.79 2.30 4.74 3.37 1.47 2.50 
4 8.62 2.68 5.85 3.44 3.86 1.51 
5 2.23 1.31 0.79 2.13 1.37 1.58 
6 1.74 2.07 1.12 1.95 1.02 1.64 
7 1.11 0.72 0.82 0.67 0.70 0.71 
8 3.39 4.04 2.03 3.52 4.29 3.87 
9 0.82 0.44 0.41 0.52 0.88 0.99 
10 1.06 0.63 0.76 0.43 0.49 0.42 
11 1.17 1.19 0.90 0.51 0.66 1.02 
12 0.65 0.97 0.76 3.14 2.12 2.74 
13 1.84 4.23 6.79 2.99 1.93 5.04 
14 2.66 2.99 1.59 3.78 2.50 3.65 
15 1.25 2.00 1.67 0.73 2.24 1.28 
       
Middle Stage of AMD       
16 1.78 1.91 1.52 1.29 2.02 1.85 
17 0.74 1.18 1.05 1.86 1.79 1.76 
18 0.72 0.73 0.68 0.85 1.02 0.69 
19 3.42 3.43 1.45 2.46 2.61 3.28 
20 2.46 3.78 3.80 2.27 3.06 1.65 
21 2.21 1.21 2.19 2.98 1.84 1.61 
22 4.67 4.63 3.62 2.70 1.23 2.67 
23 4.25 4.62 3.93 3.23 13.96 6.95 
24 6.06 15.93 3.76 4.70 4.54 4.43 
25 1.54 1.56 0.50 0.44 0.42 0.81 
26 1.36 0.92 2.15 4.28 1.38 1.48 
27 4.07 4.92 6.84 4.74 4.95 8.11 
28 1.79 4.02 2.94 2.10 1.88 3.98 
29 3.40 5.00 4.48 5.46 4.74 4.11 
30 3.15 3.76 1.81 3.35 5.47 2.30 
       
End Stage of AMD       
31 2.06 1.18 1.86 2.28 2.24 2.08 
32 7.30 2.60 11.60 2.79 7.94 4.44 
33 3.01 2.91 1.58 1.26 4.50 1.65 
34 2.76 1.63 1.76 1.79 2.42 3.43 
35 2.65 2.51 3.06 2.09 2.17 2.62 
36 4.60 3.33 3.26 * * * 
37 1.26 1.04 1.32 1.49 1.95 1.27 
38 2.83 2.77 2.96 2.74 3.09 1.39 
39 4.76 2.73 3.90 4.35 2.59 2.76 
40 4.57 2.80 3.89 4.41 2.66 3.14 
41 1.60 1.74 1.58 1.49 1.75 1.32 
42 1.04 1.22 1.19 1.13 1.15 1.01 
43 0.57 0.73 0.95 0.88 0.72 0.70 
44 1.98 0.95 0.92 1.04 0.94 0.94 
45 1.78 2.99 1.36 2.35 1.59 1.73 
• not assessed 
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APPENDIX F. SERUM LUTEIN CONCENTRATIONS IN SUBJECTS AT VARIOUS INTERVALS 
 
      Lutein (All-E +Z) serum concentrations in subjects at various intervals throughout the entire study.  
Lutein (All-E+Z) Concentrations (nmol/L) Subjects ID# 
 Week 0 Week 1 Week 4 Week 12 Week 26 Week 38 Week 52 
        
No AMD        
1 101.82 94.73 634.49 399.08 1143.30 48.13 186.00 
2 48.50 64.21 643.91 365.31 618.86 150.24 101.19 
3 638.54 408.32 862.38 830.26 512.77 402.61 427.01 
4 332.99 207.83 1449.04 1290.25 2598.15 487.37 173.49 
5 225.40 170.63 514.74 539.37 559.42 107.65 202.32 
6 76.01 294.27 147.13 348.90 256.63 77.70 276.41 
7 104.62 154.01 274.58 535.28 433.33 91.15 191.53 
8 97.20 109.30 530.11 725.53 701.28 152.84 252.08 
9 148.91 100.96 284.76 496.74 572.71 236.77 267.39 
10 98.21 152.32 267.41 345.14 229.32 226.44 228.25 
11 368.56 516.52 785.92 828.39 557.88 369.61 480.43 
12 305.27 230.27 627.83 115.15 333.11 492.66 195.66 
13 24.83 40.91 319.71 322.52 514.26 233.23 294.69 
14 438.40 553.00 713.60 1457.92 1885.64 629.11 546.27 
15 408.71 189.23 537.27 668.71 421.38 326.06 239.45 
        
Middle stage of AMD        
16 344.79 308.64 325.96 492.81 240.50 185.62 238.12 
17 228.44 155.88 794.81 272.21 646.13 208.53 217.83 
18 111.71 187.57 827.75 877.59 227.85 180.86 138.37 
19 50.14 151.32 617.38 960.67 600.03 984.86 146.89 
20 444.24 506.59 660.16 817.95 502.86 249.32 422.38 
21 105.09 215.64 183.11 282.74 760.72 231.71 451.00 
22 246.76 281.93 440.67 412.16 708.77 146.38 367.92 
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Lutein (All-E+Z) Concentrations (nmol/L) Subjects ID# 
 Week 0 Week 1 Week 4 Week 12 Week 26 Week 38 Week 52 
23 526.95 281.88 478.22 682.73 826.49 669.85 566.64 
24 187.53 172.59 556.39 390.14 274.26 247.30 147.45 
25 424.85 263.12 259.47 405.37 455.69 221.46 97.75 
26 239.85 225.74 1093.37 746.17 646.40 288.01 163.23 
27 166.35 118.51 528.46 1435.63 1140.56 653.25 605.99 
28 109.38 133.23 444.13 744.69 351.74 305.73 345.93 
29 354.63 217.13 1000.13 610.41 490.67 232.68 309.41 
30 263.85 388.61 612.85 1420.31 625.25 387.15 516.75 
        
End Stage of AMD        
31 86.25 118.86 825.06 609.39 1314.14 275.93 121.03 
32 200.52 133.44 455.94 687.13 1158.29 227.48 129.47 
33 254.87 378.77 485.38 608.90 554.44 312.74 204.71 
34 460.38 326.73 955.05 1855.62 605.71 391.40 200.75 
35 97.95 127.77 611.45 638.22 1244.33 270.86 76.67 
36 457.28 408.79 1858.42 890.69 * * * 
37 166.85 146.69 205.09 249.41 317.01 298.10 315.09 
38 133.06 134.14 1742.98 515.50 710.63 151.75 141.28 
39 379.56 205.40 196.24 360.61 641.26 406.04 156.09 
40 343.05 282.29 195.31 448.06 228.13 248.65 109.28 
41 304.87 217.67 334.45 561.44 455.92 574.07 430.61 
42 236.93 166.52 244.39 260.74 312.75 213.35 198.94 
43 173.86 167.10 387.57 1622.39 1475.78 224.47 198.94 
44 109.72 79.34 328.27 278.20 394.32 273.26 315.90 
45 131.38 214.31 83.82 996.97 1091.11 375.86 209.14 




APPENDIX G. SERUM ZEAXANTHIN CONCENTRATIONS IN SUBJECTS AT VARIOUS INTERVALS 
 
  Zeaxanthin (All-E +Z) serum concentrations in subjects at various intervals throughout the entire study.  
Zeaxanthin (All E+Z) Concentrations (nmol/L) Subjects ID# 
 Week 0 Week 1 Week 4 Week 12 Week 26 Week 38 Week 52 
        
No AMD        
1 28.19 22.63 75.39 50.30 136.39 20.18 53.78 
2 15.33 24.66 69.01 38.98 53.39 47.88 20.53 
3 104.59 68.23 125.55 106.54 82.23 80.44 135.24 
4 60.16 38.57 138.58 130.20 214.98 84.09 42.41 
5 37.57 31.67 51.39 39.68 42.73 22.75 41.96 
6 25.18 55.80 44.77 50.07 39.50 24.15 54.57 
7 34.06 41.26 41.92 69.74 86.23 33.83 63.78 
8 23.52 24.23 60.21 70.95 62.63 27.54 50.87 
9 51.32 34.70 52.99 72.55 94.73 68.93 45.15 
10 18.27 24.58 40.24 44.88 39.70 71.77 65.41 
11 80.34 104.24 98.99 105.42 101.86 89.43 117.73 
12 44.53 46.18 61.18 16.29 54.65 144.93 69.18 
13 7.50 8.14 43.73 50.46 69.41 39.44 66.22 
14 94.32 117.82 81.41 159.44 306.42 155.87 118.94 
15 111.43 62.59 199.16 171.26 158.55 167.23 188.87 
        
Middle Stage of AMD        
16 77.96 77.30 40.38 60.67 33.18 31.67 43.27 
17 46.88 44.94 107.87 33.40 66.17 33.61 42.68 
18 31.65 54.99 87.12 81.59 24.01 41.27 41.34 
19 15.77 48.18 69.55 95.32 56.74 97.18 45.64 
20 69.64 78.98 79.56 99.65 59.29 31.75 88.17 
21 26.20 49.55 19.54 31.97 88.02 46.38 71.71 
22 31.14 43.83 54.69 49.16 69.62 24.51 64.03 
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Zeaxanthin (All E+Z) Concentrations (nmol/L) Subjects ID# 
 Week 0 Week 1 Week 4 Week 12 Week 26 Week 38 Week 52 
23 94.79 44.36 46.49 70.76 81.74 81.46 74.54 
24 50.95 52.31 72.69 44.85 47.87 65.94 32.55 
25 97.56 65.15 64.01 82.31 87.04 84.06 43.61 
26 59.11 49.81 114.98 73.61 78.19 49.75 40.25 
27 38.88 26.22 48.48 124.25 100.94 84.37 71.82 
28 23.54 25.04 63.30 91.25 39.26 53.40 52.00 
29 102.31 46.36 147.90 108.67 103.68 80.13 88.58 
30 43.40 70.10 60.58 154.52 75.46 88.25 85.64 
        
End Stage of AMD        
31 18.73 23.98 70.07 51.01 110.95 45.96 23.14 
32 40.03 33.68 55.18 80.10 112.18 34.19 27.31 
33 49.77 74.57 52.72 70.83 47.44 54.08 45.07 
34 76.22 65.31 89.82 179.39 71.21 56.18 36.66 
35 28.26 30.39 59.15 61.46 115.63 39.31 24.14 
36 67.85 70.55 190.71 88.64 * * * 
37 50.61 42.47 65.14 58.21 61.19 74.68 89.25 
38 41.68 47.30 143.55 43.60 71.09 52.50 62.58 
39 61.14 35.23 24.98 52.57 95.94 98.65 55.73 
40 53.95 42.88 21.82 63.99 34.24 59.79 35.38 
41 52.41 31.62 37.45 86.26 60.49 78.43 60.36 
42 71.00 43.14 63.32 62.08 76.76 64.11 61.50 
43 52.91 51.60 36.27 140.21 140.22 57.78 45.01 
44 27.75 25.98 48.36 36.91 51.71 62.99 61.66 
45 16.76 30.64 10.13 84.84 103.13 60.37 34.19 




APPENDIX H. SERUM CONCENTRATIONS OF LUTEIN, ZEAXANTHIN IN SUBJECTS AT WEEK 0  
 
          Serum concentrations of lutein, zeaxanthin and their stereoisomers in human subjects at week 0.  






























No AMD           
1 88.29 2.11 1.49 9.93 21.17 3.79 3.24 101.82 28.19 3.61 
2 41.96 1.33 0.95 4.26 12.71 1.43 1.19 48.50 15.33 3.16 
3 537.59 10.80 7.34 82.81 68.03 16.75 19.81 638.54 104.59 6.11 
4 271.91 12.34 6.94 41.79 37.89 10.00 12.26 332.99 60.16 5.54 
5 196.96 3.61 3.47 21.36 25.31 5.32 6.94 225.40 37.57 6.00 
6 64.71 1.18 1.04 9.08 18.42 2.98 3.78 76.01 25.18 3.02 
7 85.66 2.27 1.69 14.99 22.18 4.48 7.40 104.62 34.06 3.07 
8 80.82 1.67 1.25 13.46 15.92 3.45 4.14 97.20 23.52 4.13 
9 120.91 2.93 2.31 22.75 33.76 6.19 11.36 148.91 51.32 2.90 
10 80.29 3.11 1.87 12.94 12.99 2.08 3.20 98.21 18.27 5.37 
11 305.19 9.30 9.76 44.31 56.83 8.74 14.76 368.56 80.34 4.59 
12 250.09 8.71 3.69 42.77 38.79 5.74 0.00 305.27 44.53 6.86 
13 21.51 0.62 0.66 2.05 6.36 1.15 0.00 24.83 7.50 3.31 
14 379.50 7.72 5.13 46.06 65.51 11.71 17.10 438.40 94.32 4.65 
15 337.88 10.96 5.75 54.13 76.07 13.89 21.47 408.71 111.43 3.67 
           
Middle Stage AMD           
16 307.88 5.75 4.18 26.98 70.24 7.72 0.00 344.79 77.96 4.42 
17 189.29 5.19 5.48 28.48 32.32 6.28 8.28 228.44 46.88 4.87 
18 90.05 2.99 2.15 16.52 24.39 3.42 3.84 111.71 31.65 3.53 
19 42.96 0.93 0.70 5.55 11.59 2.09 2.09 50.14 15.77 3.18 
20 356.03 10.90 8.12 69.19 46.47 9.34 13.82 444.24 69.64 6.38 
21 84.10 4.29 1.88 14.82 18.37 3.55 4.29 105.09 26.20 4.01 
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22 206.79 5.31 3.91 30.76 19.50 4.47 7.17 246.76 31.14 7.92 
23 435.41 9.26 8.10 74.18 49.09 17.64 28.06 526.95 94.79 5.56 
24 154.11 4.32 2.81 26.29 33.11 8.38 9.47 187.53 50.95 3.68 
25 344.47 11.30 8.79 60.29 65.72 16.93 14.91 424.85 97.56 4.35 
26 199.89 3.43 2.46 34.06 39.94 7.51 11.66 239.85 59.11 4.06 
27 139.82 5.18 2.58 18.77 25.91 4.80 8.18 166.35 38.88 4.28 
28 90.43 2.20 1.94 14.80 15.65 3.39 4.50 109.38 23.54 4.65 
29 291.72 5.52 5.67 51.71 63.85 11.36 27.10 354.63 102.31 3.47 
30 225.78 4.26 2.85 30.97 28.74 5.76 8.91 263.85 43.40 6.08 
End Stage of AMD           
31 72.49 1.89 1.16 10.70 13.94 2.46 2.33 86.25 18.73 4.60 
32 164.25 7.20 4.41 24.66 29.02 4.18 6.83 200.52 40.03 5.01 
33 217.06 5.39 6.66 25.77 36.07 6.02 7.67 254.87 49.77 5.12 
34 370.97 9.42 14.38 65.62 52.29 10.35 13.59 460.38 76.22 6.04 
35 80.40 2.21 1.77 13.56 18.19 4.13 5.94 97.95 28.26 3.47 
36 405.58 6.66 5.63 39.41 54.76 9.99 3.10 457.28 67.85 6.74 
37 133.28 4.66 3.87 25.04 36.06 5.96 8.58 166.85 50.61 3.30 
38 108.48 2.78 2.41 19.39 27.79 4.86 9.03 133.06 41.68 3.19 
39 307.70 7.86 11.31 52.69 37.84 12.35 10.94 379.56 61.14 6.21 
40 276.64 8.15 4.44 53.83 32.82 6.73 14.40 343.05 53.95 6.36 
41 253.05 8.17 7.15 36.49 37.86 14.55 0.00 304.87 52.41 5.82 
42 200.17 5.62 3.85 27.29 49.12 10.64 11.23 236.93 71.00 3.34 
43 148.73 4.14 2.78 18.20 37.23 7.03 8.65 173.86 52.91 3.29 
44 91.56 2.41 1.77 13.98 19.17 4.40 4.18 109.72 27.75 3.95 




APPENDIX I. SERUM CONCENTRATIONS OF LUTEIN, ZEAXANTHIN IN SUBJECTS AT WEEK 1  
 
          Serum concentrations of lutein, zeaxanthin and their stereoisomers in human subjects at week 1.  






























No AMD           
1 79.07 2.43 1.95 11.28 15.53 3.98 3.12 94.73 22.63 4.19 
2 55.69 1.45 1.19 5.87 19.08 3.20 2.38 64.21 24.66 2.60 
3 339.22 11.15 10.22 47.73 46.30 9.85 12.07 408.32 68.23 5.98 
4 174.75 3.77 3.79 25.51 26.74 4.98 6.84 207.83 38.57 5.39 
5 147.56 3.13 2.55 17.39 20.61 4.50 6.57 170.63 31.67 5.39 
6 261.92 3.01 2.28 27.06 41.02 6.45 8.33 294.27 55.80 5.27 
7 129.31 3.22 2.50 18.98 35.50 5.76 0.00 154.01 41.26 3.73 
8 91.37 1.87 1.36 14.71 15.31 3.31 5.61 109.30 24.23 4.51 
9 83.52 1.85 1.44 14.15 22.43 3.90 8.37 100.96 34.70 2.91 
10 126.33 4.11 3.07 18.82 17.11 2.93 4.53 152.32 24.58 6.20 
11 426.70 16.05 14.60 59.17 76.70 11.45 16.08 516.52 104.24 4.96 
12 183.74 4.95 5.91 35.67 30.97 7.98 7.23 230.27 46.18 4.99 
13 37.12 0.33 0.28 3.19 8.14 0.00 0.00 40.91 8.14 5.03 
14 482.83 9.43 6.09 54.66 82.50 14.05 21.27 553.00 117.82 4.69 
15 154.50 4.21 3.70 26.83 44.98 6.39 11.21 189.23 62.59 3.02 
           
Middle Stage AMD           
16 269.35 5.84 4.43 29.01 69.43 7.87 0.00 308.64 77.30 3.99 
17 132.77 4.77 1.64 16.69 35.56 5.05 4.32 155.88 44.94 3.47 
18 156.78 3.86 3.17 23.75 38.06 3.69 13.25 187.57 54.99 3.41 
19 125.74 2.83 2.78 19.97 35.54 4.23 8.41 151.32 48.18 3.14 
20 417.64 9.58 8.06 71.31 51.06 12.69 15.23 506.59 78.98 6.41 
21 177.33 3.44 3.08 31.79 42.30 4.29 2.96 215.64 49.55 4.35 
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22 227.31 6.85 4.36 43.40 27.42 6.02 10.38 281.93 43.83 6.43 
23 232.87 4.92 3.18 40.91 30.24 6.06 8.05 281.88 44.36 6.35 
24 140.74 4.32 2.81 24.71 33.11 9.75 9.46 172.59 52.31 3.30 
25 221.27 4.75 3.08 34.02 44.00 8.67 12.48 263.12 65.15 4.04 
26 185.14 3.92 2.72 33.96 30.50 7.81 11.50 225.74 49.81 4.53 
27 101.93 2.68 1.57 12.33 17.99 3.04 5.18 118.51 26.22 4.52 
28 109.24 3.94 2.41 17.65 16.19 3.59 5.26 133.23 25.04 5.32 
29 183.75 2.80 2.38 28.21 37.87 8.50 0.00 217.13 46.36 4.68 
30 331.99 6.73 5.17 44.72 47.08 8.43 14.59 388.61 70.10 5.54 
End Stage of AMD           
31 96.85 3.45 1.71 16.85 16.93 3.25 3.80 118.86 23.98 4.96 
32 108.62 3.83 2.79 18.21 25.06 3.73 4.89 133.44 33.68 3.96 
33 325.27 7.94 7.70 37.86 57.03 7.45 10.09 378.77 74.57 5.08 
34 259.30 8.45 5.57 53.41 42.80 9.02 13.49 326.73 65.31 5.00 
35 108.97 2.90 2.47 13.44 23.73 2.94 3.72 127.77 30.39 4.20 
36 325.55 6.61 3.07 73.55 46.94 11.80 11.82 408.79 70.55 5.79 
37 118.02 3.43 2.35 22.90 29.05 5.64 7.77 146.69 42.47 3.45 
38 109.74 2.73 2.09 19.58 33.11 4.87 9.31 134.14 47.30 2.84 
39 165.16 4.55 4.29 31.40 24.08 6.46 4.69 205.40 35.23 5.83 
40 225.51 9.51 8.82 38.45 29.04 6.80 7.03 282.29 42.88 6.58 
41 182.78 4.09 1.93 28.86 21.16 4.08 6.38 217.67 31.62 6.88 
42 122.18 3.17 22.51 18.66 29.20 6.43 7.51 166.52 43.14 3.86 
43 140.89 5.02 2.96 18.24 35.21 7.10 9.30 167.10 51.60 3.24 
44 65.25 1.92 1.35 10.82 19.22 3.44 3.32 79.34 25.98 3.05 




APPENDIX J. SERUM CONCENTRATIONS OF LUTEIN, ZEAXANTHIN IN SUBJECTS AT WEEK 4  
 
          Serum concentrations of lutein, zeaxanthin and their stereoisomers in human subjects at week 4.  






























No AMD           
1 560.87 7.36 5.22 61.04 52.96 10.51 11.93 634.49 75.39 8.42 
2 588.16 5.52 4.85 45.37 52.47 8.88 7.66 643.91 69.01 9.33 
3 734.71 15.66 9.17 102.85 59.83 19.25 46.46 862.38 125.55 6.87 
4 1282.67 15.75 11.09 139.54 89.11 22.58 26.89 1449.04 138.58 10.46 
5 460.89 5.19 4.06 44.60 33.70 8.03 9.66 514.74 51.39 10.02 
6 108.30 20.93 1.92 15.98 32.45 5.16 7.16 147.13 44.77 3.29 
7 233.36 3.96 2.78 34.48 26.67 7.02 8.23 274.58 41.92 6.55 
8 459.16 5.21 3.14 62.61 38.07 10.09 12.05 530.11 60.21 8.80 
9 243.14 5.98 2.47 33.16 35.28 7.15 10.56 284.76 52.99 5.37 
10 229.46 4.24 2.45 31.26 29.06 4.00 7.18 267.41 40.24 6.65 
11 679.96 10.39 7.43 88.15 66.27 12.92 19.80 785.92 98.99 7.94 
12 551.24 8.70 5.37 62.52 39.52 10.60 11.06 627.83 61.18 10.26 
13 282.67 4.11 3.13 29.81 31.59 6.37 5.77 319.71 43.73 7.31 
14 614.26 15.82 8.04 75.49 52.87 16.57 11.97 713.60 81.41 8.77 
15 461.87 7.46 6.95 60.99 136.96 17.76 44.44 537.27 199.16 2.70 
           
Middle Stage AMD           
16 287.02 4.82 3.73 30.39 33.09 7.30 0.00 325.96 40.38 8.07 
17 711.53 8.16 5.87 69.25 77.48 9.41 20.98 794.81 107.87 7.37 
18 745.88 9.76 5.80 66.31 65.65 7.90 13.58 827.75 87.12 9.50 
19 533.84 8.72 6.78 68.03 48.20 9.79 11.57 617.38 69.55 8.88 
20 547.03 11.43 8.86 92.84 50.28 13.04 16.23 660.16 79.56 8.30 
21 159.14 2.53 1.81 19.63 14.04 3.15 2.35 183.11 19.54 9.37 
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22 377.70 7.32 3.99 51.65 35.86 6.91 11.91 440.67 54.69 8.06 
23 408.57 7.75 4.16 57.74 30.17 8.26 8.06 478.22 46.49 10.29 
24 488.04 6.72 4.92 56.72 48.21 12.63 11.84 556.39 72.69 7.65 
25 222.30 4.37 3.01 29.78 43.81 7.32 12.88 259.47 64.01 4.05 
26 935.28 13.84 9.54 134.71 72.24 18.55 24.19 1093.37 114.98 9.51 
27 474.62 4.97 3.35 45.52 33.68 6.55 8.25 528.46 48.48 10.90 
28 379.69 8.96 5.36 50.13 45.90 6.91 10.50 444.13 63.30 7.02 
29 867.20 19.51 11.27 102.15 106.71 13.06 28.13 1000.13 147.90 6.76 
30 542.05 6.48 5.36 58.95 41.49 9.99 9.11 612.85 60.58 10.12 
End Stage of AMD           
31 720.06 10.70 7.12 87.17 46.75 12.96 10.36 825.06 70.07 11.78 
32 389.48 7.53 5.48 53.46 38.41 8.61 8.16 455.94 55.18 8.26 
33 429.44 8.23 6.85 40.86 39.56 6.40 6.76 485.38 52.72 9.21 
34 812.57 21.09 17.32 104.07 57.35 20.64 11.82 955.05 89.82 10.63 
35 533.63 8.73 6.86 62.24 36.77 12.77 9.60 611.45 59.15 10.34 
36 1648.08 34.70 24.13 151.51 158.32 32.39 0.00 1858.42 190.71 9.74 
37 170.87 3.63 2.53 28.07 47.17 6.66 11.31 205.09 65.14 3.15 
38 1504.73 22.51 13.22 202.52 91.13 26.98 25.44 1742.98 143.55 12.14 
39 151.55 3.90 3.40 37.38 17.18 7.80 0.00 196.24 24.98 7.85 
40 156.57 5.81 3.50 29.43 16.37 5.45 0.00 195.31 21.82 8.95 
41 276.91 9.66 4.29 43.59 22.13 5.72 9.60 334.45 37.45 8.93 
42 210.59 5.14 3.49 25.17 41.11 8.52 13.69 244.39 63.32 3.86 
43 335.18 8.71 5.98 37.70 25.50 6.39 4.38 387.57 36.27 10.69 
44 278.85 6.94 6.39 36.09 32.98 8.55 6.83 328.27 48.36 6.79 





APPENDIX K. SERUM CONCENTRATIONS OF LUTEIN, ZEAXANTHIN IN SUBJECTS AT WEEK 12  
 
          Serum concentrations of lutein, zeaxanthin and their stereoisomers in human subjects at week 12.  






























No AMD           
1 343.08 6.47 3.85 45.70 30.67 9.46 10.17 399.08 50.30 7.93 
2 327.14 3.88 2.42 31.87 27.23 6.28 5.46 365.31 38.98 9.37 
3 710.69 14.69 8.75 96.13 69.70 18.91 17.93 830.26 106.54 7.79 
4 1103.30 17.45 12.08 157.43 74.67 22.81 32.72 1290.25 130.20 9.91 
5 477.58 6.20 4.51 51.08 25.15 8.30 6.23 539.37 39.68 13.59 
6 295.99 5.04 6.13 41.75 34.45 9.57 6.05 348.90 50.07 6.97 
7 462.34 6.40 3.81 62.73 46.13 9.91 13.70 535.28 69.74 7.68 
8 614.37 7.91 5.00 98.24 40.87 14.87 15.21 725.53 70.95 10.23 
9 408.61 7.11 6.53 74.49 44.20 9.26 19.08 496.74 72.55 6.85 
10 298.03 4.37 2.90 39.84 29.32 6.77 8.79 345.14 44.88 7.69 
11 713.47 12.20 7.28 95.44 68.72 16.07 20.62 828.39 105.42 7.86 
12 95.04 2.96 3.21 13.95 11.10 2.89 2.30 115.15 16.29 7.07 
13 273.80 5.57 4.99 38.16 36.70 6.20 7.56 322.52 50.46 6.39 
14 1236.96 25.14 15.84 179.99 100.18 27.94 31.32 1457.92 159.44 9.14 
15 555.23 10.13 9.95 93.39 107.81 23.89 39.55 668.71 171.26 3.90 
           
Middle Stage AMD           
16 434.70 7.61 5.23 45.27 50.55 10.12 0.00 492.81 60.67 8.12 
17 234.68 5.00 3.06 29.47 20.99 5.52 6.89 272.21 33.40 8.15 
18 776.26 11.90 7.43 81.99 57.61 10.81 13.17 877.59 81.59 10.76 
19 842.94 9.15 6.01 102.57 65.73 14.99 14.60 960.67 95.32 10.08 
20 684.31 13.51 11.05 109.08 66.54 13.69 19.42 817.95 99.65 8.21 
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22 341.72 7.87 4.90 57.66 26.37 6.96 15.82 412.16 49.16 8.38 
23 588.49 9.86 5.08 79.30 57.29 13.47 0.00 682.73 70.76 9.65 
24 326.40 6.34 3.57 53.83 26.43 10.14 8.28 390.14 44.85 8.70 
25 350.05 5.91 4.11 45.29 56.76 10.03 15.53 405.37 82.31 4.92 
26 643.49 6.45 7.50 88.72 44.81 13.36 15.44 746.17 73.61 10.14 
27 1286.04 13.02 8.57 128.00 88.33 18.93 16.99 1435.63 124.25 11.55 
28 636.23 15.09 8.95 84.42 62.57 15.12 13.57 744.69 91.25 8.16 
29 518.32 12.66 6.28 73.15 74.61 13.16 20.90 610.41 108.67 5.62 
30 1243.50 19.37 12.05 145.39 102.80 22.76 28.97 1420.31 154.52 9.19 
End Stage of AMD           
31 508.14 10.09 6.65 84.51 32.15 11.34 7.53 609.39 51.01 11.95 
32 580.03 13.30 9.24 84.56 56.08 12.00 12.02 687.13 80.10 8.58 
33 538.45 8.40 6.45 55.61 52.62 7.54 10.66 608.90 70.83 8.60 
34 1560.12 25.99 15.96 253.55 109.96 37.12 32.31 1855.62 179.39 10.34 
35 554.03 10.43 8.43 65.33 39.77 10.99 10.70 638.22 61.46 10.38 
36 777.87 15.00 10.36 87.47 58.82 14.40 15.43 890.69 88.64 10.05 
37 198.64 5.71 3.27 41.79 39.56 6.92 11.72 249.41 58.21 4.28 
38 434.19 6.52 5.83 68.96 25.18 10.39 8.03 515.50 43.60 11.82 
39 302.26 4.94 3.82 49.60 30.97 8.64 12.96 360.61 52.57 6.86 
40 375.06 6.25 5.01 61.73 38.45 10.11 15.44 448.06 63.99 7.00 
41 476.23 8.04 5.31 71.85 53.99 12.98 19.29 561.44 86.26 6.51 
42 204.08 6.22 9.40 41.04 43.23 6.22 12.63 260.74 62.08 4.20 
43 1412.71 26.65 18.85 164.18 87.58 33.49 19.14 1622.39 140.21 11.57 
44 219.50 5.39 9.17 44.13 25.68 11.23 0.00 278.20 36.91 7.54 




APPENDIX L. SERUM CONCENTRATIONS OF LUTEIN, ZEAXANTHIN IN SUBJECTS AT WEEK 26  
 
          Serum concentrations of lutein, zeaxanthin and their stereoisomers in human subjects at week 26.  






























No AMD           
1 983.22 22.61 10.40 127.07 114.36 22.03 0.00 1143.30 136.39 8.38 
2 557.34 5.78 4.28 51.47 38.28 7.96 7.15 618.86 53.39 11.59 
3 442.42 10.03 6.02 54.29 54.00 11.71 16.52 512.77 82.23 6.24 
4 2194.66 38.58 22.06 342.85 125.86 45.13 43.98 2598.15 214.98 12.09 
5 497.03 7.09 5.19 50.11 28.86 7.31 6.57 559.42 42.73 13.09 
6 223.53 2.89 1.87 28.34 26.65 5.32 7.53 256.63 39.50 6.50 
7 351.74 9.00 4.53 68.05 58.38 12.40 15.45 433.33 86.23 5.03 
8 607.94 9.31 3.72 80.31 41.35 12.05 9.23 701.28 62.63 11.20 
9 493.30 8.47 4.65 66.28 65.10 13.12 16.50 572.71 94.73 6.05 
10 188.47 4.56 3.72 32.58 27.35 5.20 7.15 229.32 39.70 5.78 
11 445.45 11.74 8.90 91.78 53.78 14.68 33.40 557.88 101.86 5.48 
12 272.80 7.26 6.00 47.04 38.33 7.30 9.02 333.11 54.65 6.09 
13 442.52 13.89 10.87 46.99 47.29 12.85 9.28 514.26 69.41 7.41 
14 1658.62 31.69 19.99 175.35 169.05 43.52 93.85 1885.64 306.42 6.15 
15 351.68 12.79 4.96 51.95 106.53 17.58 34.44 421.38 158.55 2.66 
           
Middle Stage AMD           
16 202.90 4.95 5.77 26.88 22.91 4.77 5.50 240.50 33.18 7.25 
17 563.72 6.48 8.56 67.38 43.48 12.41 10.27 646.13 66.17 9.77 
18 200.48 3.24 3.04 21.09 16.91 4.80 2.31 227.85 24.01 9.49 
19 524.34 7.32 4.72 63.66 38.33 10.13 8.28 600.03 56.74 10.57 
20 418.97 8.16 5.71 70.03 34.19 11.58 13.53 502.86 59.29 8.48 
21 654.88 8.21 5.33 92.30 58.84 14.48 14.71 760.72 88.02 8.64 
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22 605.62 10.79 5.91 86.44 40.40 14.29 14.93 708.77 69.62 10.18 
23 688.08 12.06 6.53 119.82 47.29 14.79 19.65 826.49 81.74 10.11 
24 217.57 7.02 4.54 45.13 29.34 7.94 10.59 274.26 47.87 5.73 
25 396.17 5.83 4.29 49.40 58.82 9.83 18.39 455.69 87.04 5.24 
26 532.64 7.68 4.29 101.80 44.62 15.07 18.50 646.40 78.19 8.27 
27 1012.27 13.43 8.57 106.28 70.30 16.81 13.82 1140.56 100.94 11.30 
28 300.16 5.38 3.54 42.66 29.69 7.91 1.66 351.74 39.26 8.96 
29 392.47 9.88 8.53 79.80 71.08 11.79 20.80 490.67 103.68 4.73 
30 510.92 11.77 10.76 91.80 47.96 12.74 14.77 625.25 75.46 8.29 
End Stage of AMD           
31 1111.27 17.29 10.58 174.99 67.19 22.84 20.92 1314.14 110.95 11.84 
32 978.48 23.72 12.03 144.06 65.04 25.55 21.58 1158.29 112.18 10.33 
33 491.81 5.73 3.13 53.77 38.14 9.30 0.00 554.44 47.44 11.69 
34 455.08 11.40 5.50 133.72 37.93 16.88 16.39 605.71 71.21 8.51 
35 1103.23 18.21 8.70 114.19 74.25 17.02 24.36 1244.33 115.63 10.76 
36 261.99 8.08 5.04 41.90 51.12 10.07 0.00 317.01 61.19 5.18 
37 598.36 10.55 5.29 96.43 43.04 14.28 13.77 710.63 71.09 10.00 
38 495.80 12.69 14.95 117.81 56.26 17.86 21.82 641.26 95.94 6.68 
39 177.94 5.15 4.86 40.18 21.22 6.02 6.99 228.13 34.24 6.66 
40 380.07 8.99 5.49 61.38 36.82 12.36 11.32 455.92 60.49 7.54 
41 265.22 6.13 6.34 35.07 52.56 11.35 12.85 312.75 76.76 4.07 
42 1288.52 25.58 19.48 142.21 92.40 31.01 16.81 1475.78 140.22 10.52 
43 337.16 5.79 4.87 46.50 32.22 10.84 8.66 394.32 51.71 7.62 
44 953.79 19.61 15.51 102.20 67.27 21.86 14.01 1091.11 103.13 10.58 




APPENDIX M. SERUM CONCENTRATIONS OF LUTEIN, ZEAXANTHIN IN SUBJECTS AT WEEK 38  
 
          Serum concentrations of lutein, zeaxanthin and their stereoisomers in human subjects at week 38.  






























No AMD           
1 39.97 1.31 0.94 5.91 12.46 2.56 5.16 48.13 20.18 2.39 
2 135.03 2.17 0.00 13.04 42.90 4.97 0.00 150.24 47.88 3.14 
3 333.77 6.04 4.67 58.13 52.91 12.03 15.50 402.61 80.44 5.01 
4 396.76 10.65 7.03 72.93 50.49 13.37 20.23 487.37 84.09 5.80 
5 86.18 2.83 3.50 15.14 16.15 3.12 3.47 107.65 22.75 4.73 
6 62.29 1.65 2.50 11.26 18.30 2.58 3.26 77.70 24.15 3.22 
7 65.65 3.60 2.22 19.68 24.23 3.65 5.95 91.15 33.83 2.69 
8 118.12 3.71 2.04 28.97 17.63 4.38 5.53 152.84 27.54 5.55 
9 182.05 5.86 4.72 44.13 46.51 6.45 15.98 236.77 68.93 3.43 
10 170.80 11.47 9.56 34.62 45.27 13.69 12.81 226.44 71.77 3.16 
11 311.27 9.82 6.78 41.74 59.00 12.80 17.62 369.61 89.43 4.13 
12 414.83 7.99 4.46 65.37 80.54 21.25 43.14 492.66 144.93 3.40 
13 174.74 35.65 2.32 20.53 32.98 6.46 0.00 233.23 39.44 5.91 
14 526.09 18.14 11.89 72.99 100.78 24.92 30.16 629.11 155.87 4.04 
15 273.70 7.43 4.00 40.92 147.33 19.90 0.00 326.06 167.23 1.95 
           
Middle Stage AMD           
16 158.84 3.67 3.18 19.93 20.53 3.85 7.28 185.62 31.67 5.86 
17 179.33 4.09 2.58 22.53 28.91 4.69 0.00 208.53 33.61 6.21 
18 142.17 6.31 5.03 27.35 29.19 4.75 7.32 180.86 41.27 4.38 
19 863.95 12.79 6.68 101.44 67.44 13.53 16.21 984.86 97.18 10.13 
20 200.96 6.65 4.13 37.58 20.32 4.96 6.46 249.32 31.75 7.85 
21 184.38 3.97 3.40 39.96 31.67 4.98 9.73 231.71 46.38 5.00 
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22 115.94 3.87 2.08 24.50 14.65 4.62 5.23 146.38 24.51 5.97 
23 563.81 10.04 4.51 91.49 52.40 15.18 13.88 669.85 81.46 8.22 
24 203.97 5.45 3.78 34.10 46.15 8.58 11.21 247.30 65.94 3.75 
25 190.61 3.27 2.47 25.11 61.63 7.44 14.99 221.46 84.06 2.63 
26 218.79 6.31 4.95 57.96 29.10 8.36 12.29 288.01 49.75 5.79 
27 591.65 8.09 5.17 48.33 63.18 10.72 10.47 653.25 84.37 7.74 
28 243.71 12.20 17.33 32.49 37.80 9.92 5.67 305.73 53.40 5.73 
29 189.87 7.38 4.70 30.72 56.99 8.38 14.76 232.68 80.13 2.90 
30 330.64 7.74 3.97 44.81 56.62 12.10 19.54 387.15 88.25 4.39 
End Stage of AMD           
31 220.48 9.35 3.71 42.39 27.56 6.92 11.47 275.93 45.96 6.00 
32 177.41 8.77 5.39 35.90 21.82 4.62 7.76 227.48 34.19 6.65 
33 267.32 6.05 7.33 32.05 39.39 7.96 6.73 312.74 54.08 5.78 
34 312.29 8.28 4.81 66.02 33.81 10.18 12.19 391.40 56.18 6.97 
35 225.05 5.03 3.35 37.43 26.37 6.51 6.43 270.86 39.31 6.89 
37 252.09 5.62 3.69 36.71 47.77 10.76 16.15 298.10 74.68 3.99 
38 104.80 7.76 6.46 32.73 35.11 4.82 12.57 151.75 52.50 2.89 
39 333.20 11.76 7.59 53.49 68.09 14.35 16.21 406.04 98.65 4.12 
40 207.74 5.56 3.49 31.85 38.51 9.05 12.23 248.65 59.79 4.16 
41 480.99 12.32 8.59 72.17 62.13 16.30 0.00 574.07 78.43 7.32 
42 182.70 4.79 4.30 21.56 47.34 8.07 8.70 213.35 64.11 3.33 
43 189.45 5.89 3.03 26.10 37.07 10.92 9.79 224.47 57.78 3.88 
44 224.30 9.91 7.25 31.81 39.90 9.30 13.80 273.26 62.99 4.34 
45 322.33 9.18 4.40 39.95 50.63 9.74 0.00 375.86 60.37 6.23 




APPENDIX N. SERUM CONCENTRATIONS OF LUTEIN, ZEAXANTHIN IN SUBJECTS AT WEEK 52  
 
          Serum concentrations of lutein, zeaxanthin and their stereoisomers in human subjects at week 52.  






























No AMD           
1 141.52 5.01 4.22 35.25 35.21 8.16 10.41 186.00 53.78 3.46 
2 85.17 2.22 1.49 12.30 15.63 2.41 2.49 101.19 20.53 4.93 
3 340.68 8.65 6.26 71.42 97.72 9.36 28.16 427.01 135.24 3.16 
4 130.88 5.22 5.14 32.25 28.34 5.92 8.15 173.49 42.41 4.09 
5 175.59 4.78 4.33 17.63 30.45 7.22 4.29 202.32 41.96 4.82 
6 241.40 7.54 3.46 24.01 38.91 7.69 7.98 276.41 54.57 5.06 
7 155.03 5.87 4.94 25.69 43.81 8.61 11.36 191.53 63.78 3.00 
8 209.52 4.79 3.06 34.71 29.35 8.45 13.07 252.08 50.87 4.96 
9 229.30 6.04 2.91 29.13 37.45 7.70 0.00 267.39 45.15 5.92 
10 195.82 6.35 5.50 20.57 50.49 7.54 7.38 228.25 65.41 3.49 
11 417.33 12.21 7.24 43.65 85.96 14.62 17.15 480.43 117.73 4.08 
12 159.45 6.21 3.61 26.40 46.80 8.00 14.38 195.66 69.18 2.83 
13 257.69 6.34 4.71 25.95 47.25 8.20 10.77 294.69 66.22 4.45 
14 470.21 10.74 7.39 57.93 80.01 16.25 22.69 546.27 118.94 4.59 
15 202.04 5.04 3.67 28.70 129.02 14.54 45.31 239.45 188.87 1.27 
           
Middle Stage AMD           
16 191.06 9.89 8.14 29.04 30.90 3.96 8.41 238.12 43.27 5.50 
17 181.14 7.20 2.94 26.55 29.83 2.91 9.94 217.83 42.68 5.10 
18 115.75 4.14 2.13 16.35 30.21 5.65 5.48 138.37 41.34 3.35 
19 124.12 2.16 1.53 19.09 32.62 4.73 8.29 146.89 45.64 3.22 
20 332.88 10.29 11.17 68.05 56.02 14.46 17.69 422.38 88.17 4.79 
21 389.26 8.24 3.70 49.81 49.44 10.53 11.73 451.00 71.71 6.29 
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22 302.28 7.24 3.80 54.60 37.30 10.45 16.29 367.92 64.03 5.75 
23 472.20 8.45 4.94 81.04 46.53 13.10 14.92 566.64 74.54 7.60 
24 119.48 3.55 1.84 22.58 22.23 3.93 6.38 147.45 32.55 4.53 
25 78.72 2.16 1.46 15.41 30.31 4.24 9.05 97.75 43.61 2.24 
26 129.73 3.28 1.85 28.37 26.26 6.89 7.10 163.23 40.25 4.06 
27 530.66 7.74 6.17 61.42 45.80 13.34 12.68 605.99 71.82 8.44 
28 302.55 5.76 3.47 34.15 36.28 8.77 6.96 345.93 52.00 6.65 
29 259.98 4.69 4.88 39.86 76.57 12.01 0.00 309.41 88.58 3.49 
30 451.19 8.15 5.77 51.64 57.23 12.90 15.50 516.75 85.64 6.03 
End Stage of AMD           
31 93.57 3.83 3.18 20.46 14.73 3.74 4.67 121.03 23.14 5.23 
32 103.57 3.23 1.66 21.00 16.89 4.67 5.75 129.47 27.31 4.74 
33 178.27 2.90 2.67 20.87 31.82 5.56 7.69 204.71 45.07 4.54 
34 145.99 5.64 4.36 44.76 22.83 6.30 7.53 200.75 36.66 5.48 
35 53.92 5.50 4.53 12.72 18.10 2.50 3.54 76.67 24.14 3.18 
37 267.97 7.31 4.58 35.23 57.82 9.29 22.14 315.09 89.25 3.53 
38 98.05 7.84 10.17 25.22 27.59 11.06 23.93 141.28 62.58 2.26 
39 124.16 4.29 3.07 24.56 36.65 7.97 11.12 156.09 55.73 2.80 
40 85.04 4.19 5.57 14.49 21.99 5.03 8.36 109.28 35.38 3.09 
41 374.08 6.99 5.37 44.17 50.29 10.07 0.00 430.61 60.36 7.13 
42 165.89 5.90 4.78 22.38 40.43 8.03 13.04 198.94 61.50 3.23 
43 164.23 7.15 3.91 23.65 29.30 9.29 6.42 198.94 45.01 4.42 
44 264.63 6.05 3.82 41.40 41.33 9.91 10.43 315.90 61.66 5.12 
45 181.38 3.48 2.99 21.28 22.21 6.16 5.82 209.14 34.19 6.12 




APPENDIX O. SERUM CONCENTRATIONS OF LUTEIN AND ZEAXANTHIN METABOLITES IN SUBJECTS 
                                   AT WEEK 0 
 
    Serum concentrations of lutein, zeaxanthin and their metabolites in human subjects at week 0.  
Carotenoids Concentration (nmol/L) 








(All E+Z) 3'-epilutein 3'-oxolutein1
 
3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
No AMD        
1 101.82 28.19 8.31 22.09  14.42 11.88 
2 48.50 15.33 5.64 13.56  27.98 3.95 
3 638.54 104.59 71.48 107.19  70.81 21.65 
4 332.99 60.16 60.46 66.29  35.78 19.79 
5 225.40 37.57 31.98 53.23  65.21 39.97 
6 76.01 25.18 2.52 18.47  9.19 7.36 
7 104.62 34.06 6.56 33.62  19.35 15.43 
8 97.20 23.52 13.95 18.43  11.74 8.42 
9 148.91 51.32 16.74 40.93  18.47 15.70 
10 98.21 18.27 6.24 17.22  10.87 10.85 
11 368.56 80.34 23.10 85.47  50.95 29.02 
12 305.27 44.53 25.54 52.34  33.68 18.48 
13 24.83 7.50 0.81 6.67  4.01 2.77 
14 438.40 94.32 61.72 98.44  26.25 33.42 
15 408.71 111.43 43.27 104.06  48.19 33.47 
        
Middle Stage of AMD        
16 344.79 77.96 52.59 74.78  72.70 41.67 
17 228.44 46.88 24.22 66.80  29.70 31.83 
18 111.71 31.65 1.94 34.30  17.22 16.04 
19 50.14 15.77 1.21 10.19  5.01 4.13 
20 444.24 69.64 16.28 87.64  54.58 28.34 
21 105.09 26.20 6.43 27.14  12.56 9.73 
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Carotenoids Concentration (nmol/L) 







(All E+Z) 3'-epilutein 3'-oxolutein  3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
22 246.76 31.14 36.08 33.88  15.05 9.07 
23 526.95 94.79 14.54 91.28  68.08 29.03 
24 187.53 50.95 22.76 62.50  34.83 22.31 
25 424.85 97.56 25.42 74.66  53.32 28.99 
26 239.85 59.11 12.41 39.57  21.16 14.73 
27 166.35 38.88 17.89 46.72  25.74 23.36 
28 109.38 23.54 8.40 31.15  13.14 7.49 
29 354.63 102.31 30.09 88.57  44.75 25.46 
30 263.85 43.40 16.66 51.12  35.79 21.88 
End Stage of AMD        
31 86.25 18.73 8.66 22.03  14.15 7.08 
32 200.52 40.03 35.30 42.91  15.89 13.76 
33 254.87 49.77 39.86 56.02  22.01 16.76 
34 460.38 76.22 7.40 62.53  32.62 16.01 
35 97.95 28.26 7.86 23.06  17.49 9.33 
36 457.28 67.85 43.24 72.45  59.99 25.73 
37 166.85 50.61 17.23 50.67  27.45 17.60 
38 133.06 41.68 13.01 31.87  13.33 9.31 
39 379.56 61.14 22.83 64.53  29.49 13.95 
40 343.05 53.95 35.21 59.23  61.62 30.29 
41 304.87 52.41 29.59 52.68  56.70 20.54 
42 236.93 71.00 13.71 46.41  34.12 20.59 
43 173.86 52.91 8.95 42.99  27.93 19.44 
44 109.72 27.75 9.60 18.49  10.34 9.80 
45 131.38 16.76 12.12 61.10  31.81 24.76 
                          1 3’-oxolutein refers to (All-E+Z)-3-Hydroxy-β,ε-Catoten-3’-one 
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APPENDIX P. SERUM CONCENTRATIONS OF LUTEIN AND ZEAXANTHIN METABOLITES IN SUBJECTS 
                                   AT WEEK 1 
 
    Serum concentrations of lutein, zeaxanthin and their metabolites in human subjects at week 1.  
Carotenoids Concentration (nmol/L) 








(All E+Z) 3'-epilutein 3'-oxolutein1
 
3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
No AMD        
1 94.73 22.63 6.52 21.54  12.43 12.10 
2 64.21 24.66 6.40 17.50  8.52 5.34 
3 408.32 68.23 58.10 70.03  44.26 35.16 
4 207.83 38.57 38.76 44.87  22.50 18.89 
5 170.63 31.67 31.56 48.95  66.31 50.97 
6 294.27 55.80 5.87 44.63  25.45 12.15 
7 154.01 41.26 11.67 42.89  33.78 17.00 
8 109.30 24.23 13.88 21.13  14.66 11.49 
9 100.96 34.70 9.85 30.57  19.52 10.20 
10 152.32 24.58 11.30 27.77  15.96 13.26 
11 516.52 104.24 62.45 116.02  71.49 41.74 
12 230.27 46.18 16.98 47.97  22.45 15.63 
13 40.91 8.14 2.97 16.09  10.50 4.39 
14 553.00 117.82 78.54 110.95  68.17 31.11 
15 189.23 62.59 25.34 54.21  25.73 19.50 
        
Middle Stage of AMD        
16 308.64 77.30 41.79 84.02  57.91 23.77 
17 155.88 44.94 17.98 43.83  19.54 15.64 
18 187.57 54.99 5.10 54.85  29.87 24.54 
19 151.32 48.18 2.19 38.51  20.51 13.77 
20 506.59 78.98 21.72 96.25  58.24 28.41 
21 215.64 49.55 18.60 48.77  9.91 11.94 
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APPENDIX P. (continued) 
 
Carotenoids Concentration (nmol/L) 







(All E+Z) 3'-epilutein 3'-oxolutein  3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
22 281.93 43.83 35.47 45.99  22.81 12.86 
23 281.88 44.36 7.27 52.78  36.14 16.26 
24 172.59 52.31 22.76 62.50  34.83 22.31 
25 263.12 65.15 17.92 54.83  43.90 26.41 
26 225.74 49.81 12.95 37.25  25.27 10.97 
27 118.51 26.22 13.13 29.92  19.28 17.31 
28 133.23 25.04 10.83 23.49  18.05 8.78 
29 217.13 46.36 21.96 47.79  25.75 16.06 
30 388.61 70.10 25.69 74.47  47.55 30.09 
End Stage of AMD        
31 118.86 23.98 5.97 22.72  17.00 9.70 
32 133.44 33.68 14.45 34.45  13.13 12.10 
33 378.77 74.57 39.65 79.45  32.60 20.27 
34 326.73 65.31 5.92 52.85  29.45 15.10 
35 127.77 30.39 11.95 24.78  14.85 11.68 
36 408.79 70.55 19.27 67.38  58.47 26.86 
37 146.69 42.47 15.03 43.37  24.28 16.68 
38 134.14 47.30 16.20 33.22  13.31 11.21 
39 205.40 35.23 11.00 38.83  17.38 9.91 
40 282.29 42.88 20.37 41.12  20.40 17.74 
41 217.67 31.62 11.14 35.35  29.17 14.02 
42 166.52 43.14 8.67 34.63  17.19 12.96 
43 167.10 51.60 5.68 35.99  23.16 13.70 
44 79.34 25.98 6.86 16.13  12.21 8.86 
45 214.31 30.64 21.32 48.21  31.24 21.45 
                          1 3’-oxolutein refers to (All-E+Z)-3-Hydroxy-β,ε-Catoten-3’-one 
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APPENDIX Q. SERUM CONCENTRATIONS OF LUTEIN AND ZEAXANTHIN METABOLITES IN SUBJECTS 
                                   AT WEEK 4 
 
    Serum concentrations of lutein, zeaxanthin and their metabolites in human subjects at week 4.  
Carotenoids Concentration (nmol/L) 








(All E+Z) 3'-epilutein 3'-oxolutein1
 
3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
No AMD        
1 634.49 75.39 0.00 90.81  63.86 37.55 
2 643.91 69.01 27.55 62.74  36.97 18.46 
3 862.38 125.55 80.24 118.04  98.19 50.06 
4 1449.04 138.58 106.03 163.48  151.74 62.27 
5 514.74 51.39 26.66 71.41  157.59 69.59 
6 147.13 44.77 3.95 35.10  15.61 9.83 
7 274.58 41.92 11.38 56.69  47.21 19.43 
8 530.11 60.21 20.37 56.60  50.41 24.20 
9 284.76 52.99 18.64 57.49  29.62 12.76 
10 267.41 40.24 11.67 58.58  25.52 15.66 
11 785.92 98.99 39.12 155.94  83.35 47.39 
12 627.83 61.18 26.00 67.83  56.73 26.34 
13 319.71 43.73 13.51 49.54  31.84 18.96 
14 713.60 81.41 39.81 114.39  106.04 51.32 
15 537.27 199.16 41.53 127.94  60.93 36.18 
        
Middle Stage of AMD        
16 325.96 40.38 26.00 49.14  46.86 24.29 
17 794.81 107.87 41.97 103.83  78.58 44.39 
18 827.75 87.12 24.20 90.08  62.81 31.66 
19 617.38 69.55 15.49 88.31  63.26 30.77 
20 660.16 79.56 22.27 112.27  77.93 36.09 
21 183.11 19.54 4.45 29.03  20.18 7.34 
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APPENDIX Q. (continued) 
 
Carotenoids Concentration (nmol/L) 







(All E+Z) 3'-epilutein 3'-oxolutein  3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
22 440.67 54.69 23.00 39.89  23.42 9.34 
23 478.22 46.49 7.60 62.93  45.24 21.41 
24 556.39 72.69 25.00 74.98  58.44 29.35 
25 259.47 64.01 17.91 51.80  30.10 17.48 
26 1093.37 114.98 35.33 87.66  62.59 23.53 
27 528.46 48.48 20.71 59.30  44.21 22.76 
28 444.13 63.30 26.60 61.14  37.25 17.16 
29 1000.13 147.90 60.21 134.96  84.73 42.39 
30 612.85 60.58 23.25 96.08  79.03 37.66 
End Stage of AMD        
31 825.06 70.07 19.04 80.39  85.73 36.63 
32 455.94 55.18 24.63 57.27  33.22 17.64 
33 485.38 52.72 26.79 58.92  34.84 14.82 
34 955.05 89.82 16.63 75.39  59.65 23.85 
35 611.45 59.15 54.21 80.21  67.02 30.87 
36 1858.42 190.71 80.86 240.93  197.71 77.10 
37 205.09 65.14 17.70 70.06  31.21 21.16 
38 1742.98 143.55 59.69 145.75  103.59 35.91 
39 196.24 24.98 10.82 30.29  17.55 8.69 
40 195.31 21.82 16.09 31.33  23.36 15.47 
41 334.45 37.45 16.09 61.30  37.66 24.48 
42 244.39 63.32 18.86 44.95  28.98 16.37 
43 387.57 36.27 11.52 43.16  49.08 24.56 
44 328.27 48.36 14.59 41.27  32.94 15.51 
45 83.82 10.13 5.13 13.01  11.75 6.12 
                           1 3’-oxolutein refers to (All-E+Z)-3-Hydroxy-β,ε-Catoten-3’-one 
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APPENDIX R. SERUM CONCENTRATIONS OF LUTEIN AND ZEAXANTHIN METABOLITES IN SUBJECTS 
                                   AT WEEK 12 
 
    Serum concentrations of lutein, zeaxanthin and their metabolites in human subjects at week 12.  
Carotenoids Concentration (nmol/L) 








(All E+Z) 3'-epilutein 3'-oxolutein1
 
3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
No AMD        
1 399.08 50.30 15.13 65.96  43.80 24.62 
2 365.31 38.98 13.43 45.42  29.00 15.40 
3 830.26 106.54 82.66 141.16  106.86 50.35 
4 1290.25 130.20 71.16 144.80  147.66 57.98 
5 539.37 39.68 25.55 72.05  160.72 61.46 
6 348.90 50.07 10.66 58.33  33.45 12.79 
7 535.28 69.74 13.71 75.40  61.48 22.26 
8 725.53 70.95 36.99 68.45  64.89 26.13 
9 496.74 72.55 20.65 71.09  45.88 23.48 
10 345.14 44.88 12.68 41.57  33.45 18.28 
11 828.39 105.42 0.00 135.79  96.78 46.32 
12 115.15 16.29 3.64 17.93  12.77 6.67 
13 322.52 50.46 35.64 66.88  39.28 30.20 
14 1457.92 159.44 61.10 168.55  128.67 52.20 
15 668.71 171.26 49.11 137.97  60.31 40.64 
        
Middle Stage of AMD        
16 492.81 60.67 62.95 79.34  79.68 38.35 
17 272.21 33.40 11.23 43.70  37.29 23.29 
18 877.59 81.59 18.08 116.26  104.94 55.01 
19 960.67 95.32 14.21 99.74  86.98 35.29 
20 817.95 99.65 25.79 145.31  84.96 43.04 
21 282.74 31.97 3.18 36.80  24.56 10.09 
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APPENDIX R. (continued) 
 
Carotenoids Concentration (nmol/L) 







(All E+Z) 3'-epilutein 3'-oxolutein  3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
22 412.16 49.16 18.26 44.73  27.57 12.61 
23 682.73 70.76 14.62 96.90  55.83 22.89 
24 390.14 44.85 14.80 64.47  51.29 26.38 
25 405.37 82.31 19.17 62.76  40.87 27.19 
26 746.17 73.61 25.09 46.59  36.13 13.71 
27 1435.63 124.25 58.39 145.14  137.50 53.17 
28 744.69 91.25 55.41 111.99  67.17 24.61 
29 610.41 108.67 46.07 132.26  104.34 55.27 
30 1420.31 154.52 47.94 187.50  157.43 60.71 
End Stage of AMD        
31 609.39 51.01 11.16 77.14  89.07 40.28 
32 687.13 80.10 41.64 80.44  50.47 25.21 
33 608.90 70.83 21.18 84.63  52.40 24.40 
34 1855.62 179.39 26.24 189.67  118.21 43.04 
35 638.22 61.46 17.12 78.81  69.88 28.88 
36 890.69 88.64 25.73 109.28  85.78 36.11 
37 249.41 58.21 16.67 71.12  72.58 26.42 
38 515.50 43.60 0.00 40.81  29.40 9.60 
39 360.61 52.57 16.92 48.12  33.83 12.56 
40 448.06 63.99 30.82 59.58  74.62 31.32 
41 561.44 86.26 23.65 80.52  59.86 27.32 
42 260.74 62.08 13.17 74.51  37.02 31.38 
43 1622.39 140.21 25.17 129.08  141.84 47.03 
44 278.20 36.91 9.66 32.07  29.29 10.07 
45 996.97 84.84 29.79 130.34  137.45 66.88 
                           1 3’-oxolutein refers to (All-E+Z)-3-Hydroxy-β,ε-Catoten-3’-one 
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APPENDIX S. SERUM CONCENTRATIONS OF LUTEIN AND ZEAXANTHIN METABOLITES IN SUBJECTS 
                                   AT WEEK 26 
 
    Serum concentrations of lutein, zeaxanthin and their metabolites in human subjects at week 26.  
Carotenoids Concentration (nmol/L) 








(All E+Z) 3'-epilutein 3'-oxolutein1
 
3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
No AMD        
1 1143.30 136.39 56.54 160.87  118.78 53.67 
2 618.86 53.39 22.51 60.03  51.77 27.07 
3 512.77 82.23 52.03 65.95  40.64 21.63 
4 2598.15 214.98 124.75 251.48  255.27 99.39 
5 559.42 42.73 36.53 71.14  150.62 65.91 
6 256.63 39.50 6.63 39.76  24.64 12.11 
7 433.33 86.23 11.60 83.01  61.70 22.72 
8 701.28 62.63 31.95 66.43  68.06 27.68 
9 572.71 94.73 30.46 95.66  61.41 25.50 
10 229.32 39.70 9.78 55.23  38.57 33.14 
11 557.88 101.86 24.77 162.42  120.11 78.19 
12 333.11 54.65 15.89 52.05  36.82 20.49 
13 514.26 69.41 34.60 91.04  81.13 44.38 
14 1885.64 306.42 96.56 248.42  183.32 91.86 
15 421.38 158.55 36.96 85.97  54.66 37.54 
        
Middle Stage of AMD        
16 240.50 33.18 13.94 41.30  28.61 16.77 
17 646.13 66.17 30.77 93.73  66.08 31.08 
18 227.85 24.01 4.82 38.05  20.62 9.29 
19 600.03 56.74 11.42 79.76  63.60 27.17 
20 502.86 59.29 18.84 96.26  73.40 33.25 
21 760.72 88.02 14.19 94.12  61.48 19.16 
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APPENDIX S. (continued) 
 
Carotenoids Concentration (nmol/L) 







(All E+Z) 3'-epilutein 3'-oxolutein  3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
22 708.77 69.62 23.95 56.15  33.21 10.67 
23 826.49 81.74 20.19 121.20  88.09 54.08 
24 274.26 47.87 20.99 58.00  39.01 24.68 
25 455.69 87.04 24.95 77.72  41.96 22.40 
26 646.40 78.19 22.94 69.14  52.29 20.96 
27 1140.56 100.94 44.03 130.97  111.00 61.15 
28 351.74 39.26 15.56 58.34  42.71 16.53 
29 490.67 103.68 27.97 109.06  110.92 41.39 
30 625.25 75.46 23.50 116.02  103.63 58.08 
End Stage of AMD        
31 1314.14 110.95 26.03 132.39  159.29 55.38 
32 1158.29 112.18 55.16 114.62  73.95 25.36 
33 554.44 47.44 29.68 79.31  45.19 17.29 
34 605.71 71.21 9.86 84.80  64.46 26.82 
35 1244.33 115.63 37.46 136.44  122.25 50.52 
37 317.01 61.19 30.85 56.78  48.15 24.36 
38 710.63 71.09 20.22 72.15  47.44 15.38 
39 641.26 95.94 30.34 123.90  68.91 35.11 
40 228.13 34.24 14.46 57.73  56.02 45.20 
41 455.92 60.49 21.03 61.04  55.91 21.77 
42 312.75 76.76 17.60 51.42  41.54 17.17 
43 1475.78 140.22 34.13 145.23  172.28 56.37 
44 394.32 51.71 26.95 42.21  29.89 16.82 
45 1091.11 103.13 39.21 136.25  99.30 46.38 
31 1314.14 110.95 26.03 132.39  159.29 55.38 
                           1 3’-oxolutein refers to (All-E+Z)-3-Hydroxy-β,ε-Catoten-3’-one 
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APPENDIX T. SERUM CONCENTRATIONS OF LUTEIN AND ZEAXANTHIN METABOLITES IN SUBJECTS 
                                   AT WEEK 38 
 
    Serum concentrations of lutein, zeaxanthin and their metabolites in human subjects at week 38.  
Carotenoids Concentration (nmol/L) 








(All E+Z) 3'-epilutein 3'-oxolutein1
 
3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
No AMD        
1 48.13 20.18 3.11 19.74  13.31 6.83 
2 150.24 47.88 18.17 32.82  40.90 7.93 
3 402.61 80.44 57.53 84.58  46.32 40.70 
4 487.37 84.09 67.23 83.54  29.62 50.79 
5 107.65 22.75 11.83 45.17  43.94 36.88 
6 77.70 24.15 3.15 27.18  11.90 6.23 
7 91.15 33.83 9.34 32.34  24.35 14.75 
8 152.84 27.54 26.53 37.05  22.49 19.56 
9 236.77 68.93 27.15 76.90  23.19 21.07 
10 226.44 71.77 36.52 44.75  49.73 24.18 
11 369.61 89.43 27.66 109.90  71.21 46.66 
12 492.66 144.93 54.45 78.19  36.19 27.08 
13 233.23 39.44 17.10 40.92  20.52 14.62 
14 629.11 155.87 112.74 106.25  86.97 57.80 
15 326.06 167.23 0.00 84.20  32.83 28.97 
        
Middle Stage of AMD        
16 185.62 31.67 16.78 40.88  21.74 20.60 
17 208.53 33.61 27.35 56.64  27.85 19.81 
18 180.86 41.27 4.54 40.70  20.86 16.09 
19 984.86 97.18 19.09 105.38  91.05 35.27 
20 249.32 31.75 19.26 51.53  28.53 16.17 
21 231.71 46.38 13.29 67.13  20.07 11.72 
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APPENDIX T. (continued) 
 
Carotenoids Concentration (nmol/L) 







(All E+Z) 3'-epilutein 3'-oxolutein  3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
22 146.38 24.51 13.56 25.58  11.04 6.73 
23 669.85 81.46 9.09 119.74  86.51 38.77 
24 247.30 65.94 25.96 64.06  36.46 24.72 
25 221.46 84.06 20.86 54.38  22.99 21.39 
26 288.01 49.75 10.93 52.18  32.43 16.15 
27 653.25 84.37 31.78 82.61  70.58 35.05 
28 305.73 53.40 32.32 65.61  77.88 44.67 
29 232.68 80.13 40.51 63.27  56.71 33.88 
30 387.15 88.25 41.12 67.44  64.39 39.03 
End Stage of AMD        
31 275.93 45.96 17.21 41.55  33.54 17.78 
32 227.48 34.19 24.29 46.83  19.51 17.94 
33 312.74 54.08 28.57 68.90  23.37 13.25 
34 391.40 56.18 7.37 68.17  43.14 20.82 
35 270.86 39.31 28.68 55.13  36.81 19.43 
37 298.10 74.68 42.47 49.57  40.36 18.36 
38 151.75 52.50 25.52 44.92  17.35 12.50 
39 406.04 98.65 57.38 75.40  57.40 19.80 
40 248.65 59.79 40.08 52.86  87.97 53.06 
41 574.07 78.43 34.97 83.11  52.31 27.71 
42 213.35 64.11 25.73 42.51  40.44 11.69 
43 224.47 57.78 9.08 50.83  39.41 24.28 
44 273.26 62.99 58.08 34.01  27.33 14.62 
45 375.86 60.37 35.28 75.97  70.24 27.38 
31 275.93 45.96 17.21 41.55  33.54 17.78 
                           1 3’-oxolutein refers to (All-E+Z)-3-Hydroxy-β,ε-Catoten-3’-one 
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APPENDIX U. SERUM CONCENTRATIONS OF LUTEIN AND ZEAXANTHIN METABOLITES IN SUBJECTS 
                                   AT WEEK 52 
 
    Serum concentrations of lutein, zeaxanthin and their metabolites in human subjects at week 52.  
Carotenoids Concentration (nmol/L) 








(All E+Z) 3'-epilutein 3'-oxolutein1
 
3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
No AMD        
1 186.00 53.78 19.08 58.94  29.05 22.36 
2 101.19 20.53 13.75 34.70  0.00 17.53 
3 427.01 135.24 44.77 129.46  79.01 55.56 
4 173.49 42.41 26.09 61.73  37.18 26.21 
5 202.32 41.96 38.02 58.05  59.40 47.58 
6 276.41 54.57 25.12 50.47  44.40 24.36 
7 191.53 63.78 16.93 45.65  31.30 16.73 
8 252.08 50.87 37.69 40.49  40.25 21.90 
9 267.39 45.15 38.40 62.17  36.46 20.75 
10 228.25 65.41 0.00 101.27  38.41 19.76 
11 480.43 117.73 45.32 209.72  85.84 64.95 
12 195.66 69.18 25.67 37.15  19.96 12.63 
13 294.69 66.22 32.13 69.63  41.17 30.13 
14 546.27 118.94 75.09 122.00  65.78 38.08 
15 239.45 188.87 42.90 117.56  33.87 55.14 
        
Middle Stage of AMD        
16 238.12 43.27 14.93 43.44  22.03 17.47 
17 217.83 42.68 20.14 50.98  41.09 19.99 
18 138.37 41.34 2.87 44.66  18.51 13.13 
19 146.89 45.64 4.53 36.48  20.29 10.05 
20 422.38 88.17 32.13 105.32  51.87 30.87 
21 451.00 71.71 9.40 61.14  40.91 14.76 
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APPENDIX U. (continued) 
 
Carotenoids Concentration (nmol/L) 







(All E+Z) 3'-epilutein 3'-oxolutein  3’-hydroxy-ε,ε-caroten-3-one ε,ε-caroten-3,3'-dione
22 367.92 64.03 22.95 46.53  26.04 10.18 
23 566.64 74.54 10.46 75.49  62.36 29.88 
24 147.45 32.55 15.22 36.86  29.32 17.78 
25 97.75 43.61 10.30 32.43  13.53 17.22 
26 163.23 40.25 14.32 22.33  17.12 10.02 
27 605.99 71.82 23.14 71.10  80.55 42.49 
28 345.93 52.00 29.06 58.20  48.34 20.28 
29 309.41 88.58 55.90 114.80  42.79 32.47 
30 516.75 85.64 36.95 92.39  69.74 49.06 
End Stage of AMD        
31 121.03 23.14 5.93 25.91  22.17 14.66 
32 129.47 27.31 16.78 33.11  7.06 12.07 
33 204.71 45.07 20.57 40.69  14.17 15.39 
34 200.75 36.66 4.21 57.53  32.37 22.95 
35 76.67 24.14 5.81 24.87  13.90 12.75 
37 315.09 89.25 35.36 75.81  52.10 31.27 
38 141.28 62.58 21.38 23.69  20.34 9.60 
39 156.09 55.73 19.39 37.83  21.64 15.09 
40 109.28 35.38 16.62 20.73  22.36 26.79 
41 430.61 60.36 27.09 53.20  42.88 17.21 
42 198.94 61.50 20.15 55.92  45.17 24.40 
43 198.94 45.01 7.09 42.29  42.25 20.83 
44 315.90 61.66 16.36 57.71  38.92 16.59 
45 209.14 34.19 17.48 49.96  43.29 24.04 
31 121.03 23.14 5.93 25.91  22.17 14.66 
                           1 3’-oxolutein refers to (All-E+Z)-3-Hydroxy-β,ε-Catoten-3’-one 
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APPENDIX V. SERUM CONCENTRATIONS OF MAJOR DIETARY CAROTENOIDS, VITAMIN A, AND  
VITAMIN E IN SUBJECTS AT WEEK 0 
 
   Serum concentrations of major dietary carotenoids, 2,6-cyclolycopene-1,5-diol I & II, retinol, α-tocopherol, and γ-tocopherol in  
   human subjects at week 0. 




























No AMD             
1 83.79 6.42 14.48 66.70 17.85 86.59 11.26 24.59 7.87 0.41 6.75 0.44 
2 157.56 26.24 33.77 144.84 22.34 103.18 13.96 30.96 10.30 0.78 22.15 0.75 
3 104.87 58.78 40.04 185.79 35.95 114.43 23.90 24.06 0.00 2.42 7.31 1.29 
4 205.87 140.50 24.16 98.69 19.64 71.18 26.14 39.67 11.54 1.36 10.59 1.04 
5 203.24 96.25 19.99 83.92 18.52 29.17 11.91 52.88 23.82 2.03 21.40 2.62 
6 84.00 28.37 16.05 77.73 7.30 21.82 2.00 10.96 0.00 0.64 16.47 0.64 
7 70.17 20.47 12.48 77.43 6.79 19.88 2.16 5.87 4.43 0.92 11.54 1.21 
8 113.21 22.70 17.73 37.12 19.14 44.45 6.11 17.35 3.83 0.50 8.18 0.67 
9 37.41 54.93 32.39 78.19 8.93 80.25 16.71 34.97 0.00 0.81 18.09 1.35 
10 105.19 36.15 14.40 50.64 50.27 109.92 15.77 37.07 12.20 0.68 5.91 0.67 
11 60.72 38.17 21.98 64.01 12.48 30.79 5.71 13.67 5.80 2.12 13.55 1.19 
12 114.96 39.33 34.91 129.16 33.04 94.43 16.99 18.78 8.78 1.82 15.15 0.66 
13 46.92 4.76 4.11 16.87 11.91 31.53 2.81 7.93 8.75 0.20 3.78 0.45 
14 153.08 121.87 50.97 178.81 19.13 64.36 14.25 28.30 0.00 1.65 14.18 1.40 
15 64.85 23.28 64.64 597.22 25.38 53.56 17.25 34.15 11.03 1.85 37.54 1.32 
             
Middle Stage of AMD             
16 201.61 161.04 26.18 131.84 23.33 57.67 41.72 54.44 0.00 2.98 12.37 0.84 
17 252.82 100.94 43.11 270.91 67.61 208.33 41.41 49.40 13.70 2.72 17.48 1.27 
18 135.03 33.06 18.73 81.81 10.17 55.12 8.91 22.94 5.03 1.50 19.92 1.66 
19 57.77 6.38 8.92 28.79 9.26 22.57 2.01 6.01 2.11 0.57 2.62 0.71 
20 97.67 71.48 19.89 53.36 12.12 39.35 5.84 19.46 3.70 1.35 18.54 0.59 
21 67.70 24.13 27.81 114.39 9.18 20.07 3.57 12.45 5.27 0.62 9.39 0.32 
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22 35.86 9.07 23.19 82.97 10.88 48.85 2.01 9.30 0.11 1.08 8.46 1.26 
23 148.95 56.61 26.15 45.72 23.83 55.46 36.57 49.54 0.00 1.88 12.06 1.19 
24 106.07 51.17 28.14 155.27 21.03 52.43 12.13 21.42 8.41 1.21 15.72 0.83 
25 153.96 48.05 63.87 226.05 134.70 525.57 19.75 23.60 8.03 2.36 19.99 0.92 
26 110.41 48.46 36.27 101.79 11.14 60.66 10.20 25.55 9.17 1.36 15.95 2.06 
27 118.62 28.78 17.44 57.44 11.68 37.86 6.74 14.95 8.70 1.95 12.92 1.45 
28 136.93 27.80 16.79 70.54 17.83 48.11 15.15 31.64 0.00 0.74 18.58 0.32 
29 290.55 154.21 54.73 216.06 33.42 103.36 22.81 46.23 0.00 2.35 22.61 2.15 
30 154.56 36.63 32.01 130.13 39.04 183.66 32.78 32.87 4.65 0.88 14.92 0.59 
             
End Stage of AMD             
31 34.18 12.68 15.24 60.33 10.61 39.17 4.93 9.94 2.40 0.53 9.63 1.50 
32 130.60 63.78 32.01 150.12 19.98 68.13 8.61 17.11 0.00 0.99 10.42 2.03 
33 187.35 87.82 15.34 51.97 11.80 32.77 11.60 31.00 13.38 1.87 22.13 0.75 
34 79.72 28.68 28.05 124.66 18.95 58.83 3.28 11.52 0.00 2.04 13.53 1.54 
35 111.09 20.30 8.63 27.49 13.92 26.22 33.62 16.29 2.82 1.77 5.17 1.88 
36 161.92 49.57 25.25 105.97 26.40 83.19 18.57 29.60 0.00 2.50 16.03 1.83 
37 83.33 43.86 20.38 73.51 20.04 53.34 10.18 13.73 7.76 0.69 8.14 1.77 
38 47.65 30.81 16.91 80.01 10.22 18.34 25.13 12.75 7.85 1.35 10.31 0.86 
39 164.86 81.99 45.64 195.66 17.24 86.41 16.19 24.28 4.26 2.00 21.48 0.85 
40 299.33 77.14 42.50 126.80 17.41 109.63 17.41 15.94 0.73 1.41 11.98 0.59 
41 156.01 60.88 20.97 70.75 43.15 86.70 23.58 26.36 0.00 1.20 10.46 1.63 
42 103.62 66.79 37.45 116.23 13.97 54.43 6.62 19.43 4.52 1.94 25.36 0.70 
43 70.67 17.62 18.03 26.87 6.53 26.03 1.49 10.96 0.84 1.81 14.02 3.53 
44 54.25 31.17 18.05 43.89 10.69 73.67 5.21 15.25 3.12 0.52 20.33 1.02 
45 47.71 72.18 10.85 35.51 7.08 125.24 7.27 14.27 4.76 0.53 21.77 0.40 
       1 Cyclolycopenes refers to stereoisomeric 2,6-Cyclolycopene-1,5-diol I and 2,6-Cyclolycopene-1,5-diol II. 
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APPENDIX W. SERUM CONCENTRATIONS OF MAJOR DIETARY CAROTENOIDS, VITAMIN A, AND  
VITAMIN E IN SUBJECTS AT WEEK 1 
 
   Serum concentrations of major dietary carotenoids, 2,6-cyclolycopene-1,5-diol I & II, retinol, α-tocopherol, and γ-tocopherol in  
   human subjects at week 1. 




























No AMD             
1 59.73 5.96 14.68 62.41 21.08 75.95 7.53 18.06 3.05 0.44 4.81 0.44 
2 102.22 61.40 18.88 88.77 15.73 62.38 11.41 24.22 8.02 1.18 19.17 0.79 
3 58.78 34.91 31.61 147.16 27.04 89.22 13.81 14.22 2.51 1.33 5.79 0.86 
4 121.37 63.35 9.23 45.30 13.45 41.48 8.40 21.37 5.93 1.12 11.55 0.46 
5 151.07 75.49 16.50 92.12 21.59 28.11 12.31 47.51 19.90 1.41 18.12 1.48 
6 128.97 31.15 23.84 107.80 10.42 39.00 6.12 18.05 0.00 1.47 27.46 1.02 
7 116.44 29.51 12.78 75.10 7.69 23.93 3.17 11.72 2.43 1.36 11.29 1.37 
8 100.82 27.73 16.78 39.31 17.35 41.57 8.34 18.99 5.36 0.56 10.80 0.69 
9 85.82 38.88 28.63 122.68 8.08 63.16 11.22 23.34 15.23 0.51 12.00 0.78 
10 103.59 46.20 13.82 49.34 51.15 118.59 19.27 45.61 9.92 0.92 8.26 1.40 
11 84.16 21.41 30.13 89.74 17.05 52.80 10.55 18.71 0.00 2.37 20.19 4.92 
12 191.42 44.21 47.69 158.59 52.63 181.19 49.37 36.88 3.33 1.67 20.35 1.04 
13 92.67 4.42 13.66 40.25 18.82 51.95 6.37 13.96 2.00 0.45 11.06 0.78 
14 108.07 58.33 32.94 152.80 13.26 52.45 9.52 29.27 9.75 2.01 13.34 2.48 
15 52.32 23.49 61.72 613.26 21.87 58.53 22.45 34.88 9.45 0.91 28.05 0.78 
             
Middle Stage of AMD             
16 63.98 83.72 17.24 119.94 14.08 42.00 3.28 5.15 0.00 2.87 6.34 0.76 
17 321.00 69.13 31.38 126.66 33.30 73.70 45.66 79.23 22.39 0.97 12.36 1.24 
18 125.13 57.53 19.77 76.29 11.35 44.97 9.45 24.18 3.43 2.58 22.18 2.20 
19 126.43 25.64 36.90 103.53 9.97 33.56 7.90 16.65 2.13 0.98 7.42 1.91 
20 107.86 77.71 18.63 47.09 14.28 53.02 6.93 34.13 6.39 1.54 19.48 0.46 
21 94.61 42.72 33.21 130.40 11.49 25.12 7.21 18.60 4.36 2.22 10.40 0.53 
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22 45.90 21.89 21.32 72.48 12.27 49.02 3.34 10.71 0.00 1.82 8.25 1.12 
23 203.93 47.23 25.62 46.43 14.93 44.46 24.53 45.25 15.52 1.08 10.65 1.76 
24 145.28 50.41 27.68 150.82 15.98 43.58 11.73 25.41 11.38 1.17 16.75 0.70 
25 117.13 32.17 54.73 188.42 104.12 403.83 15.73 17.02 0.00 1.47 11.46 1.03 
26 109.10 39.40 31.57 104.52 9.44 56.42 7.68 26.32 3.69 1.28 17.10 2.95 
27 65.60 20.56 14.24 47.02 11.05 36.51 5.78 8.33 0.00 1.12 8.22 1.19 
28 107.72 21.41 17.84 53.02 13.12 37.89 7.44 22.50 10.63 0.72 11.03 0.32 
29 205.52 101.41 35.13 156.90 16.34 67.88 15.93 37.56 33.76 1.34 15.26 0.92 
30 215.00 57.46 54.98 195.54 50.23 243.77 36.17 43.44 7.90 1.48 20.64 0.82 
             
End Stage of AMD             
31 28.98 11.76 10.98 40.42 14.10 41.85 6.87 10.24 2.00 0.87 7.49 0.84 
32 126.36 46.21 28.55 138.78 24.70 86.90 10.80 18.83 4.56 0.79 9.85 2.06 
33 224.83 124.93 28.52 72.48 17.63 46.07 15.61 46.85 15.55 2.34 22.69 1.22 
34 91.01 26.37 25.94 122.28 30.84 72.93 3.16 9.88 4.72 2.07 13.63 1.28 
35 105.12 18.65 9.76 24.45 13.23 28.59 16.96 15.27 0.00 1.56 5.08 2.50 
36 88.64 66.25 22.77 74.00 18.56 46.27 10.96 19.79 11.18 2.75 12.69 1.54 
37 91.30 43.16 25.82 85.96 20.93 57.69 13.97 16.77 8.42 0.62 10.15 1.54 
38 55.04 34.00 22.44 131.22 7.88 20.15 28.22 17.74 15.82 1.43 11.18 1.34 
39 81.86 39.78 25.89 137.95 13.97 74.57 7.67 13.71 2.27 1.15 16.03 0.40 
40 228.13 65.91 55.26 219.80 27.18 129.32 16.29 29.76 5.79 1.10 14.06 0.94 
41 190.69 25.33 25.23 86.55 41.32 79.88 18.94 25.41 9.21 0.89 11.26 1.98 
42 73.94 41.95 33.30 118.13 13.66 103.44 8.08 15.29 3.82 1.34 27.81 0.49 
43 87.03 21.66 22.48 27.17 6.31 25.37 2.04 10.19 6.42 1.74 15.34 3.15 
44 53.29 25.55 15.07 39.94 10.29 86.03 4.20 14.26 4.03 0.35 16.80 0.69 
45 43.87 64.34 8.73 30.19 6.85 95.63 3.38 11.74 4.77 1.35 15.89 0.55 
       1 Cyclolycopenes refers to stereoisomeric 2,6-Cyclolycopene-1,5-diol I and 2,6-Cyclolycopene-1,5-diol II. 
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APPENDIX X. SERUM CONCENTRATIONS OF MAJOR DIETARY CAROTENOIDS, VITAMIN A, AND  
VITAMIN E IN SUBJECTS AT WEEK 4 
 
   Serum concentrations of major dietary carotenoids, 2,6-cyclolycopene-1,5-diol I & II, retinol, α-tocopherol, and γ-tocopherol in  
   human subjects at week 4. 




























No AMD             
1 55.54 17.72 29.75 97.34 16.83 64.40 7.35 12.46 3.97 0.95 10.78 0.64 
2 205.82 98.31 34.10 151.95 19.82 138.44 23.27 44.20 17.37 1.84 25.36 0.92 
3 197.28 75.53 63.49 311.51 51.73 185.71 28.45 30.00 0.00 1.71 13.83 1.93 
4 177.60 98.63 26.38 116.31 13.65 64.32 17.53 31.05 8.82 1.26 18.75 0.77 
5 114.09 28.56 14.18 62.40 10.79 22.09 7.56 35.47 10.39 1.18 16.41 1.75 
6 110.76 35.24 25.84 127.03 9.29 26.44 4.36 16.90 3.85 0.97 23.73 0.64 
7 79.49 15.43 17.96 89.39 7.64 23.85 5.63 11.04 1.16 0.54 11.36 1.33 
8 133.76 41.62 25.41 54.69 18.55 50.85 11.61 21.27 4.77 1.35 17.57 1.78 
9 84.53 34.98 30.21 175.45 11.82 91.42 14.07 40.91 17.66 1.19 23.82 0.78 
10 161.38 52.16 28.76 104.63 104.33 168.70 35.32 64.30 0.00 1.10 11.42 1.78 
11 66.99 36.16 28.46 105.24 14.26 35.91 6.69 10.60 3.77 1.99 18.89 2.00 
12 69.21 30.51 27.75 122.59 39.49 131.00 23.05 21.22 13.66 0.72 17.11 0.40 
13 92.08 28.50 21.03 59.19 15.81 51.59 17.34 26.41 0.00 0.83 10.27 1.35 
14 120.58 50.91 36.39 122.61 10.41 43.08 11.98 25.29 6.62 0.91 10.50 1.04 
15 40.04 0.00 70.55 542.14 22.91 104.48 12.34 17.18 0.72 0.96 29.28 1.13 
             
Middle Stage of AMD             
16 126.34 76.38 21.93 91.82 23.60 76.21 17.48 18.32 14.67 1.65 10.01 0.41 
17 221.23 108.54 36.63 102.60 31.32 79.65 27.89 59.96 10.28 1.83 14.38 1.25 
18 96.73 35.66 27.48 90.40 9.28 79.83 7.13 21.28 3.97 2.43 15.83 1.35 
19 143.15 40.98 34.55 95.31 7.88 26.23 11.21 15.32 6.49 1.58 6.59 2.10 
20 132.80 70.89 19.57 44.70 14.08 52.78 8.71 25.15 8.70 1.55 24.18 0.44 
21 36.63 7.55 9.70 34.31 6.28 16.09 0.00 4.20 0.00 0.26 3.56 0.61 
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22 42.32 10.42 26.58 82.01 12.46 52.13 0.98 9.92 0.00 1.47 10.00 1.81 
23 172.59 50.49 21.29 35.82 11.72 39.73 22.44 42.32 6.81 0.92 8.79 0.67 
24 96.30 17.30 40.28 155.76 23.48 54.36 15.56 23.23 0.00 0.90 20.00 1.09 
25 76.07 43.81 41.92 178.84 51.76 285.54 9.26 15.18 7.01 0.99 14.98 0.42 
26 184.77 45.47 26.18 56.08 18.28 102.18 9.67 25.99 2.12 2.45 10.26 1.76 
27 63.45 25.91 13.23 57.22 11.58 119.75 6.14 12.08 1.40 1.24 15.23 0.63 
28 150.75 28.14 26.34 116.84 15.61 45.70 14.40 28.55 13.51 1.13 21.26 0.51 
29 294.70 113.91 57.72 240.55 18.64 104.54 17.35 40.17 8.12 1.99 24.69 0.80 
30 126.01 26.54 34.76 132.62 31.47 187.18 18.98 24.59 5.55 0.74 16.14 0.55 
             
End Stage of AMD             
31 31.16 14.96 14.93 44.25 14.74 53.52 2.65 8.98 0.00 0.90 5.82 1.07 
32 142.92 53.29 35.43 158.53 21.25 87.56 17.84 19.65 4.97 0.87 11.47 2.49 
33 189.15 84.54 22.60 62.38 15.15 40.33 15.94 49.87 12.48 1.65 16.35 1.03 
34 71.40 15.62 27.29 98.54 32.49 59.78 4.07 9.73 5.49 0.90 9.65 0.94 
35 112.69 35.20 22.29 60.90 9.34 34.09 11.80 15.92 10.17 1.45 6.94 2.66 
36 151.75 116.50 29.03 90.01 25.70 87.30 17.05 23.14 15.47 4.14 14.01 1.65 
37 211.63 58.80 51.83 192.70 24.65 136.53 22.18 37.53 9.17 1.23 15.86 5.05 
38 89.55 35.93 30.70 80.47 13.72 36.35 11.53 14.10 7.50 3.08 14.85 0.95 
39 131.52 38.76 36.12 189.83 14.78 91.49 9.24 19.67 14.61 0.78 23.54 0.47 
40 181.30 52.84 29.62 143.13 15.80 73.57 10.30 24.24 8.72 0.43 8.59 0.43 
41 146.99 47.19 24.22 100.98 39.06 74.13 21.60 31.59 9.54 1.01 13.24 1.69 
42 96.39 32.15 48.33 133.83 17.02 206.74 10.66 18.54 3.96 1.17 33.47 0.62 
43 54.26 0.00 25.43 41.27 6.00 24.72 1.43 7.26 2.24 0.35 11.56 2.11 
44 66.70 34.48 22.66 53.24 16.13 118.39 13.64 25.54 11.92 0.81 24.47 0.85 
45 40.72 12.56 6.79 24.53 21.24 64.45 2.04 8.53 13.44 0.13 9.92 0.32 
       1 Cyclolycopenes refers to stereoisomeric 2,6-Cyclolycopene-1,5-diol I and 2,6-Cyclolycopene-1,5-diol II. 
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APPENDIX Y. SERUM CONCENTRATIONS OF MAJOR DIETARY CAROTENOIDS, VITAMIN A, AND  
VITAMIN E IN SUBJECTS AT WEEK 12 
 
   Serum concentrations of major dietary carotenoids, 2,6-cyclolycopene-1,5-diol I & II, retinol, α-tocopherol, and γ-tocopherol in  
   human subjects at week 12. 




























No AMD             
1 55.39 17.52 21.71 91.28 15.09 59.35 7.93 13.20 6.45 0.49 5.91 0.88 
2 177.73 66.07 40.34 162.46 26.56 194.39 44.03 85.08 17.54 1.14 24.01 0.47 
3 56.72 19.75 38.83 170.02 19.55 72.41 8.51 11.40 12.23 1.98 11.18 2.39 
4 189.26 67.68 27.80 94.01 22.62 64.62 20.90 38.55 0.00 1.02 13.68 2.08 
5 100.61 35.55 12.08 46.73 14.36 28.69 6.86 30.49 16.90 0.91 14.47 1.55 
6 309.23 61.11 40.02 154.04 15.42 48.28 15.06 31.60 7.49 1.56 34.41 1.11 
7 71.54 19.22 16.57 35.73 9.77 33.28 4.89 13.68 0.00 1.09 11.01 1.51 
8 95.12 22.48 47.22 65.05 23.37 63.74 8.69 16.46 0.00 1.12 18.82 2.12 
9 140.86 56.96 41.54 174.45 20.01 100.59 9.52 30.70 2.28 1.73 32.09 1.33 
10 209.48 77.94 26.91 94.60 60.84 175.09 32.34 75.49 0.00 1.21 13.23 1.95 
11 117.79 51.36 33.55 101.94 17.49 43.06 5.66 17.52 0.00 1.56 17.40 2.21 
12 29.92 4.53 11.60 36.79 16.66 105.17 5.16 6.69 4.38 0.18 5.02 0.27 
13 105.53 35.05 24.72 80.85 13.53 52.61 9.18 20.80 7.15 1.42 13.73 1.32 
14 107.11 92.60 48.42 143.68 15.85 53.65 16.25 32.21 12.27 1.43 16.45 1.48 
15 29.89 0.00 55.02 458.45 30.08 92.01 18.17 18.82 8.90 1.24 23.69 0.72 
             
Middle Stage of AMD             
16 196.60 128.67 27.98 113.99 38.24 99.54 28.30 24.89 10.77 2.37 18.56 0.45 
17 79.46 34.55 14.42 33.53 15.27 40.45 11.04 29.11 4.00 0.56 8.22 0.42 
18 68.31 37.14 16.28 57.69 6.83 35.88 3.58 12.80 1.37 1.71 21.45 0.65 
19 94.18 34.28 22.84 73.63 8.64 24.10 6.01 11.58 2.95 1.97 5.20 1.70 
20 137.85 66.56 26.50 53.06 17.77 65.10 10.70 37.22 10.32 1.55 21.68 0.94 
21 67.04 14.77 33.00 111.41 10.93 40.21 3.84 12.16 2.86 0.64 9.89 0.42 
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22 60.60 16.47 28.95 104.26 10.16 40.23 3.56 11.56 2.55 1.23 10.39 1.93 
23 151.05 55.23 26.51 44.80 19.32 40.04 18.91 44.68 4.78 1.18 9.55 2.08 
24 64.49 19.59 19.40 73.99 10.92 35.03 8.43 12.28 9.09 0.67 9.22 1.34 
25 201.41 93.44 61.19 211.11 52.09 344.07 17.20 29.76 13.54 1.42 20.31 0.65 
26 105.33 45.19 24.10 65.80 15.18 137.56 13.54 24.57 7.57 1.51 26.11 0.79 
27 80.76 26.16 25.94 86.85 20.52 103.72 6.74 11.58 0.00 1.93 25.70 1.08 
28 178.25 71.52 25.81 116.30 16.97 46.67 17.36 45.11 12.21 1.43 14.26 0.83 
29 155.45 68.27 42.86 179.63 13.36 99.13 12.17 29.93 6.59 1.37 14.93 0.75 
30 165.16 36.82 52.63 188.01 51.26 303.18 50.87 51.25 15.59 2.10 26.94 1.04 
             
End Stage of AMD             
31 46.81 18.58 22.18 70.94 11.33 36.75 3.40 9.89 0.01 0.59 7.47 1.29 
32 140.85 49.29 35.97 147.19 24.59 90.21 9.50 24.01 8.16 0.75 10.22 2.45 
33 119.46 75.66 22.81 40.77 9.22 29.09 10.02 31.37 7.17 1.73 18.20 1.91 
34 125.99 25.57 47.30 256.70 17.18 55.75 5.18 18.33 7.97 1.63 24.49 1.06 
35 93.87 21.72 21.44 87.02 9.25 26.84 7.30 15.45 8.51 1.25 7.45 3.32 
36 81.28 30.80 37.73 106.21 29.08 68.90 12.16 14.55 12.29 1.57 17.47 3.21 
37 110.46 0.00 44.84 192.84 25.72 89.79 15.04 22.38 13.87 1.12 22.15 1.69 
38 49.96 15.53 14.11 30.05 9.92 31.44 5.59 5.39 1.67 0.69 8.27 0.72 
39 123.92 23.67 32.36 154.45 11.62 85.69 5.90 14.76 2.64 0.93 20.87 0.68 
40 234.40 67.90 42.87 184.59 15.90 172.93 9.96 23.26 4.37 0.96 18.13 0.78 
41 222.65 62.87 38.20 134.06 34.70 75.16 21.65 52.85 18.44 1.40 15.41 1.89 
42 103.15 68.64 45.97 128.08 20.58 215.53 16.67 20.66 5.94 1.85 34.74 0.64 
43 77.91 0.00 20.55 34.40 6.69 29.91 1.65 10.48 1.40 1.54 10.17 2.26 
44 61.02 18.63 21.45 48.45 15.78 99.08 6.38 10.51 2.36 0.77 18.32 0.97 
45 198.23 91.81 26.49 117.79 10.66 261.71 10.31 24.81 11.72 1.25 29.13 1.01 
       1 Cyclolycopenes refers to stereoisomeric 2,6-Cyclolycopene-1,5-diol I and 2,6-Cyclolycopene-1,5-diol II. 
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APPENDIX Z. SERUM CONCENTRATIONS OF MAJOR DIETARY CAROTENOIDS, VITAMIN A, AND  
VITAMIN E IN SUBJECTS AT WEEK 26 
 
   Serum concentrations of major dietary carotenoids, 2,6-cyclolycopene-1,5-diol I & II, retinol, α-tocopherol, and γ-tocopherol in  
   human subjects at week 26. 




























No AMD             
1 61.52 10.33 54.91 236.03 16.65 109.88 6.81 10.24 7.77 1.13 10.07 1.08 
2 132.67 88.61 20.71 69.05 19.08 53.52 8.34 42.51 17.19 1.73 20.72 2.54 
3 71.25 33.98 38.75 363.35 22.80 71.27 12.66 10.88 0.00 1.25 8.73 1.38 
4 312.31 144.69 44.06 91.07 19.64 79.64 17.43 35.94 13.22 2.00 13.78 1.28 
5 210.37 31.65 30.65 94.89 30.08 91.59 16.79 66.15 34.70 1.16 27.47 3.76 
6 142.27 46.19 24.08 99.08 11.93 30.82 5.03 16.54 0.00 0.98 18.44 0.78 
7 53.52 12.46 25.18 47.99 7.53 20.98 0.86 7.35 0.00 1.22 13.84 3.84 
8 103.82 16.62 31.41 45.87 18.31 52.27 4.88 14.54 3.53 1.20 15.35 1.71 
9 81.39 37.18 26.14 196.48 12.24 64.42 7.92 23.82 11.98 1.17 24.11 0.69 
10 86.31 65.43 14.32 59.98 32.32 98.07 18.99 48.87 9.65 0.84 8.57 1.05 
11 76.53 61.85 22.38 75.85 12.04 34.60 6.87 20.90 11.60 1.39 15.85 1.42 
12 68.19 19.03 34.73 152.15 15.08 239.37 7.28 9.70 4.84 0.36 17.88 0.44 
13 121.67 67.95 17.21 37.95 13.57 56.85 4.07 11.93 0.00 1.79 8.14 0.68 
14 204.41 104.63 63.14 309.53 19.01 92.01 19.81 34.83 8.29 2.20 12.38 1.06 
15 60.43 49.42 35.95 245.93 64.83 161.02 35.95 42.09 12.50 1.43 21.17 0.51 
             
Middle Stage of AMD             
16 109.20 50.25 19.25 63.32 33.53 64.27 23.30 28.73 15.15 0.81 17.30 0.27 
17 226.86 117.13 31.56 78.61 33.86 68.02 33.72 63.85 12.25 1.24 17.73 0.71 
18 32.88 13.13 9.84 28.40 6.20 22.90 1.26 6.99 0.00 0.53 6.76 0.87 
19 115.85 21.83 26.44 90.40 8.33 24.22 7.60 11.61 10.54 1.08 7.15 2.19 
20 84.39 44.84 15.43 41.47 15.18 46.25 8.45 23.65 8.70 0.85 13.75 0.57 
21 137.51 26.30 45.36 121.48 9.22 46.45 7.90 17.82 12.62 1.36 9.81 1.11 
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22 71.16 24.98 38.25 174.77 16.18 42.78 16.41 19.94 5.76 1.41 11.81 2.45 
23 209.61 90.88 50.73 72.48 22.61 64.29 27.12 64.08 0.00 1.20 13.77 1.68 
24 96.57 38.61 19.70 80.08 13.98 36.72 7.93 15.28 15.04 1.05 12.21 2.49 
25 155.96 100.71 75.76 208.50 51.71 347.45 20.60 34.07 15.52 2.06 14.12 0.57 
26 114.46 56.95 30.66 102.04 8.54 60.35 9.59 20.52 1.93 1.21 16.80 0.68 
27 55.82 3.27 25.87 87.90 8.25 75.99 3.61 11.78 2.33 1.70 37.07 0.93 
28 67.67 41.86 19.19 73.90 8.60 55.19 6.72 23.75 7.49 1.23 12.09 0.49 
29 152.70 0.00 52.36 201.64 13.64 95.08 14.68 25.01 7.00 1.32 19.16 0.82 
30 64.56 27.04 36.26 125.08 25.33 148.63 13.97 16.59 3.05 0.98 14.10 0.51 
             
End Stage of AMD             
31 82.47 40.25 51.30 178.31 14.72 45.10 5.35 19.17 4.52 1.20 15.60 2.21 
32 80.10 25.63 33.43 123.40 15.43 57.36 5.18 9.85 0.00 1.41 7.62 1.90 
33 152.64 100.36 17.20 42.39 12.41 38.20 12.56 40.01 33.64 1.69 11.40 0.87 
34 67.02 17.70 34.05 127.53 21.46 82.93 3.33 10.50 66.01 0.77 13.11 1.26 
35 94.35 22.95 26.34 51.51 14.81 29.81 10.75 13.52 6.42 2.42 8.58 3.91 
37 61.39 45.25 22.06 78.05 18.48 82.96 7.80 14.47 7.00 1.53 13.83 1.00 
38 46.36 14.86 17.62 33.05 7.32 56.22 1.58 5.79 0.00 1.12 10.32 1.08 
39 105.59 74.09 38.39 161.65 13.36 114.52 5.33 18.38 7.37 1.95 26.70 0.81 
40 170.69 78.54 34.66 136.42 13.67 161.04 8.40 22.20 5.66 0.57 17.19 0.71 
41 268.31 85.20 21.09 106.97 29.80 73.81 26.06 53.69 22.38 1.16 17.29 1.64 
42 183.03 59.56 48.13 198.73 338.46 35.59 25.74 27.02 11.25 1.48 31.68 0.59 
43 193.31 0.00 47.14 73.81 11.20 93.05 9.35 19.46 3.97 1.85 17.65 3.19 
44 62.76 37.42 20.29 65.39 15.33 148.56 5.91 10.54 8.31 0.93 17.35 0.91 
45 171.73 98.47 26.78 90.60 207.42 40.77 10.54 21.24 21.01 1.71 28.63 0.83 
31 82.47 40.25 51.30 178.31 14.72 45.10 5.35 19.17 4.52 1.20 15.60 2.21 
       1 Cyclolycopenes refers to stereoisomeric 2,6-Cyclolycopene-1,5-diol I and 2,6-Cyclolycopene-1,5-diol II. 
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APPENDIX AA. SERUM CONCENTRATIONS OF MAJOR DIETARY CAROTENOIDS, VITAMIN A, AND  
VITAMIN E IN SUBJECTS AT WEEK 38 
 
   Serum concentrations of major dietary carotenoids, 2,6-cyclolycopene-1,5-diol I & II, retinol, α-tocopherol, and γ-tocopherol in  
   human subjects at week 38. 




























No AMD             
1 148.63 11.22 34.81 183.27 21.38 95.12 20.95 32.97 7.73 0.23 11.59 1.00 
2 240.32 120.02 35.70 210.19 29.60 156.59 20.77 52.15 21.64 2.19 20.13 0.65 
3 70.27 62.57 30.83 164.79 15.64 51.54 6.28 18.74 0.00 1.83 10.54 1.67 
4 471.14 205.06 40.51 218.65 27.21 83.52 47.04 85.50 33.54 1.94 23.02 1.67 
5 65.08 22.49 12.17 46.40 13.29 21.39 5.43 23.28 0.00 1.39 15.60 1.67 
6 97.34 30.66 19.71 74.71 8.09 19.90 3.70 16.57 2.48 0.71 21.41 0.68 
7 79.92 0.00 17.52 46.13 7.05 20.95 2.03 10.65 1.85 0.43 10.28 1.48 
8 117.52 18.92 18.53 39.39 14.06 46.96 4.64 13.00 6.58 0.97 13.08 1.45 
9 107.24 43.23 37.67 166.73 13.45 86.96 13.01 26.05 9.08 1.37 27.62 0.68 
10 138.70 83.55 23.15 108.86 64.44 169.89 29.24 76.03 18.54 1.91 12.77 1.54 
11 88.54 70.04 40.61 109.36 15.61 40.54 11.57 12.42 0.00 1.85 13.28 0.86 
12 283.02 53.57 63.27 355.95 240.31 456.57 175.88 83.68 66.42 2.22 27.53 0.87 
13 197.72 22.28 24.41 50.94 19.57 71.44 14.75 19.38 10.62 1.71 12.83 1.66 
14 152.43 153.68 50.22 174.24 19.78 55.30 20.40 46.28 16.07 2.73 15.76 1.90 
15 74.97 36.18 46.57 420.83 48.92 335.96 28.04 30.40 4.61 1.87 33.15 0.95 
             
Middle Stage of AMD             
16 151.11 128.86 28.49 74.97 29.46 94.33 34.81 36.11 11.54 1.70 13.66 1.23 
17 146.04 99.63 19.83 68.79 22.12 50.15 20.26 37.47 0.00 1.24 14.71 0.45 
18 115.92 39.33 21.31 75.14 10.73 37.80 6.97 18.40 9.45 2.20 18.64 2.20 
19 166.69 45.42 50.15 153.31 21.65 41.14 15.96 12.79 0.00 2.20 9.91 2.88 
20 156.46 45.08 26.74 67.79 24.04 75.61 23.47 31.55 14.91 0.57 19.25 0.49 
21 264.08 57.47 52.26 151.13 17.87 57.66 18.97 37.93 6.86 1.96 16.00 1.99 
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22 52.35 12.97 23.16 86.37 15.44 44.17 7.96 11.30 0.00 0.69 9.83 2.14 
23 142.69 52.75 31.53 54.67 15.64 49.46 19.91 34.63 7.77 1.17 13.72 0.55 
24 88.63 64.35 28.33 96.40 11.19 38.40 10.09 16.13 6.16 1.33 12.21 2.44 
25 181.91 91.31 65.54 201.09 56.02 354.24 25.24 33.16 12.51 1.89 21.72 0.96 
26 108.23 34.92 31.96 112.54 8.92 52.28 12.50 29.52 8.67 0.96 18.93 0.75 
27 93.77 38.85 23.89 113.67 13.55 111.08 7.20 13.26 6.48 2.30 23.70 0.53 
28 118.79 48.56 12.55 41.43 25.11 35.25 9.43 19.25 5.08 1.82 19.23 0.48 
29 155.20 91.72 31.80 152.90 12.87 100.28 10.46 24.31 5.77 1.14 13.27 0.47 
30 222.50 80.88 48.20 202.14 44.53 409.39 38.96 45.40 11.93 1.48 25.38 1.62 
             
End Stage of AMD             
31 95.98 35.07 24.37 108.80 16.70 42.25 14.62 21.25 4.98 1.79 14.60 2.06 
32 106.84 60.16 28.10 132.21 16.82 56.25 10.83 17.72 11.13 0.78 9.67 2.18 
33 405.75 149.12 24.93 72.19 19.25 62.89 45.40 88.89 33.04 2.56 25.92 1.56 
34 42.88 10.32 25.00 56.77 13.51 124.82 2.97 8.47 2.30 0.97 25.87 0.66 
35 86.22 23.81 22.29 52.71 9.48 159.62 4.71 12.87 1.98 1.38 21.78 1.49 
37 73.88 56.08 27.06 107.95 21.23 120.73 12.65 20.73 8.80 1.70 12.63 1.39 
38 43.46 20.10 21.47 34.37 6.64 82.49 3.15 6.38 3.94 1.17 18.33 1.00 
39 98.73 67.35 35.53 183.46 22.29 122.85 10.73 18.51 13.22 2.29 19.68 0.65 
40 152.46 101.55 31.23 148.60 22.82 180.88 11.31 24.55 11.84 1.33 16.68 0.55 
41 290.26 31.45 42.15 138.16 66.48 185.95 35.07 44.98 22.95 2.03 17.70 2.49 
42 114.07 69.73 41.25 137.51 22.15 299.38 20.83 20.79 9.11 2.50 35.86 0.96 
43 81.94 29.97 19.41 28.02 6.20 24.80 4.71 14.34 5.89 1.29 13.47 2.81 
44 62.87 32.17 25.78 71.76 13.82 100.74 9.28 17.31 2.73 1.36 27.36 1.11 
45 73.27 76.15 18.57 93.83 7.59 76.83 3.53 9.35 0.00 1.98 22.93 0.68 
31 95.98 35.07 24.37 108.80 16.70 42.25 14.62 21.25 4.98 1.79 14.60 2.06 
       1 Cyclolycopenes refers to stereoisomeric 2,6-Cyclolycopene-1,5-diol I and 2,6-Cyclolycopene-1,5-diol II. 
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APPENDIX BB. SERUM CONCENTRATIONS OF MAJOR DIETARY CAROTENOIDS, VITAMIN A, AND  
VITAMIN E IN SUBJECTS AT WEEK 52 
 
   Serum concentrations of major dietary carotenoids, 2,6-cyclolycopene-1,5-diol I & II, retinol, α-tocopherol, and γ-tocopherol in  
   human subjects at week 52. 




























No AMD             
1 43.12 0.00 32.17 136.65 11.77 47.66 6.31 10.53 6.70 0.47 9.33 1.09 
2 221.11 112.07 48.04 185.98 23.64 145.53 38.03 73.67 30.33 1.18 26.11 0.72 
3 98.35 0.00 45.09 182.48 23.47 76.94 20.44 27.79 10.92 1.89 15.26 1.53 
4 149.34 86.24 28.36 96.66 13.19 170.14 15.48 28.84 0.00 0.99 18.29 0.71 
5 110.41 69.42 11.86 64.20 20.85 32.82 10.03 31.88 12.40 2.14 18.02 2.00 
6 145.36 0.00 25.01 106.73 10.45 31.16 6.11 18.45 2.39 2.00 23.65 0.81 
7 51.81 22.09 14.78 93.24 9.30 19.51 0.67 7.09 5.11 0.90 8.16 1.79 
8 73.84 36.29 15.99 33.06 15.07 37.35 3.72 9.78 3.16 2.06 13.57 2.34 
9 154.73 20.76 42.05 205.03 20.44 131.87 17.52 28.57 20.39 1.01 18.18 0.69 
10 74.84 69.61 16.33 58.44 43.07 85.55 20.31 39.19 13.02 1.50 9.85 0.91 
11 80.70 80.36 25.34 102.48 55.81 79.06 29.86 41.04 16.54 1.48 18.45 1.03 
12 110.49 45.99 42.12 144.92 21.40 180.76 11.73 17.79 0.00 0.88 20.07 0.71 
13 138.40 33.46 22.19 53.85 21.03 82.89 7.45 10.82 1.03 1.98 10.95 1.90 
14 123.25 83.61 49.14 151.38 14.56 62.63 7.65 17.93 4.23 2.06 12.31 1.30 
15 44.10 23.36 52.06 789.41 28.86 178.08 12.29 12.01 3.73 1.27 19.84 0.55 
             
Middle Stage of AMD             
16 172.52 107.04 28.34 81.43 27.47 82.37 18.78 26.67 5.04 2.61 13.41 0.90 
17 202.89 77.46 27.32 45.20 25.91 51.11 24.23 37.81 18.53 1.08 8.68 0.92 
18 66.37 38.94 15.25 46.16 8.52 82.36 3.58 13.04 3.34 2.26 25.58 1.52 
19 120.68 23.46 35.94 98.66 9.70 63.63 11.07 20.84 1.71 1.61 21.92 0.73 
20 96.69 78.18 29.84 142.36 20.90 51.11 10.75 25.37 9.55 1.06 22.67 0.86 
21 83.79 28.89 33.33 101.05 9.54 30.45 4.84 14.68 5.73 1.65 13.06 1.00 
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22 77.54 19.04 28.66 75.90 13.29 73.42 3.56 15.23 2.74 2.69 21.37 1.27 
23 155.03 38.39 28.69 52.46 12.49 51.15 11.99 24.64 3.24 1.03 15.52 1.33 
24 51.38 0.00 12.83 47.02 7.63 22.25 5.77 9.61 1.67 0.88 7.76 1.32 
25 125.36 43.70 79.03 322.81 48.27 481.22 38.07 37.75 17.97 0.80 29.53 0.54 
26 88.96 31.73 22.03 79.87 9.28 194.38 24.36 17.99 6.83 1.18 19.69 0.93 
27 70.67 0.00 21.98 86.09 18.65 105.40 11.25 15.32 2.30 1.67 24.17 0.53 
28 60.63 35.50 16.41 49.44 26.29 46.77 12.25 24.31 14.00 1.88 20.69 0.72 
29 312.52 65.16 61.18 297.45 25.51 198.89 21.78 32.64 12.59 2.20 23.03 0.58 
30 162.56 63.89 51.37 193.56 66.20 507.69 26.57 28.84 8.18 1.99 22.41 0.92 
             
End Stage of AMD             
31 39.43 9.30 27.70 91.93 14.03 59.28 8.77 11.73 9.05 0.61 11.41 1.97 
32 103.68 63.71 24.48 100.37 16.43 58.57 10.60 20.58 3.61 0.46 7.74 1.73 
33 403.18 121.64 23.98 70.26 20.00 43.14 31.86 77.36 16.45 1.57 28.98 1.70 
34 71.85 16.32 31.05 88.44 28.78 178.45 9.20 18.55 4.20 0.82 25.81 0.57 
35 37.61 13.56 16.78 40.73 7.53 96.79 1.67 4.02 5.62 0.91 20.09 0.86 
37 110.40 39.13 36.72 141.15 19.13 78.11 7.79 8.99 2.45 1.60 10.77 1.46 
38 70.71 36.85 12.04 37.51 6.94 90.75 7.42 10.17 4.11 1.44 12.09 0.65 
39 76.78 42.15 33.76 181.21 12.17 194.20 8.89 14.28 9.84 0.99 28.82 0.68 
40 90.90 46.29 22.77 85.84 11.66 206.86 11.33 14.22 5.65 0.83 15.56 0.40 
41 242.12 64.94 23.10 77.10 40.40 72.80 16.49 32.84 9.09 1.21 13.37 1.44 
42 156.74 68.92 44.14 163.88 23.79 537.54 10.85 16.27 0.54 2.30 29.11 0.91 
43 83.14 25.75 20.28 37.90 9.15 34.52 5.56 8.34 0.00 1.50 12.07 2.05 
44 77.43 42.87 23.43 56.89 13.35 129.70 6.22 9.57 0.00 1.26 14.77 1.83 
45 108.56 70.02 17.60 52.59 12.59 122.73 11.25 21.41 12.67 1.48 23.37 0.37 
31 39.43 9.30 27.70 91.93 14.03 59.28 8.77 11.73 9.05 0.61 11.41 1.97 
       1 Cyclolycopenes refers to stereoisomeric 2,6-Cyclolycopene-1,5-diol I and 2,6-Cyclolycopene-1,5-diol II. 
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APPENDIX CC. SUBJECT VISUAL ACUITY OF SUBJECTS THROUGHOUT THE STUDY 
 
        Subject Visual Acuity of the Left (VAOS) and the Right (VAOD) Eye.  
Week 0 Week 4 Week 12 Week 26 Week 38 Week 52 Subject ID# 
 VAOS VAOD VAOS VAOD VAOS VAOD VAOS VAOD VAOS VAOD VAOS VAOD
             
No AMD             
1 88 90 91 89 87 91 88 90 90 90 89 90 
2 94 89 90 89 94 90 92 93 98 94 98 92 
3 91 95 94 94 95 95 92 95 94 95 91 92 
4 83 88 81 87 81 88 81 86 77 84 57 84 
5 81 80 85 80 82 81 83 81 82 82 82 83 
6 84 84 80 80 85 85 85 85 84 85 84 85 
7 84 85 87 86 85 84 86 89 84 86 86 84 
8 90 89 89 90 89 91 90 91 89 88 91 91 
9 98 93 94 94 96 96 98 95 97 96 97 96 
10 89 90 91 93 89 94 92 95 93 90 93 90 
11 82 84 83 87 86 89 85 86 84 86 80 86 
12 88 89 87 87 88 89 87 87 88 88 90 90 
13 67 83 73 84 75 86 76 90 76 89 77 89 
14 95 88 99 95 99 98 100 95 96 97 99 98 
15 84 80 80 80 82 79 83 79 81 79 83 83 
             
Middle stage of AMD             
16 90 89 91 90 90 88 90 91 88 94 90 86 
17 90 88 88 87 88 84 90 83 84 83 85 85 
18 74 80 69 76 73 77 73 83 73 84 68 78 
19 85 90 88 90 80 84 82 86 83 89 81 90 
20 78 74 80 75 79 68 83 68 83 68 82 67 
21 78 82 84 80 89 81 85 79 83 82 90 82 
22 76 70 74 78 79 71 76 73 71 77 68 69 
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APPENDIX CC. (continued) 
 
Baseline Week 4 Week 12 Week 26 Week 38 Week 52 Subject ID# 
 VAOS VAOD VAOS VAOD VAOS VAOD VAOS VAOD VAOS VAOD VAOS VAOD
23 89 78 85 81 90 85 90 89 88 89 87 88 
24 85 65 79 65 85 65 84 63 82 66 84 64 
25 88 88 90 86 89 84 87 87 87 83 85 83 
26 73 73 77 80 78 82 75 82 77 80 74 78 
27 77 80 74 82 75 84 75 81 74 85 70 79 
28 79 83 82 82 84 82 87 82 85 84 89 83 
29 86 92 91 92 91 92 91 90 91 88 90 90 
30 90 85 87 85 92 85 94 91 90 85 94 92 
             
End Stage of AMD             
31 74 77 75 70 74 78 85 78 64 76 75 80 
32 10 57 11 55 12 58 9 52 12 38 25 13 
33 76 79 75 82 73 77 74 81 79 81 78 85 
34 78 23 79 17 76 23 80 19 77 21 73 24 
35 66 16 69 17 69 22 66 23 66 18 63 25 
36 18 65 24 60 26 54 * * * * * * 
37 58 14 54 13 58 15 54 15 57 14 33 14 
38 0 81 0 83 0 80 0 84 0 80 0 84 
39 61 36 55 36 48 42 50 25 37 27 28 15 
40 65 80 65 79 65 78 61 74 64 78 67 80 
41 45 75 39 80 42 81 34 80 38 71 28 77 
42 32 75 32 86 22 86 15 80 18 81 18 84 
43 4 8 5 10 3 15 9 17 10 15 7 14 
44 13 19 21 19 21 11 28 28 17 13 14 15 
45 63 14 67 21 68 19 63 19 61 20 65 17 




APPENDIX DD. SUBJECT MACULAR PIGMENT OPTICAL DENSITY THROUGHOUT THE STUDY 
 
       Subject Macular Pigment Optical Density of the Left (MPOS) and the Right (MPOD) Eye.  
Week 0 Week 1 Week 4 Week 12 Week 26 Subject ID# 
 MPOS MPOD MPOS MPOD MPOS MPOD MPOS MPOD MPOS MPOD 
           
No AMD           
1 * * 0.28 0.41 0.29 0.42 0.32 0.32 0.30 0.38 
2 0.46 0.43 0.47 0.41 0.43 0.34 0.52 0.43 0.56 0.47 
3 0.56 0.53 * * 0.34 0.25 0.29 0.43 0.48 0.23 
4 * * 0.09 0.23 0.28 0.48 0.14 0.72 0.35 0.13 
5 0.1 * 0.15 * 0.2 * 0.18 * 0.04 * 
6 0.19 0.26 0.16 0.19 * 0.14 0.18 0.2 0.14 0.21 
7 * * * * * * * * * * 
8 * 0.47 * 0.45 * 0.43 * 0.23 * 0.23 
9 * * * * * * * * * * 
10 0.52 0.42 0.50 0.46 0.39 0.38 0.45 0.43 0.38 0.44 
11 0.49 * 0.49 * 0.46 * 0.44 * 0.35 * 
12 * * * * * * * * * * 
13 * * 0.06 * 0.08 * 0.11 * 0.02 * 
14 0.53 0.47 0.63 0.49 0.69 0.49 0.64 0.50 0.50 0.59 
15 * * * * * * * * 0.02 * 
           
Middle stage of AMD           
16 0.41 * 0.52 * 0.51 * 0.77 * 0.75 * 
17 * * * 0.47 * 0.38 * 0.54 * 0.63 
18 0.15 * * 0.09 * 0.14 0.35 0.07 * 0.48 
19 * 0.24 * 0.08 * 0.24 * * * 0.31 
20 * * * * * * * * * * 
21 * * * * * * * * * * 
22 * * * 0.32 * 0.7 * * * 0.03 
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APPENDIX DD. (continued) 
 
Week 0 Week 1 Week 4 Week 12 Week 26 Subject ID# 
 MPOS MPOD MPOS MPOD MPOS MPOD MPOS MPOD MPOS MPOD 
23 * 0.42 0.42 0.39 0.43 0.41 0.48 0.57 0.42 0.61 
24 0.34 * 0.57 0.48 0.58 0.58 0.75 0.91 * 0.82 
25 0.4 * 0.54 * 0.46 * 0.43 * 0.52 * 
26 * * * * * * * * * * 
27 * * * * * * * * * * 
28 * * * * * * * * * * 
29 * * * * * * * * * * 
30 0.37 0.36 0.33 0.36 0.42 0.37 0.48 0.39 0.3 0.43 
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